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Abstract
During the last decades, drug discovery development has made considerable progress. How-
ever, annual numbers of released drugs for novel targets have been decreasing concomitantly.
Limited success rates of combinatorial chemistry and high-throughput screening, as well as
availability of feasible targets are some reasons for this problem. A strategy to overcome it is
exploration of novel target classes in order to expand the druggable space. An example are
protein-protein interactions (PPIs) that can be inhibited or stabilized. Inhibition aims at devel-
oping binders for one protein to prevent complex formation. However, known PPI inhibitors
differ significantly from conventional drugs and current active site-biased compound libraries
are probably inappropriate to discover them. The design of novel screening libraries is thus
very important. PPI stabilization aims at developing molecules that bind to a protein complex
to increase its stability like a molecular glue. In contrast to inhibition, it is rather unexplored
but ground-breaking examples from nature inspire research efforts.
This work presents novel theoretical and experimental drug discovery approaches for these
challenges. In the first part, we introduce novel chemoinformatics approaches for clustering
of large chemical libraries. The development of a fast algorithm for pairwise similarity calcula-
tions forms the basis for an exact and deterministic clustering method, which is able to process
the available chemical space in a short time. We complement our chemoinformatics work by
a novel approach for fast classification of small molecules according to the similarity of their
frameworks, the so-called scaffolds. The method generates families of molecules that share
geometry conserving scaffolds and we show that family members possess similar activity on
identical targets.
The second part introduces computational methods for PPI modulation. First, we present
structure-based analysis of known stabilized PPIs, which enables the development of novel in
silico approaches to screen for small molecule PPI stabilizers. We demonstrate their applica-
bility by an experimentally tested virtual screening for 14-3-3 protein interaction stabilizers.
Finally, we present a virtual screening approach dedicated to identify small molecule inhibitors
of 14-3-3 protein interactions. Predicted inhibitors are experimentally verified and character-
ized by in vitro assays and X-ray crystallography. Structure-activity relationship studies yielded
PPI inhibitors in the low micromolar range, which are also active in cell-based experiments.
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Zusammenfassung
Die technologische Entwicklung der niedermolekularen Wirkstoffforschung hat in den vergan-
genen Jahrzenten große Fortschritte gemacht. Dennoch geht die jährliche Anzahl neuer Wirk-
stoffe zurück. Die niedrige Erfolgsquote von kombinatorischer Chemie und Hochdurchsatz-
Screening sowie die mangelnde Verfügbarkeit handhabbarer molekularer Ziele sind Gründe
hierfür. Eine Strategie dieses Problem zu lösen ist die Erforschung neuer molekularer Zielklas-
sen. Ein Beispiel sind Protein-Protein Interaktionen (PPIs), deren Modulation zwei Möglichkei-
ten umfasst: (1) Inhibition und (2) Stabilisierung. Das Ziel der Inhibition ist die Entwicklung
von Bindern, die sich an ein Protein anlagern und Komplexbildung verhindern. Bekannte Inhi-
bitoren unterscheiden sich aber deutlich von herkömmlichen, wirkstoffähnlichen Molekülen
und vorhandene Bibliotheken sind deshalb möglicherweise zur Suche ungeeignet. Die Ent-
wicklung neuer Molekülbibliotheken ist deshalb von großer Bedeutung. PPI Stabilisierung hat
zum Ziel, Moleküle zu entwickeln, die an Proteinkomplexe binden und deren Stabilität wie ein
Molekularkleber erhöhen. Im Gegensatz zur Inhibition ist dieser Ansatz kaum erforscht, aber
die Natur liefert wegweisende Beispiele die Forschung auf diesem Gebiet anregen.
Diese Arbeit stellt neue theoretische und experimentelle Methoden für diese Herausforde-
rungen vor. Der erste Teil beschreibt Methoden der Chemoinformatik zum Clustering großer
Substanzbibliotheken. Die Entwicklung eines schnellen Algorithmus zur paarweisen Ähnlich-
keitsberechnung bildet die Grundlage eines exakten und deterministischen Clusteringverfah-
rens, das den verfügbaren chemischen Raum in kurzer Zeit verarbeiten kann. Ergänzend
stellen wir eine Methode zur Klassifizierung von niedermolekularen Substanzen nach der
Ähnlichkeit ihrer Grundgerüste vor. Die Methode erzeugt Molekülfamilien mit konservierter
Grundgerüstgeometrie und wir zeigen, dass Mitglieder einer Familie ähnliche Aktivität auf
einem Zielprotein haben. Der zweite Teil behandelt computergestützte Methoden zur PPI Mo-
dulation. Auf Basis strukturbioinformatischer Analysen stabilisierter PPIs entwickeln wir in
silico Methoden zur PPI Stabilisatorsuche. Ein Beispiel für eine ausgewählte 14-3-3 PPI und die
experimentelle Überprüfung der Ergebnisse zeigen deren Anwendung. Schließlich stellen wir
die Ergebnisse eines virtuellen Screenings nach Inhibitoren von 14-3-3 PPIs vor. Vorhergesagte
Inhibitorkandidaten werden in vitro, durch Röntgenkristallographie und in einem zellulären
Assay experimentell validiert.
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General Remarks
• In accordance with the standard scientific protocol, I will use the personal pronoun we
to indicate the reader and the writer, or my scientific collaborators and myself.
• Unless stated otherwise, all figures of protein structures were generated using the freely
available visualization software BALLView.1,2
• We use the symbol ’◦’ to indicate the interaction of molecules in a complex. Thus, the
notation Ras◦Raf would indicate a binary complex between the proteins Ras and Raf.
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Chapter 1
Introduction
Motivation
The history of drug discovery can be traced back to the famous Egyptian Papyrus Ebers, a
medical record which is dated before 1600 BC.3 Despite this long history, the past 200 years
were probably the period with most rapid and important progress leading to modern drug
discovery. Starting with the identification of single organic molecules as active ingredient,
their synthesis and modification in the 19th century, organic chemistry was the first discipline
contributing to this development. In the 20th century, advancements in molecular biology
and biochemistry led to the availability of purified proteins, which formed the basis for the
development of in vitro assay systems and the elucidation of the three-dimensional structure
of biological macromolecules by X-ray crystallography, nuclear magnetic sesonance (NMR) or
cryo-electron microscopy. Finally, the initial sequencing of the human genome in 2001 by the
groups of Lander and Venter formed a further milestone for various disciplines.4,5 In the area
of drug discovery, the human genome in the first place provided the material to estimate the
number of druggable targets in humans, which is also known as druggable genome.6 Various
studies have been performed and the size of the druggable genome has been estimated to
range in the order of 103, whereof a few hundred are already addressed by marketed drugs.7,8
However, despite this steady progress in drug discovery and the availability of not yet
addressed targets, the number of new molecular entities (NME) released per year has been
decreasing continuously. As shown in Fig. 1.1, this holds true especially for small molecule
based drugs. A possible reason for this trend could be an increased intractability of the
non-addressed fraction of currently considered drug targets using the existing drug discovery
strategies. To overcome this problem, novel approaches are being explored and developed
aiming at expanding the druggable genome. These efforts are of utmost importance for
prospective drug discovery. They will form the basis for novel therapies and probably pave the
way for the treatment of yet incurable diseases.
1
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Figure 1.1: Number of yearly approved small molecule based NMEs by the U.S. Food and
Drug Administration (FDA).
Expanding the Druggable Genome
To expand the space of druggable targets various strategies were developed in the recent past.
One promising approach is to move from classic enzyme inhibition to enzyme activation.9,10
Here, allosteric sites or regulatory subunits are modulated by small molecules. An advantage
of this strategy is the possible reutilization of existing, established, and over the past decades
optimized technologies like high-throughput screening (HTS) or protein-ligand docking. An-
other interesting approach is targeted therapy, where for example highly cytotoxic compounds
are attached to monoclonal antibodies for site-specific application in malignant tissue.11,12
Here, the high selectivity and specificity of monoclonal antibodies is a major advantage. An
actual expansion of the druggable genome is the targeting of cellular processes on the DNA
and RNA level. Here, small non-coding RNAs like siRNAs or shRNAs are used to modulate gene
expression by RNA interference.13,14 Even addressing RNA by small molecules is subject of
current research.15 However, these strategies are quite challenging because of major obstacles
like application and transport of RNA.
A further target class which has the potency to tremendously expand the druggable genome
are protein-protein interactions (PPI). The latter are of fundamental importance for all living
organisms and they form a huge and complex network termed as interactome, which substan-
tially contributes to the regulation and execution of the majority of biological processes. The
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size of the binary human interactome has recently been re-estimated to comprise over 300,000
binary PPIs, of which only a fraction has yet been identified.16
In the recent past, the inhibition of PPIs by small molecules or by modified peptides
has been accepted as a viable way to interfere with disease-related signaling pathways.17–19
Successful examples have been presented for various anticancer, antiviral, antibacterial, and
anti-inflammatory applications. However, it has also been recognized that the discovery of PPI
inhibitors is a quite challenging task and standard HTS attempts often fail to yield validated
hits.20 As a possible reason for this observation, physicochemical property differences of small
molecule PPI inhibitors and classical active site binders are discussed.20,21 Existing screening
libraries are historically grown and probably lack the chemotypes appropriate for binding to
the surfaces of PPIs.
For a long time, the scientific community has overlooked that PPI modulation does not
exclusively mean complex inhibition. Evidently, the complementary side of disrupting a tran-
sient biological system is its stabilization.22 This fascinating mechanism is demonstrated by
impressive examples from nature, where PPIs are stabilized by a small molecule. It has already
been shown that protein complexes exhibit surface-exposed pockets at their binding interfaces
with structural and physicochemical characteristics that are comparable to typical enzymatic
active sites.23,24 Additionally, the proof of concept for rational PPI stabilizer discovery has
recently been provided by Ottmann and co-workers.25 At all times, drug discovery has learned,
copied, and adapted from nature and in contrast to the increasing number of examples for
PPI stabilization, these examples for PPI inhibition are yet missing. Thus, PPI stabilization is a
novel drug design concept with the potency to expand the druggable genome.
Challenges in Computer-Assisted PPI Modulation
Computational methods made their way into modern drug discovery and today some of them
are an integral part of various steps in the drug discovery pipeline.26 In general, these methods
can be classified into three major fields, namely computational chemistry, chemoinformat-
ics and structural bioinformatics.
A major challenge in chemoinformatics is the increasing number of – also virtually – avail-
able compounds. As described previously, contemporary HTS libraries seem to be unsuited for
PPI inhibitor screening and the design and assembly of new compound collections will be nec-
essary. Taking into account that virtually curated compound libraries nearly comprise a billion
druglike molecules, sophisticated algorithms and tools are needed to handle and to analyze
such huge amounts of data. Some of the existing chemoinformatics tools for similarity-based
tasks like clustering are too slow and improved algorithms and approaches are needed. In
addition, abstractions and representations of molecules reflecting medicinal chemistry needs
would also be helpful to meaningfully reduce the complexity of these data sets.
3
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In contrast to inhibition, the stabilization of PPIs is a rather unexplored field, especially
from a computational perspective. Currently, no comprehensive analysis of the known ex-
amples has been performed. The availability of their crystal structures enables a detailed
analysis of their mode of action. Learning from these examples allows us to define rules to
augment existing virtual screening (VS) techniques and protocols for the identification of PPI
stabilizers. An interesting task is also to analyze the stabilizing ligands themselves. If these
compounds possess classic druglike chemotypes, this would preset a reasonable chance to
identify candidates in existing screening libraries.
Thesis outline
This work is located at the interface of theoretical computer-assisted and experimental drug
discovery. Novel theoretical approaches in chemoinformatics and structure-based drug design
are presented and transferred into in vitro experiments to discover and characterize novel
modulators of PPIs. Chapter 2 gives the theoretical and biological background necessary to
understand the following chapters. First, selected topics from computer science, chemoin-
formatics and structure-based drug design are introduced. Second, fundamentals of X-ray
crystallography are given, followed by the biological background on PPIs and their modula-
tion. Finally, the protein family 14-3-3 is introduced, which forms the model system for our
studies.
Part I: Chemoinformatics
The first part of this work introduces approaches for rapid analysis, clustering, and classifica-
tion of large chemical spaces. Chapter 3 presents a novel chemoinformatics method for fast
clustering of large chemical spaces. It is based on a sophisticated data structure in combination
with an efficient algorithm that enables the calculation of all pairwise similarity coefficients
– that is the similarity matrix – for libraries comprising tens of millions of compounds using
standard hardware. The design goals of our algorithm are architecture independence and
optimization for usage on modern multi-core machines. We demonstrate that this method is
competitive to state-of-the-art methods for high-throughput similarity calculations. At its peak
performance it calculates almost 400 million Tanimoto similarities per second. Analsyis of the
method’s runtime behavior and hardware demands allows us to infer important guidelines for
parallel application. This method forms the core for our clustering approach, which yields an
exact and deterministic clustering of a given compound library. We compare the clustering
method to implementations of Jarvis-Patrick and Ward and show that its runtime is competitive
or significantly better. As a final application example, we demonstrate that clustering of the
available chemical space with over 17 million compounds takes only 64 hours to complete.
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In Chapter 4, we introduce a method for the classification of druglike molecules based on
their molecular frameworks, that is their scaffolds. The goals of this method are to generate
a compound grouping in a way that is meaningful to medicinal chemists and a short compu-
tation time even for large compound libraries. Using the fast similarity calculation method
introduced before, we show that similarity network generation at high Tanimoto thresholds
yields homogeneous scaffold families and leads to a significant reduction of the input data set
size. We show examples of scaffold families, which comprise molecules that are related by their
structure-activity on two different targets.
Part II: Structure-based PPI Modulator Discovery
The second part of this work introduces computer-assisted drug discovery methods applied to
the promising and challenging target class of PPIs and presents approaches for the development
of stabilizers as well as inhibitors. In Chapter 5 we focus on PPI stabilization. We analyze
the crystal structures of the currently described protein complexes that are stabilized by a
small molecule in order to obtain quantitative knowledge on this mode of action. We use this
knowledge to develop approaches to explicitely screen for PPI stabilizers in silico. As a first
application, we use the approach to search for stabilized PPIs within the Protein Data Bank
and indeed uncover six stabilized PPIs that were not part of the analyzed input data set. As
a second application, we set up, perform, and experimentally test a VS for stabilizers of the
interaction between 14-3-3 protein and its target Task3. Our virtual screening identified 258
stabilizer candidates from which 89 were tested in an in vitro stabilization assay. Finally, one
compound shows stabilizing activity in the low micromolar range.
In the final Chapter 6, we present a VS study dedicated to the identification of 14-3-3 protein
interaction inhibitors. We analyze the binding modes of representative crystal structures of
14-3-3 bound to different of its partner proteins. The information is used to formulate a bind-
ing mode hypothesis and use it to set up a virtual screening for inhibitors of 14-3-3 protein
interactions. From a compound library comprising more than 8 million small molecules we
retrieve candidates from virtual screening and manually selected 14 candidates for in vitro
testing. Two candidates have been validated and show inhibitory activity in the low micromo-
lar range. Structure-activity relationship studies of these hits led to more potent inhibitors,
from which two are active in a cellular assay. We finally present an inhibitory compound that
covalently binds to 14-3-3 .
5

Chapter 2
Background
The content of Section 2.4 is an extended version of the review article:
Small-molecule stabilization of protein-protein interactions:
an underestimated concept in drug discovery?22
This chapter introduces the theoretical and biological background of this thesis. The first
two parts provide the theoretical background of selected topics from computer science and
chemoinformatics. Part three gives experimental and theoretical basics of X-ray crystallography.
The biological background of PPIs and their modulation are content of part four. The family
of 14-3-3 proteins, which serves as an example to study PPIs, is introduced in part five. Each
of these topics forms a wide area of research by themselves. Thus, the single parts only focus
on the topics that are necessary to understand the following chapters.
2.1 Graph Theory
Graph theory is a major research area in theoretical computer science and also in mathematics.
Thus, it is a tremendously wide field and we only introduce the fundamentals necessary to
understand the work presented in Chapter 3. The following content is primarily based on the
textbook by Cormen et al..27
2.1.1 Definition of a Graph
A graph G is a tuple (V, E), where V is a set of vertices with n = |V | members. E is a set of
m = |E| edges. An edge is simply a pair (u, v) with u, v ∈ V and u 6= v, and thus connects a
7
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pair of vertices. Edges can have a direction or they can be undirected. In the latter case, the
incident vertices of an edge form an unordered pair {u, v}. The resulting graph is then termed
undirected, otherwise it is a directed graph. The number of incident edges of a single vertex is
its degree. A path from vertex u to vertex v is a sequence of edges
{u, w1}, {w1, w2}, . . . , {wk−1, wk}, {wk, v} (2.1)
and the connected vertices u and v are called reachable from each other. The length of a path
is the number of edges it spans. If every vertex in a graph is reachable from every other vertex,
the graph is connected. Otherwise the graph is disconnected. A connected and undirected
graph without cycles is a tree. A simple example of an undirected and disconnected graph is
shown in Fig. 2.1.
v1
v2
v3
v4
v5
v6
v7
v8
v9
v10
v11
v12
Figure 2.1: Example of an undirected and disconnected graph with n= 12 vertices and
m= 12 edges. The graph is split up into three connected components.
2.1.2 Connected Components
Connected components (CC) are disjoint subsets of V where all vertices within a CC are
reachable from each other. In contrast, there is no path that connects any two vertices of
different CCs. The size of a CC is its cardinality, that is the number of its member vertices.
The graph shown in Fig. 2.1 consists of three connected components. For the calculation
of CCs in-memory and external memory algorithms have been described.27,28 For our tasks,
we concentrated on in-memory algorithms to avoid hard disk write access. The most basic
in-memory algorithm to solve this problem is a depth-first search and its time complexity is
linear in |V |+ |E|. For huge graphs with millions of vertices and a high average vertex degree
the algorithm can become infeasible due to memory limitations.
If the actual structure of a graph is not important, the CCs can be calculated incrementally
without storing the edges. Such algorithms use union-find data structures, which are disjoint
sets supporting the operations union and find. Initially, every vertex is a CC and E = {;}. An
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edge {u, v} is processed by a find operation, which identifies the representative vertices of
the CCs to which u and v belong. A subsequent union operation concatenates the identified
subtrees, if necessary. By the application of path compression strategies, which try to reduce the
path length of vertices to their CC representative, these algorithms have near-linear runtimes.
2.2 Computational Methods in Drug Discovery
This section introduces selected fundamental concepts of computational methods in modern
drug discovery that is commonly referred to as computer-aided drug design (CADD). We start
with a brief overview on chemoinformatics in general and then describe the relevant theory in
more detail. The second part of this chapter shortly introduces essential theory from structural
bioinformatics.
2.2.1 Chemoinformatics
Chemoinformatics is a research field covering all aspects of information processing, storage
and analysis of druglike molecules. Fundamental tasks comprise the digital representation of
molecules, their comparison and classification, as well as database searching.29,30
Small Molecules
Small molecules – also frequently referred to as compounds – is a rather loose definition,
which comprises stable organic molecules with a molecular weight (MW) roughly lower than
1,000 Da. The basic chemical element of these organic molecules is carbon. Together with
hydrogen, nitrogen, oxygen, phosphorus, and sulfur it builds connected scaffolds that can
contain further elements as substitutes including fluorine, chlorine, bromine and iodine. De-
pending on the elements and their hybridization, two atoms are connected by covalent single,
double, aromatic or triple bonds.
In contrast to biologics, small molecules are with more than 90 % still the most important
active substance of currently marketed drugs.31 It has been observed that approved drugs
form a subgroup of the entire set of small molecules with respect to selected physicochemical
properties. This was first described by Lipinski et al., who analyzed the MW, the number of
hydrogen bond donors and acceptors, and the calculated logP of marketed drugs.32 These
properties are commonly referred to as Lipinski’s Rule-of-Five (Ro5) and they are frequently
used to estimate the oral bioavailability of small molecules.
In Silico Representations
Atoms and the connecting bonds describe the topology of a molecule structure, that is its two-
dimensional (2D) appearance. This information can be described explicitly, for example, by
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the Simplified Molecular Input Line Entry System (SMILES).33 The latter is a chemical language
to store the information in a single string, which can be translated back into a 2D topology.
If the topology of a small molecule is extended by three-dimensional (3D) coordinates for
every atom, the representation is a 3D geometry. The latter enables further representations
like molecular surfaces. Examples for these representations are shown in Fig. 2.2A-C. An
appropriate in silico data structure to map small molecules in 2D and 3D are graphs, where
atoms are stored as vertices and bonds as edges.34 Various properties like atom type, charge
or the bond order can be assigned to vertices and edges.
OP(O)(=O)c1ccc(F)cc1OCC(=O)NC1CCCCC1
1 1 1 0 1 0 1
A B
C D
Figure 2.2: Different representations of a small molecule. (A) SMILES notation. (B) 2D
topology. (C) 3D geometry and solvent-excluded surface (SES). (D) Abstract structural
key fingerprint.
Molecular Fingerprints
In contrast to these explicit representations, molecule structures can be stored in abstract ways,
for example as molecular fingerprints. The most basic fingerprint type is the structural key
and an example is shown in Fig. 2.2D.35 Here, a set of substructural patterns is defined and
small molecules are represented by a boolean array, where every array position indicates the
presence or absence of one of these patterns in the molecule it represents. If a substructure
is present in a molecule the corresponding array position is true (1-bit), otherwise it is false
(0-bit). A drawback of structural keys is their limitation to the set of predefined patterns.
Molecules containing other substructural patterns cannot be described comprehensively by
such fingerprints.
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An advancement of structural keys are hashed fingerprints, which dynamically generate
the set of substructural patterns from a small molecule itself. An example are path-based
fingerprints (PBFP).35 Here, all linear paths up to a predefined length are enumerated and
obtain a unique ID. These IDs are then hashed into fixed-length bit arrays and all hashes
for a single small molecule are combined by bitwise OR. A similar strategy is the extraction
of radial substructures instead of linear paths.36 In contrast to PBFPs, branching patterns
can be captured by this fingerprint type. An example for this type are extended-connectivity
fingerprints (ECFP).37
The density of fingerprints describes the fraction of 1-bits.35 The fingerprint types tend to
yield different densities. Structural keys and PBFPs tend to result in a higher density, whereas
ECFPs are of low density.
A further level of abstraction can be achieved by introducing different atom descriptions.
Frequently used descriptions are force-field-based atom types or the generalization of explicit
atom types by pharmacophoric features like hydrogen bond donor and acceptor, hydrophobic,
aromatic or charged.
Chemical Similarity
A commonly used technique to express the similarity between a pair of small molecules is to
compare their substructural compositions. As described in the previous subsection the latter
can be encoded by 2D fingerprints, where a distinct position indicates the absence (0-bit)
or presence (1-bit) of a substructural element or a higher order feature of the corresponding
molecule. To compare the substructural compositions of a molecule pair, two important param-
eters can be calculated from their fingerprints. First, the number of 1-bits of every fingerprint
itself is calculated, which is computationally easy and has to be done only once. Second, the
number of shared 1-bits of a fingerprint pair is calculated, which is used as an estimate for their
substructural overlap. This shared feature count is individual for every fingerprint pair and is
a computationally quite demanding task. Based on these simple parameters various related
similarity and dissimilarity coefficients have been defined. One of the most intensively stud-
ied and frequently used similarity measures in chemoinformatics is the Jaccard or Tanimoto
coefficient STan:
38,39
STan =
c
a+ b− c (2.2)
Here, a is the number of 1-bits in fingerprint A, b is the number of 1-bits in fingerprint B and
c is the number of shared 1-bits of A and B. The Tanimoto similarity is a metric and has a co-
domain of [0.0, 1.0]. STan = 0.0 indicates two maximal dissimilar fingerprints and STan = 1.0
two identical fingerprints. It is important to mention that STan = 1.0 does not imply identity
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of the underlying molecules in general. As already mentioned, the computational challenge
of all similarity and dissimilarity coefficients based on these parameters is the calculation of
the number of shared 1-bits, c. In set notation, the number of shared 1-bits between two
fingerprints A and B can be expressed as
c = |A∩B| (2.3)
and, for this reason, the calculation can be split up into a binary AND operation of A and B
followed by counting the 1-bits in the resulting array. Different strategies and algorithms have
been developed to calculate c efficiently. In Chapter 3, we present an algorithm we developed
as the core part of a clustering method and we give an overview of existing solutions and
applications.
Clustering
Clustering – or cluster analysis – in general is an unsupervised data mining technique aiming
at splitting up a set of input objects into multiple groups, thereby maximizing inter-object
similarities within the generated groups. Various clustering approaches have been described
and only a subset of them is frequently used in chemoinformatics, whereat all have different
strengths and weaknesses.40 The methods can further be classified as shown in Fig. 2.3
Nearest NeighborRelocationSingle Pass
Important Chemoinformatics
Clustering Methods
Non-Hierarchical Hierarchical
Agglomerative Divisive
Leader k-Means Jarvis-Patrick Ward, Average Linkage MacNaughton-Smith
Figure 2.3: Classification schema of clustering methods. For every clustering strategy,
examples are given that are frequently used in chemoinformatics.
Non-hierarchical methods yield a flat clustering, which is the result of only grouping input
molecules without giving information on the relationship of the clusters. The relocation
method k-Means starts by randomly selecting c molecules as initial cluster centers.41,42 In
an iterative procedure the remaining compounds are added to the cluster with maximum
similarity to the center and subsequently the cluster centers are reassigned to the member
with highest mean intra-cluster similarity. These steps are repeated until the cluster assignment
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is stable. An advantage of this method is the ability to process large compound libraries due to
its speed. The major disadvantages are the need to initially select the number of final clusters
and, especially, that this selection process is generally random.
An example for a single-pass clustering is the Leader algorithm.43 A similarity threshold
and an initial starting molecule has to be chosen. Now, all molecules of which the similarity to
the selected molecule exceeds the threshold are added to this cluster. If unassigned molecules
are left, a new reference molecule is chosen in a subsequent assignment step. This is repeated
until all molecules are assigned to a cluster. Here, the computational efficiency is again the
advantage of this method. However, its major drawback is the outcome’s dependency on the
ordering of the input data.
The nearest neighbor method Jarvis-Patrick is also frequently used in chemoinformatics.44
This method takes the two parameters j and k as input. For every molecule, the j nearest
neighbors are calculated. Two molecules are clustered together if they are vice versa members
of their j nearest neighbors and if they have k of their nearest neighbors in common. Again,
the advantage is the computational speed. However, choosing appropriate values for j and k
is difficult. Furthermore, Jarvis-Patrick clustering often produces few large clusters and has a
high singleton rate.45
Hierarchical clustering methods can be subdivided into agglomerative and divisive tech-
niques. Agglomerative ones iteratively cluster the initially unassigned input data by binary
merge steps of next nearest neighbors. In contrast, divisive techniques start with one single
cluster comprising all input molecules and divide it by iteratively splitting up clusters. As
the agglomerative methods are mostly used in chemoinformatics we will briefly introduce
their main representatives, namely the Ward method and Average Linkage.40,46 Both methods
are based on the same algorithm, but differ in their definitions of similarity between objects.
Starting with an unclustered input data set, the most similar molecule pair is merged into a
new cluster. Recalculation of the similarity of the newly formed cluster to all other objects and
again merging the most similar pair is repeated until only one cluster is left. In the case of
Average Linkage, the similarity between two clusters is the average similarity of all inter-cluster
molecule pairs. The Ward method tries to minimize the increase in variance when merging
two clusters. To create a final cluster assignment the hierarchical clustering tree has to be
cut at a certain level, which is a disadvantage of these methods. Due to a space complexity
of O(N2) and a time complexity of O(N3), naive implementations of hierarchical methods
are infeasible for large data sets. This fact is their major disadvantage. However, in their
performance to cluster related molecules together the hierarchical methods have been shown
to perform better than Jarvis-Patrick, which is routinely used for large data sets.47,48
13
2. Background
Molecular Scaffolds
The scaffold of a small molecule can be described as the core moiety, which confers the
molecule’s 3D geometry. However, various scaffold definitions have been proposed and even
medicinal chemists have diverging opinions on how to define a molecule’s scaffold. The most
important formal scaffold definitions were introduced by Bemis and Murcko as well as by
Schuffenhauer et al..49–51
Both methods distinguish between atoms of the molecular framework – the scaffold –
and side-chain atoms forming the decoration. The basic definition treats all atoms within
cycles as part of the framework as well as all atoms lying on a direct path between cycles.
Additionally, direct neighbors of these atoms belong also to the framework if the connecting
bond order is greater than one, because bonds with these hybridization states contribute to the
molecule’s rigidity. The remaining atoms form side-chains. An example for a small molecule
and its Murcko scaffold is shown in Fig. 2.4. The method of Schuffenhauer is called scaffold
tree. It fragments a small molecule in a hierarchical way according to a set of meaningful
chemical rules. The first step also removes decorations and thus yields a Murcko scaffold.
Every further step removes one ring system and finally leaves a single ring at level 0. A scaffold
tree decomposition is also shown in Fig. 2.4.
Diazepam Murcko scaﬀold  = Level 2 Level 1 Level 0
Figure 2.4: Scaffold decomposition of Diazepam. This example follows the scaffold
tree rules and produces the corresponding hierarchy levels. The first level above the
native molecule is its Murcko scaffold.
2.2.2 Structural Bioinformatics
In comparison to chemoinformatics, structural bioinformatics also deals with the macromolec-
ular structure of drug targets. These structures are on the one hand used to predict binding
pockets and their druggability. On the other hand they are used to predict the binding of small
molecules to a target’s binding pockets or to simulate and study their flexibility. If no structure
is available, structural bioinformatics also tries to generate suitable models, which can be used
to perform the mentioned tasks.
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Protein-Ligand Docking
In this work we make extensive use of protein-ligand docking and thus give a brief introduction
into it. Protein-ligand docking in general is the prediction of ligand-binding to a target receptor.
In theory, this prediction comprises two interlocked steps, namely docking and scoring. The
docking task is a sampling problem, which has to generate meaningful ligand conformations in
a binding pocket. Various algorithms have been proposed and they differ in several key aspects
like the treatment of ligand and/or receptor flexibility and the algorithms for conformational
searches.52
The scoring has two major tasks: (1) identification of the native protein-ligand conforma-
tion(s) for a single ligand by discriminating ’true’ and ’false’ binding modes. (2) Prioritization
of the ’true’ protein-ligand conformations from different ligands in order to rank them by their
experimentally derived binding affinities. These tasks are accomplished by a so-called scoring
function, which is used to predict the binding affinity of a given protein-ligand complex (e.g. a
docking pose). It evaluates intermolecular interactions and intramolecular terms of a complex
and calculates a score.
Three types of scoring functions can be distinguished. First, empirical scoring functions,
which describe the binding free energy ∆Gbind as the additive contribution of physically moti-
vated energetic interaction terms. The coefficients of such an additive function are empirically
adjusted to fit experimentally determined data sets (complex structures + corresponding bind-
ing affinities) by regression methods. Frequently used energetic terms describe electrostatic,
ionic, aromatic, hydrophobic contacts, and entropic contributions. Examples are the scoring
function developed by Böhm or Friesner.53,54 The second group comprises knowledge-based
scoring functions like Potential of Mean Force or DrugScore.55,56 Here, the probabilities for the
interaction of defined atom type pairs are extracted from structural databases and turned into
pair potentials to score protein-ligand complexes. These scores do not estimate experimental
∆Gbind values but they usually correlate with them. The third type of scoring function is based
on force fields from molecular mechanics. However, this type is not frequently used.
2.3 X-ray Crystallography
Structure-based approaches for the development or improvement of potential therapeutic
agents are heavily based on 3D structures of their target proteins. The predominant techniques
to determine protein structures are NMR and X-ray crystallography. As of April 2013, X-ray
data account for 79,104 (88 %) and NMR data account for 9,892 (11 %) structures in the
Protein Data Bank (PDB) as the central repository for macromolecular 3D structures.
The structures presented in this thesis were all determined by X-ray crystallography. This
technique is based on the observation that X-rays are scattered by atom electrons and that pe-
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riodic 3D arrangements of a macromolecule can lead to an amplification of this signal through
constructive and destructive interference of scattered X-rays. In the following subsections,
X-ray structure determination is described with a focus on protein crystallization, diffraction
experiments and structure determination. The theoretical background is mainly based on the
textbooks of Rupp and Drenth.57,58
2.3.1 Protein Crystallization
A periodic 3D arrangement of a molecule suitable for a diffraction experiment can occur in
crystals. These can be grown in crystallization experiments. Its prerequisite is a sufficient
amount of purified protein, which in general is produced by heterologous expression. The
aim of crystallization experiments is to increase the concentration of a protein in solution up
to a point of supersaturation, where it can undergo transition into solid phase. In case of a
successful experiment, the resulting solid phase is a crystal and not amorphous precipitate.
HD
CB
[Precipitant]
[P
ro
te
in
]
solubility line
decomposition line
metastable 
solution
A B C
Figure 2.5: Crystallization experiment. (A) Hanging-drop crystallization. Crystallization
buffer (CB) in a reservoir. The hanging-drop (HD) is a mixture of protein and crystal-
lization buffer. Water diffuses from the lower concentrated drop into the reservoir. (B)
Crystallization diagram relating protein and precipitant concentration to solution phases.
In the metastable phase, crystal germination and growing can occur. Decomposition is
the process of unstructured phase separation leading to protein precipitate. (C) Protein
crystals of 14-3-3 protein in complex with PPI inhibitor.
The experimental technique we use to grow protein crystals is the hanging-drop vapour
diffusion shown in Fig. 2.5A. Here, a small volume of a crystallization buffer from a reservoir
is mixed to equal amounts with the protein solution. This mixture is positioned on a silicone-
coated glass slide, which hermetically closes the greased aperture of the reservoir. Mixing
reservoir and protein solution yields a lower concentrated protein solution in the hanging-
drop. As a consequence, water diffuses from the drop back into the reservoir, leading to a
volume loss of the drop and thus to an increasing concentration of drop ingredients. The
crystallization buffer is usually a mixture of a buffering component to adjust the pH value, a
precipitant and optional additives. The solution’s pH value influences the charge distribution
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on the protein surface. In a crystal, intermolecular contacts between neighboring proteins are
usually weak and sparsely distributed, making protein crystals unstable. Thus, an appropriate
charge distribution on the protein surface is necessary to enable crystal formation. Precipi-
tants are chemicals that lower protein solubility with increasing concentration. Commonly
used precipitants are salts, organic molecules like polyethylene glycols (PEG) or polyalcohols.
Additives can be in principle all kinds of substances. They are used for optimization in cases
where already identified crystallization solutions lead to crystals with insufficient quality for a
successful diffraction experiment.
The crystallization experiment leads to an increased concentration of drop ingredients,
which at the same time slowly decreases the protein solubility in the drop. These process can
be outlined in a crystallization diagram as shown in Fig. 2.5B. This simplified diagram shows
three protein phases. With increasing concentrations the protein enters a metastable phase,
which separates stable solubility from an unstable phase at high concentrations where protein
spontaneously precipitates. In the metastable phase, the system is not at equilibrium and
supervening kinetic processes can induce spontaneous nucleation events. If such seed crystals
exceed a critical size, further crystal growth can lead to macroscopic protein crystals and can
bring the system back to equilibrium. Successfully grown crystals are shown in Fig. 2.5C. A
successful crystallization condition for a specific protein has to be identified by trial and error.
X-ray irradiation damages proteins by free radical formation leading to defective crystals
and finally can wipe out its diffraction power. This is prevented by cryo-conservation, where
crystals are shock-frozen in liquid nitrogen and diffraction experiments are performed at a
temperature of 100 K.
Protein-Ligand Crystallization
In structure-based drug design, crystal structures of proteins with bound ligands are of high
value. These protein-ligand complexes can be generated by two different techniques, which
are variants of the crystallization protocol described above: (1) by co-crystallization, which
works by adding the ligand to the crystallization buffer. In a successful experiment the ligand
binds to the protein and this complex undergoes crystal formation. (2) By soaking, where
ligand solution is added to drops with existing protein crystals. Under successful conditions
ligand molecules diffuse into the crystals and bind to surface-exposed pockets.
2.3.2 X-ray Diffraction
In a diffraction experiment, a frozen crystal is placed in the path of a monochromatic X-
ray beam in front of a detector sensitive to X-ray photons. After a certain exposure time
and rotation of the crystal a unique diffraction pattern emerges on the detector as shown in
Fig. 2.6C. Depending on the crystal quality, sharp spots of varying intensity become visible.
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They contain information on the crystal’s geometry, its protein content and the resolution of
the 3D structure. X-rays are electromagnetic waves, which can be expressed as complex wave
vectors of the form:
F= Feiϕ (2.4)
with ϕ being the phase angle and F = |F|. The electric field vector of an X-ray wave
interacts with electrons of an atom and the wave is scattered with a certain probability into
a certain direction. This process is specific for the number of electrons and thus for the atom
type. In fact, scattering by atoms is described by the atomic scattering factor fs and can be
calculated by integration over the atoms electron density ρ(r)
fs =
∫ V
r
ρ(r)ei(2piSr)dr =F [ρ(r)] (2.5)
where S is the vector difference of the incoming and scattered wave vector and 2piSr is the
relative phase of a partial wave scattered by a certain part of ρ(r). The right part of Eq. 2.5
indicates that fs corresponds to the Fourier transformation (F ) of the atoms electron density.
This is of great importance for reconstruction of electron density from diffraction data. A
diffraction image is an interference pattern resulting from summing up the scattered X-ray
waves of all atoms in a crystal. The relation of crystal geometry and content to the occurrence,
position and intensity of spots will be described briefly.
A lattice can be imposed on the periodic protein arrangement in a crystal. This crystal
lattice is an infinite stacking of identical points and belongs to one out of six primitive 3D
lattices. Fig. 2.6A shows a 2D projection of a crystal with four unit cells (black lattice). It
also shows a set of imaginary parallel lattice planes (grey), which slice the crystal lattice
into periodic slabs. In principle, an infinite number of such planes can be constructed and
systematically enumerated by so-called Miller indices h, k, and l. These mathematical concepts
enable the interpretation of spots in a diffraction image as reflections of an X-ray wave by
lattice planes. Accordingly, these spots are termed reflexes. A single reflex can be assigned to
a single set of lattice planes. Thus, reflexes are also identified by the Miller indices of their
corresponding lattice planes. The most important equation to relate reflecting positions to
their corresponding set of lattice planes is given by Bragg’s law:
nλ= 2dhkl sinθ (2.6)
Here, n is an integer value, λ is the wavelength of the incoming X-ray beam, dhkl is the distance
of lattice planes (hkl) and θ is half the reflecting angle. A graphical illustration of Bragg’s
law is shown in Fig. 2.6B. Additionally, the equation explains that maximum constructive
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Figure 2.6: X-ray diffraction by a crystal. (A) 2D projection of a crystal consisting of
four unit cells (black lattice). One set of parallel lattice planes (grey) identified by Miller
indices (hkl) with plane distance dhkl . (B) Reflection of an X-ray wave by lattice planes
(hkl) with reflection angle θ illustrating Bragg’s law. The orange lines equal the path
difference ∆ of a wave reflected by two adjacent lattice planes. (C) A diffraction image
with sharp reflexes resulting from maximum constructive interference
interference occurs when the path difference ∆ (orange line) is an integer multiple of the
X-ray wavelength. This is a necessary condition for origination of reflexes and integer values
fulfilling these conditions in all three dimensions can again be interpreted as the Miller indices.
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As already mentioned, the total scattering of a crystal is the sum of all scattering contributions
of atoms in the crystal. This so-called complex structure Fh is calculated as follows:
Fh =
|Atoms|∑
j=1
fs, je
i(2pihx j) ∝pIh (2.7)
where fs, j is the atomic scattering factor of atom j, h the scattering direction as vector of
Miller indices and x j the fractional coordinate vector of atom j in the unit cell. The right
half of Eq. 2.7 indicates that Fh is proportional to the observed intensity Ih of the reflex with
Miller index h= (h, k, l). These fundamental equations can be used to recalculate the electron
density at discrete points in the unit cell from experimentally measured intensities:
ρ(x) =
1
V
∑
h
Fhe
−i(2pihx)+iαh (2.8)
Here, x is a grid point (x , y, z), h the reflex (h, k, l), Fh its structure factor amplitude and αh its
associated phase. This equation points out that the phase angle αh of reflex h in addition to its
amplitude Fh is necessary to reconstruct electron density. However, αh cannot be measured by
X-ray detectors and this information is lost during a diffraction experiment. This fact is known
as the phase problem of X-ray crystallography and different techniques have been developed to
solve it. The next subsection describes the molecular replacement (MR) method, which was
used to solve all crystal structures presented in this thesis.
2.3.3 Structure Determination by Molecular Replacement
The aim of MR is to solve the crystallographic phase problem by using a model structure similar
to the protein of interest to retrieve initial phases. This strategy is based on the observation
that proteins with a sequence homology above ∼ 30 % usually possess a conserved fold. Thus,
if a structural homolog of the crystallized protein is known, its 3D model can be used to
search for suitable arrangements in the unit cell. In a brute force approach, a six-dimensional
search, that is rotation and translation in parallel, could be performed to find an optimal model
placement. The placement quality is measured by correlating observed structure factors (Fobs)
and calculated structure factors (Fcalc) derived from the model.
Due to the combinatorial explosion of brute force MR more efficient strategies are used,
which split the six-dimensional search up into consecutive rotational and translational searches.
Although no structure factors can be calculated directly in the rotational search to score possi-
ble solutions, so-called Patterson functions can be used to identify correct spatial orientations
of the search model. Patterson maps are calculated without phase information and have peak
values at the tips of inter-atomic distance vectors. Additionally, Patterson functions are sym-
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metric to their origin. The latter corresponds to the zero distances of all atom self-bijections.
Rotational search works by calculating the Patterson maps for intramolecular distances from ob-
served data and calculated model structure factors and to search for optimal peak alignments.
The best solutions are forwarded to translational searches, which use intermolecular Patterson
functions to find optimal peak alignments. The top solutions from rotation-translation searches
are optimized by rigid-body refinement and finally yields the MR solutions.
Refinement and Model Building
Initial models from phasing procedures have to be corrected and optimized in an iterative
working cycle. The latter consists of manual model building followed by automatic refinement
of model parameters. Manual model building is performed by adjusting the current model to
electron density maps in cartesian space. This comprises amongst others placement of correct
residues, adapting side-chain conformations, adding solvents or even the rebuilding of whole
domains. Subsequent automatic refinement procedures try to optimize model parameters by
minimizing the target residual (R) functions:
R=
∑ |Fobs − Fcalc|∑
Fobs
(2.9)
where Fobs are the measured structure factor amplitudes and Fcalc are the amplitudes of the
calculated model structure factors. To detect and avoid over-fitting, a subset of usually 5 %
of the measured reflexes is excluded from refinement and used to evaluate the model quality
using Eq. 2.9. The corresponding residual function is termed Rfree and is related to the mean
phase error. In contrast, the reflexes used for refinement yield the crystallographic Rwork.
Atomic Displacement and Occupancy
The arrangement of protein atoms in a real crystal lattice is not strictly periodic because of two
main reasons. First, thermal vibration causes atoms to oscillate around their mean position.
Second, crystal lattices are not perfectly periodic due to protein disorder and imperfect crystal
growth. An important parameter related to this atomic displacement used during refinement
is the isotropic B-factor or temperature factor:
Biso = 8pi
2〈u2iso〉 (2.10)
Biso is the isotropic B-factor and 〈u2iso〉 is the mean square isotropic displacement in Å2 of an
atom from its equilibrium position. Thus, Biso is directly related to 〈u2iso〉.
A further important parameter is atom occupancy, which is influenced by two major effects.
First, solvent content like ligands or ions are not necessarily occurring in all possible positions
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and unit cells. Second, protein parts can have varying positions. Especially amino acid side-
chains can adopt different conformations and the conformation of symmetry related amino
acids follow a typical distribution. This also leads to crystal atom positions that are only
partially occupied. Both effects contribute to the occupancy of an atom, which is expressed as
the fraction of actually occupied positions.
B-factor and occupancy are listed for every single atom in a PDB file and they provide
important information on the reliability of atom occurrence and position.
2.4 Modulation of Protein-Protein Interactions
Figure 2.7: Snapshot of cytosolic protein crowding from a molecular simulation. The
image is a detail taken from McGuffee and Elcock (PLOS Comp. Biol. (2010), 6,
e1000694).59
The human genome has been approximated to contain about 20,500 protein-coding
genes.60 About two-thirds of these proteins are constitutively expressed in human cells and
the fraction of macromolecules in living cells is about 20-30 %.61 The concentration of protein
together with RNA was experimentally determined to be up to 400 grams per liter where
protein makes up 80 % of it.61,62 Thus, the interior of a cell is highly crowded as illustrated
in Fig. 2.7 and as a simple consequence proteins are constantly involved in PPIs. In the recent
past, the modulation of PPIs has been accepted as a possible strategy in drug discovery.22,63
In the following subsections, we will describe the most important characteristics of PPIs rele-
vant for their modulation. Stabilization and inhibition of PPIs are discussed with a focus on
computational approaches.
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2.4.1 Protein-Protein Interactions
PPIs are of fundamental importance for all living organisms. The underlying association of
proteins into functional complexes as well as their dissociation is a highly dynamic process,
which is regulated by various cellular mechanisms as shown in Fig. 2.8A.
Local concentration
Binding energy ΔG
Competition
PPI inhibitor
Stabilization
PPI stabilizer
A B
Interface core
Interface rim
Protomer BProtomer A
Figure 2.8: (A) Important regulatory mechanisms for the association state of interacting
proteins. This equilibrium is regulated by the local concentration of the partners and
their mutual binding affinity. External factors can compete for one partner or stabilize
the complex. This figure is taken from Thiel et al. (Angew. Chem. Int. Ed. (2012), 51,
2012-8).22 Reproduction is granted under license number 3274110722038 of John Wiley
and Sons. (B) Schematic representation of a binary heterooligomer.
Classification of PPIs
PPIs are reversible assemblies of protein subunits – so-called protomers –, which form the
quaternary structure of proteins. Depending on their composition, PPIs can be classified
into homo- and heterooligomers. Homooligomers are built up of identical subunits whereas
heterooligomers consist of at least two different protein subunits. Furthermore, protein com-
plexes are classified by their lifetime into permanent and transient PPIs. In permanent PPIs,
protomers have a high binding affinity to each other and these complexes are often obligate.64
Depending on the protomers’ binding affinity, transient comlexes are sub-divided into
strong and weak transient PPIs. The oligomerization state of proteins is mainly determined
by the mutual binding affinity and the local concentration of the protomers. The binding
affinity is influenced by the physicochemical environment like the pH or the ionic strength on
the one hand and by posttranslational modifications of the protomers like phosphorylation or
methylation on the other hand as illustrated in Fig. 2.8A. The local concentration of protomers
is influenced by a variety of factors like co-expression, compartmentalization or degradation.
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Structure of PPIs
According to the O-ring model proposed by Bogan et al., we will further refer to the interface
core as the surface residues losing their solvent accessibility upon complex formation and to
the interface rim as the surface residues in close proximity to the interface core.65,66 Fig. 2.8B
schematically illustrates this classification. A lot of work has been spent on analyzing PPI
interfaces and the results vary. A comprehensive overview can be found in the review of
Janin et al..67 The size of interface cores ranges from patches < 1, 000 Å2 buried surface area
(BSA) to large cores with > 10,000 Å2 BSA with a mean value of ∼ 1,910 Å2. The interface
cores have been described to be rather flat.68 Conformational changes in the protomers upon
complex formation are more frequent for larger interfaces. These changes range from small
variations to whole domain movements. In interface cores, the contribution of single residues
to the binding free energy ∆Gbind is not equally distributed. So-called hotspot residues con-
tribute significantly to complex stability.65 Furthermore, interface cores show enrichment in
aromatic and aliphatic residues and especially of arginine, which makes up 10 % of core and
rim residues.
2.4.2 Inhibition of Protein-Protein Interactions
The inhibition of PPIs is considered a promising strategy for the development of drugs for
various kinds of diseases.20,63 However, it turned out that the experimental discovery of PPI
inhibitors is quite challenging. Classical techniques like HTS yield low hit rates probably
because current screening libraries are biased towards enzymatic active site inhibitors.21 It
has been observed that the latter markedly differ from known PPI inhibitors.69 Thus, in silico
approaches can offer beneficial alternatives to identify interaction inhibitors. As described
previously, PPI epitopes are quite large, often feature multiple shallow pockets with distinct
hotspot residues and they can undergoe conformational changes to different extends. These
characteristics make the direct application of standard in silico protocols and tools difficult
and requires the development of new tools or the adaption of standard protocols.70 Due to
the currently limited number of known inhibitors for a single PPI target, most approaches
developed so far are based on the analysis of PPI crystal structures.71
A successful example for the computer-aided development of novel inhibitors of the tran-
scription factor and tumor-suppressor p53 and mouse double minute 2 homologue (MDM2),
which increases the degradation of p53, was reported by Czarna et al..72 They identified a
tryptophan residue in p53, which is located in the center of the PPI and intrudes deeply into
MDM2. Using this residue as an anchor, they constructed a virtual compound library based on
an indole scaffold and its bioisosters. Protein-ligand docking led to the identification of MDM2
binders that are able to disrupt the p53◦MDM2 complex.
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A similar example was published by Koch et al. who identified inhibitors of the thioredoxin
reductase interaction with its substrate thioredoxin from Mycobacterium tuberculosis.73 Com-
plex structure analysis led to the identification of a distinctive sequence patch with prominent
interactions as constraints for docking a large compound library with low accuracy. Subsequent
filter steps and more accurate redocking yielded active PPI inhibitors.
In principle, these examples make use of a single crystal structure, which can be regarded
as one representative conformational snapshot of a flexible and dynamic system. Thus it
is possible that conformations of non-complexed proteins deviate significantly from their
conformation in complex. This would invalidate any binding or pharmacophore hypothesis.
Nevertheless, small molecules can bind to a protein by trapping a conformation which is
different from that observed in the complexed form as shown for a small molecule inhibitor
of Bcl-XL, which normally binds and inactivates the pro-apoptotic BAD protein.
74 To tackle
this problem in silico, Eyrisch and Helms developed a molecular dynamics (MD) simulation
protocol to analyze for the occurrence of transient surface pockets, which can be addressed
with standard tools.75 In the case of Bcl-XL, they also demonstrated accurate redocking of a
known ligand into a transient pocket derived from MD simulation.
2.4.3 Stabilization of Protein-Protein Interactions
The stabilization of PPIs by small molecules is still in its infancy and not as well established
as PPI inhibition. The basic principle of PPI stabilization is to enhance the binding affinity of
interacting proteins. Fig. 2.9 illustrates this mechanism. Here, ligand L serves as molecular
glue and binding to the PPI leads to a decrease in apparent binding energy ∆GAB.
Two general modes of action can be observed for PPI stabilizers. First, a stabilizer can
bind to a single protein partner, thereby increasing the mutual binding affinity of the protein
partners in an allosteric fashion. Second, the stabilizing molecule binds to the interface rim
of a protein complex, making contacts to both protein partners thereby decreasing the mutual
binding energy as well. Correspondingly, we termed the different types allosteric (one protein
partner) and direct (at least two protein partners) PPI stabilizers, respectively.
Allosteric Stabilization
Allosteric PPI stabilization has so far been described only for the interaction of the α- and
β-tubulin heterodimer. The α◦β-heterodimers assemble to linear protofilaments and form
cylindrical polymers – the Microtubules (MT). MTs have important functions in non-dividing
and dividing cells. To fulfil the different tasks, MTs have to be permanently rearranged
by continuous polymerization and depolymerization.76 Disturbing this process has severe
consequences for a cell, particularly during division, where MTs form the mitotic spindle
apparatus that segregates the chromosomes.77 Several natural products and derivatives induce
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Figure 2.9: Schematic illustration of direct PPI stabilization.
cell cycle arrest by modulating MT polymerization and depolymerization leading to severe
cellular disturbances and even to apoptosis. Thus, some of these molecules are used as
antimitotic agents and belong to the most important drugs in the treatment of cancer.78 One
of the most intensely studied MT stabilizers is paclitaxel, which is isolated from the bark
of Taxus brevifolia.79 It binds with high affinity to a hydrophobic pocket of MTs, which is
exclusively located on the β-subunit and thereby allosterically stabilizes the MT.80
Direct Stabilization
If a stabilizing small molecule simultaneously contacts multiple chains of a PPI, the mechanism
is termed direct stabilization.22 This can be further split up in two different modes of action.
First, the stabilizing molecule binds to one of the proteins and creates an interaction surface for
the second protein. This stabilizing effect can be so strong that dimerization of two proteins
can be induced, even though they do not bind to each other in the absence of the ligand.
This extreme case has been observed for the FKBP binding molecules FK506 and rapamycin
and will not be further discussed.81 The second mode of action is characterized by binding
of a ligand to the interface rim of a PPI, thereby increasing the apparent PPI binding affinity.
Three impressive examples are the natural products fusicoccin A (FSC), brefeldin A (AFB) and
forskolin (FOK), which are illustrated in Fig. 2.10A-F.
FSC is a metabolite from a wilt-inducing fungus. Studies on the molecular target resulted
in the identification of a complex between the regulatory domain of the plasma membrane H+-
ATPase 2 (PMA2) and 14-3-3 adapter proteins.82 FSC binds to the interface rim of this complex
and enhances the apparent affinity of the proteins about 90-fold.83 It fills a hydrophobic gap
in the interface of the two proteins. A central terpene ring is deeply buried in a funnel-
like pocket formed by 14-3-3 and the absolute C-terminus of PMA2. Two chemically diverse
compounds, unrelated to FSC, were identified as stabilizers of 14-3-3◦PMA2 in an HTS.25
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Figure 2.10: Examples of stabilized PPIs. Ligands are represented as ball-and-stick
models and a semitransparent SES. (A) Binary complex of 14-3-3 protein (gold SES) and
C-terminal domain of PMA2 (green SES). The FSC pocket is highlighted in blue. (PDB
ID: 2o98) (B) FSC bound to the binary 14-3-3◦PMA2 complex. (C) Section through the
complex of ARF1 (gold SES and cartoon) with a bound GTP analogue (stick model) and
a Sec7 domain (green SES and cartoon). (PDB ID: 1r8q) (D) AFB deeply buried in the
interface rim pocket. (E) Catalytic subunit of AC with bound ATP analogue (stick model).
The C1a domain (green SES) and C2a domain (gold SES) are shown together with the
FOK. (PDB ID: 1cju) (F) FOK bound to the interface rim pocket. This figure is taken from
Thiel et al. (Angew. Chem. Int. Ed. (2012), 51, 2012-8).22 Reproduction is granted under
license number 3274110722038 of John Wiley and Sons.
27
2. Background
Both compounds bind to distinct pockets in the interface rim. The dipeptide epibestatin binds
to a narrow surface cleft and is tightly sandwiched between the two proteins. The molecule
interacts to equal parts with 14-3-3 and PMA2. A trisubstituted pyrrolidone occupies a more
solvent-accessible site which substantially overlaps with the pocket of FSC.
The fungal metabolite AFB potently inhibits protein secretion by stabilizing the complexes
of the small guanine nucleotide-binding protein ADP ribosylation factor 1 (ARF1) and several
guanine nucleotide exchange factors like Sec7.84 This leads to blockage of the GDP-GTP
exchange activity of Sec7 and ultimately results in impairment of Golgi function.85 The crystal
structure of the ARF1-GDP◦Sec7◦AFB complex shows that AFB is deeply buried between the
two proteins.86,87 AFB binding is mostly hydrophobic in nature with few additional polar
contacts. Ligand binding leads to 10-fold stabilization of ARF1-GDP◦Sec7. AFB exclusively
binds to the ternary complex and no binding to ARF1-GDP or Sec7 alone has been observed.88
FOK is a cardioactive and blood-pressure lowering plant metabolite. Its molecular mecha-
nism is a reversible increase of adenylyl cyclase (AC) activity, resulting in significant increase of
cAMP levels in various tissues.89 AC is a transmembrane protein with the cytoplasmic domains
C1a and C2a forming the catalytic core.
90 FOK increases the apparent affinity of these subunits
from a KD > 10 µM down to 1 µM and results in a 60-fold enhanced catalytic activity of AC.
91
FOK binds to a deep and primarily hydrophobic pocket terminating a long cleft in the interface
rim of the C1a◦C2a dimer. It shares equivalent contacts to both protomers, buries ∼ 90 % of
its accessible surface and closes a hydrophobic pocket between the subunits.92,93
Computational campaigns to discover PPI stabilizers are rare and the published examples
are described in Chapter 5, where we present our approaches to identify stabilizers in silico.
2.5 The Family of 14-3-3 Proteins
For our attempts to identify PPI modulating small molecules in silico, we used human 14-3-3
proteins as a model system. These proteins are versatile molecular adapters and their main
function is to bind other protein partners. Several 14-3-3 PPIs have been shown to be related
to diseased cellular states where PPI inhibition or stabilization with small molecules could be
a valuable concept for therapeutic intervention. The following subsections briefly describe the
physiological functions, the structure and the mode of action of 14-3-3 proteins.
2.5.1 Physiological Functions
Discovered in 1967, 14-3-3 proteins owe their name to the chromatographic fraction number
(14) and the 2D electrophoretic coordinates (3,3) they were isolated from.94 The homologous
family of 14-3-3 proteins is conserved in all eukaryotes. In mammals, the seven homologs
β (α), γ, ε, η, σ, τ (Φ) and ζ (δ) are ubiquitously expressed. However, different tissues show
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varying expression patterns of these homologs.95 With an average sequence identity of 46 %,
the human homologs are highly conserved as shown in Fig. 2.11.
The basic task of 14-3-3 proteins is binding to other proteins. Up to date, more than
140 human binding partners have been identified.96 Almost all of these partners bind phos-
phorylation dependent to 14-3-3 . The phosphorylated residue is either a serine or a thre-
onine.97 Additionally, a few target proteins have been identified where binding to 14-3-3 is
phosphorylation-independent.98–100 14-3-3 proteins do not exhibit an intrinsic enzymatic ac-
tivity. 14-3-3’s activity becomes manifest in influencing the subcellular localization or the
co-localization with other proteins, or the conformation of their partner proteins.101
Due to these versatile roles and number of targets, 14-3-3 proteins directly or indirectly
take part in the regulation of all major cellular processes including cell-cycle, transcription,
protein biosynthesis, signal transduction, and apoptosis.97,105,106 Thus, various diseases are
linked to the 14-3-3 interactome and PPIs within this network are considered potential tar-
Figure 2.11: Multiple sequence alignment (MSA) of the human 14-3-3 homologs. The
top line marks the secondary structure elements (coils and turns: grey line, α-helices: blue
bars). The bottom line assigns conservation information (entirely conserved: ’*’, amino
acids with same size and hydropathy: ’:’, amino acids with comparable size or evolutionary
preserved hydropathy: ’.’). With the exception of the C-terminal coil 14-3-3 proteins are
highly conserved. The MSA was generated with T-Coffee (version 8.14) accessed through
the Bioinformatics Toolkit of MPI Tübingen.102,103 Secondary structure annotation was
added manually based on the UniProt entry of 14-3-3ε (Accession: P62258).104
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gets.107 In the following, three 14-3-3 PPIs are shortly described to exemplify the function of
14-3-3 proteins and their potential medical relevance.
Influencing the subcellular localization by 14-3-3 has been shown for many binding part-
ners. For example the human protein kinase C-Raf is a central element of the Ras-Raf-MAPK
pathway, which couples extracellular signals to transcriptional regulation.108 Phosphorylation
of C-Raf at Ser259 enables binding to 14-3-3 and inhibits the recruitment of C-Raf to the
plasma membrane, thereby suppressing MAPK downstream signaling.109 Interestingly, C-Raf
mutations clustering around Ser259 lower its affinity to 14-3-3, which results in constitutively
increased downstream signaling.110 These mutations are frequently found in patients suffering
from Noonan syndrome, a severe developmental disorder. Thus, the PPI of 14-3-3 and mutated
C-Raf forms a promising stabilizer target for this disease.
Promoting the co-localization of two proteins which do not interact directly is another
function of 14-3-3. This mechanism has been observed for several kinases and their protein
substrates where 14-3-3 brings enzyme and substrate in spatial proximity. An interesting
example is the phosphorylation of the tau protein. Tau is an MT-associated protein in neural
tissues with various functions and multiple phosphorylation sites.111 Glycogen synthase kinase
3β (GSK3β) is one of the kinases phosphorylating tau. However, phosphorylation is mediated
by binding of both proteins to 14-3-3 .112 Tau itself has been found to accumulate in various
neurodegenerative disorders like Alzheimer’s disease and is discussed as a possible target for
treatment of these disorders. As phosphorylated tau also binds directly to 14-3-3 , various
starting points for beneficial PPI modulations are possible.113
The change of a protein’s conformation upon 14-3-3 binding can lead to a modulated en-
zymatic activity. An example for this mechanism forms the arylalkylamine N-acetyltransferase
(AANAT). This enzyme plays a central role in the circadian rhythm and its activity positively in-
fluences the production of melatonin.114 Binding of phosphorylated AANAT to 14-3-3 stabilizes
a protein conformation which increases the enzymes affinity to its substrate.115 Imbalanced
melatonin production has been found to be involved in various diseased states like metabolic,
sleep or mood disorders.116,117 Thus, stabilization or inhibition of the 14-3-3◦AANAT PPI could
possibly serve as a strategy for drug intervention.
2.5.2 Structure and Mode of Action
The size of 14-3-3 monomers ranges between 25-30 kDa and their physiological assemblies
are homo- as well as heterodimers. An important consequence of 14-3-3’s dimeric assembly is
the possibility to bind two phosphorylation sites of a single protein simultaneously. This has
been described for multiple 14-3-3 target proteins including C-Raf.118,119 On the one hand,
synergistic binding increases the overall binding affinity of 14-3-3 to its target. On the other
hand, dual binding sites enables fine-grained pathway regulation.
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Figure 2.12: Structure and conservation of mammalian 14-3-3 proteins. (A) One
14-3-3 dimer is shown in cartoon representation colored by residue index (red: N-
terminus, blue: C-terminus, H: helix). The spheres indicate the amphipathic groove,
which is enclosed by helices 3, 5, 7, and 9. (B) One 14-3-3 monomer represented by it’s
SES and colored by residue conservation of all mammalian homologs. (grey SES: 0 %
conservation, red SES: 100 % conservation) The arrow direction indicates the course of
partner proteins from N- to C-terminus.
The crystal structures of all human homologs have been solved and possess the same
fold. The average pairwise root-mean-square deviation (RMSD) of the Cα backbone is 0.74 Å.
Fig. 2.12 shows different representations of 14-3-3σ. Fig. 2.12A represents a typical W-like
shaped 14-3-3 dimer and the monomer in cartoon representation shows 9 constitutive anti-
parallel α-helices (H1-H9). The most important structural feature is a longitudinal amphi-
pathic groove enclosed by H3, H5, H7, and H9, which spans the entire protein. The amino
acid variability on the 14-3-3 surface is not equally distributed (Fig 2.12B). A mapping of
the amino acid conservation onto the protein surface shows no variability in the amphipathic
groove. The highest variability can be observed on the outer surface. The flexible C-terminus
is not resolved in the crystal structure.
The amphipathic groove forms the functional unit of 14-3-3 proteins because the partner
proteins bind into it. Due to its narrow shape, no secondary structure elements like α-helices
or β-sheets fit into the groove and partner proteins bind via elongated sequence stretches.
As mentioned before, the most important characteristic of almost all binding motifs is a
phosphorylated serine or threonine residue. Typically, the binding sequences of known binding
partners are classified into one out of three different binding motifs listed in Table 2.1. The
mode I and II motifs are mainly characterized by a proline at position +2 relative to the
phosphorylated residue.120,121 In most binding partners, these prolines induce a bend, forcing
the sequence out of the amphipathic groove. Mode III motifs are characterized by their
location at the very C-terminus of the partner proteins with only one residue following the
phosphorylation site.122
It is noteworthy to mention that these motifs were defined at an early point in 14-3-3 re-
search on the basis of only a fraction of the binding partners known today.96 Thus, a lot of
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Table 2.1: 14-3-3 consensus motifs. X indicates a variable position, pi indicates aromatic
amino acids and COOH marks the C-terminus.
Motif Consensus sequence
−4 −3 −2 −1 +1 +2
Mode I R S X [pS|pT] X P
Mode II R S pi X [pS|pT] X P
Mode III [pS|pT] X COOH
binding sequences discovered later on do not fit into one of these historical classes like the yes-
associated protein (YAP), which spans the entire binding groove or the cyclin-dependent kinase
inhibitor 1B where the phosphorylated residue itself forms the C-terminus.123,124 Structural
details of the binding geometry surrounding the phosphorylation site are discussed more
detailed in Chapter 6, where it forms the basis for development of a VS approach in order to
identify 14-3-3 PPI inhibitors.
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Chapter 3
Deterministic Clustering of Large
Chemical Spaces
The content of this chapter is an extended version of the article:
Blocked Inverted Indices for Exact Clustering of Large Chemical Spaces.125
3.1 Introduction
As described in Section 2.2.1, clustering is one of the most important tasks in chemoinformat-
ics. It has manifold applications in theoretical and in experimental setups. Various methods
have been developed to address this problem and the most frequently used are agglomerative
hierarchical variants and the non-hierarchical methods k-Means and Jarvis-Patrick. A major dif-
ference between these hierarchical and most non-hierarchical methods is that non-hierarchical
ones take all pairwise molecule similarities in a data set into account. The non-hierarchical
methods prevent the calculation of the entire similarity matrix at the cost of also not be-
ing deterministic. This is especially true for k-Means but not for naïve implementations of
Jarvis-Patrick. However, to gain efficiency, the latter approach often uses non-deterministic
heuristic algorithms for nearest neighbor calculation to explicitly avoid all pairwise similarities
calculations.126
In contrast, the advantage of being deterministic due to complete similarity matrix calcu-
lation makes the hierarchical methods quite inefficient and computationally demanding with
respect to time and memory requirements. Even when using sophisticated algorithms, the
upper limit of input data sets for hierarchical methods lies in the order of 106. As a conse-
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quence, the methods of choice for clustering larger compound libraries based on 2D fingerprint
similarities are still k-Means and Jarvis-Patrick.
Bearing in mind that the size of chemical libraries comprising commercially available
compounds already exceeds 30×106 compounds and that systematically generated chemical
space with more than 109 compounds even is three orders of magnitude larger, it is highly
desirable to develop novel deterministic and efficient clustering methods, which are capable of
processing data sets of such dimensions.127,128 A key step to such efficient clustering methods
is the availability of fast algorithms to calculate 2D fingerprint similarities like the already
introduced Tanimoto coefficient. A naive implementation to calculate the similarity matrix
leads to an algorithmic complexity of O(n2), where n is the number of input molecules and
thus is not well suited for huge data sets. After a long period of stagnated algorithmic progress
in this field, novel and interesting approaches were presented in the recent past (see also
subsection on related work below).
Goals of the Project
In the present work we introduce a deterministic approach to cluster very large chemical
spaces comprising tens of millions of compounds. To handle such huge data sets we developed
a fast and flexible algorithm for high-throughput calculation of all pairwise similarities of an
input compound library based on the concept of inverted index data structures (iiDS). An
overview of our clustering workflow is shown in Fig. 3.1 and it is described in the following.
The first step shown in Fig. 3.1A makes use of a non-uniqueness property of binary fin-
gerprints. This is a consequence of the feature generation from substructural patterns, which
normally do not encompass an entire molecule. Based on this intrinsic property duplicates
of fingerprints are identified and removed in order to reduce the total number of similarities,
which have to be calculated in subsequent steps.
Fig. 3.1B shows the second step, which performs a preliminary grouping of the remaining
and unique fingerprint set. The basic concept used for this purpose is CC decomposition
as described in Section 2.1.2. In our case, every molecule or its corresponding fingerprint
represents a graph vertex and an edge between two vertices represents the similarity between
the fingerprints of its incident vertices. Due to the symmetry of the Tanimoto coefficient, all
edges and thus the graph, are undirected. Initially, the set of edges is empty and edges are
gradually inserted into the graph during this step. For this purpose, all pairwise similarities are
calculated using our efficient algorithm and all vertex – or molecule – pairs with STan ≥ SCutTan
are connected by a newly added edge. Here, the adjustable parameter SCutTan is a lower similarity
cutoff to discard molecule pairs with too low similarity. Up to this point, this step yields a
similarity network, which contains only a subset of all possible edges. Depending on the
choice of SCutTan, the generated network is disconnected and CCs can directly be calculated. The
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Figure 3.1: Clustering method schema. (A) Removal of duplicates and creation of a
unique set of input fingerprints. (B) Calculation of all pairwise Tanimoto similarities and
construction of a similarity network by applying a similarity cutoff to retrieve the induced
CCs. The right half sketches the CCs decomposition using blocked inverted indices via
construction of the complete similarity matrix. (C) Application of hierarchical clustering
on large CCs. (D) Remapping of fingerprint duplicates onto clusters containing their
representative fingerprint.
applicability of CC decomposition as a feasible strategy to cluster chemical libraries has been
shown by Zahoránszky et al..129
The third step shown in Fig. 3.1C performs hierarchical clustering of every CC, which
exceeds a predefined size. As hierarchical clustering we have implemented the agglomerative
average linkage method for three reasons. First, the method was shown to perform well for
clustering of chemical databases.47 Second, the average linkage method is compatible with
our algorithm for fast similarity calculation. Third, efficient algorithms have been described
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for average linkage clustering. Finally, a cluster assignment is generated using automatic level
selection for cutting the clustering hierarchy.
In the fourth step shown in Fig. 3.1D, a representative molecule for every cluster is cal-
culated. Again, we use our fast similarity calculation method for this purpose. Finally, the
duplicate fingerprints that were removed in step one are merged into the clusters containing
their representative fingerprint.
To demonstrate the performance of our clustering method, we process the available chem-
ical space on a current compute server. We compare our fast similarity calculation algorithm
as well as the clustering method to state-of-the-art implementations and tools. Furthermore,
we present a detailed analysis of the advantages and disadvantages of inverted index methods
for 2D fingerprint similarity applications, especially its hardware demands, and compare it to
hardware-accelerated approaches.
Related Work
The calculation of molecular similarity on the basis of 2D fingerprints has been in the focus
of several studies while this thesis was in progress. Recently published solutions for chemoin-
formatics applications tackle this problem in two different ways. On the one hand by using
specialized machine-dependent instructions on hardware level and on the other hand by algo-
rithms using iiDS.30
Hardware-Accelerated Methods. The problem of counting the number of 1-bits in an ar-
ray is well known and often referred to as the population count (popcount) of an array. Its
efficient solution is of such high importance that recent instruction set extensions of mod-
ern CPUs (for example SSE4.2 of Intel) and modern GPUs introduced this operation as a
single-cycle instruction on hardware level. Haque et al. described a thoroughly implemented
popcount-based method and a combination with cache-efficient strategies, which show im-
pressive performances.130 Nevertheless, the described cache-efficient version only provides
advantages when calculating highly regular data structures like similarity matrices. Further-
more, the performance of popcount methods drop with increasing fingerprint sizes as will be
shown in the results section of this chapter.
Inverted Index Methods. The iiDS arose from the field of information retrieval and is used as
a technique to encode text documents for subsequent similarity calculations.131 Its relationship
to tasks in the field of chemoinformatics has recently been described by Nasr et al..132 They
used iiDS based similarity calculations as one key element to speed up similarity searching.
An inverted index algorithm to accelerate LINGO similarity calculations has been described by
Kristensen et al..133 However, this work also focused on speeding up similarity searching. Our
work is based on an initial inverted index implementation developed by Lisa Peltason within
the scope of her Studienarbeit in the group of Prof. Dr. Oliver Kohlbacher.134
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3.2 Materials and Methods
This section first describes implementation details of our iiDS algorithm for fast 2D fingerprint
similarity calculation. It is followed by implementation details of the single steps of the
outlined clustering workflow. Finally, we give detailed information on employed software,
hardware and data sets for software development, evaluation, and benchmarking.
3.2.1 Implementation Details
The software we developed is implemented in the object-oriented programming language
C++ and is incorporated into the structural bioinformatics framework BALL (Biochemical
Algorithms Library).2
B CA
fn-1fn f3 f1
M1 M2
M2
M1 M2
0
M3 M3
M4
M4 M3 M3
M4
0fn fn-1 fn-2 f2 f1
10 0 0 0M1 1
10 0 1 0M2 1
B1 . . .
01 0 1 1M3 1
00 0M4 1 1 1
B2 . . .f1 f2 f3 fn-1fn-2 fn
f1 f2 f3 fn-1fn-2 fn
Sp
lit m
o
lecu
les 
in
to
 b
lo
cks
B
u
ild
Inverted
 In
d
ex
fo
r every b
lo
ck
M1 M2
M3
M4
1 2
1 0
B1:B2M1 M2
M1
M2
- 1
- -
B1:B1 M3 M4
M3
M4
- 2
- -
B2:B2
D
10 0 0 0M1 1. . .
10 0 1 0M2 1 . . .
01 0 1 1M3 1 . . .
00 0M4 1 1 1. . .
Figure 3.2: Blocked inverted index algorithm. (A) The input data set is split up into
equally sized blocks. (B) A block is a matrix where every row is a single fingerprint
and columns are fingerprint features. (C) For every block a single iiDS is generated.
(D) Pairwise comparison of all blockwise iiDS enables efficient shared feature count
calculation.
Blocked Inverted Index Algorithm
A major aim was to develop a pure algorithmic solution for the problem of 2D binary fingerprint
similarity calculation with no need for specialized hardware. We thus used the concept of iiDS
for our similarity calculation and developed an improved and flexible algorithm for pairwise
similarity calculations. A simplified overview is shown in Fig. 3.2. As shown in Fig. 3.2A, the
algorithm takes as input a set of molecules encoded as 2D fingerprints. Internally, fingerprints
are represented as feature lists, which is a list of the 1-bit array indices or higher order
substructure hashes. Fig. 3.2B illustrates the key idea of our algorithm, which is to split
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the input molecules up into blocks of equal size. The block size is a critical parameter to
the algorithm’s performance as shown in the results section. We thus call our algorithm the
blocked inverted index (bII) method. If the input library contains n fingerprints and a block
size of sb is chosen, we generate a set of blocks B with
m= |B|= d n
sb
e (3.1)
members. A single block bi can be seen as a matrix where each row contains a fingerprint and
the columns are the fingerprint features fi .
In Fig. 3.2C, the generation of an iiDS for every molecule block is shown. In principle, iiDS
generation is a reordering of the block matrix. The UML diagram of our iiDS implementation
for a block bi is shown in Fig. 3.3. As can be seen, an InvertedIndex struct has four attributes.
The attribute n_molecules stores the number of molecules contained in bi. In general, the
number of molecules per block is sb. However, the size of the last block is the remainder
a ≡ n mod sb and could be less than sb. The attribute n_features is an array, which stores the
total feature count of every corresponding fingerprint. The optional attribute parent_clusters
is only used during hierarchical clustering and indicates the cluster a molecule belongs to.
Finally, feature_skip_list is a pointer to the first instance of multiple FeatureList structs, which
are connected as a skip list. A FeatureList struct has two attributes. First, feature_id is a
unique identifier of a distinct fingerprint feature. Second, block_position is an array storing the
positional indices of all molecules in bi . These indices are used during shared feature count cal-
culation to address cells in a matrix storing the shared feature counts for all pairs of molecules
between two blocks bi and b j. The FeatureLists, which are stored in an InvertedIndex, are
decreasingly sorted according to their feature_id and terminated by a default FeatureList with
feature_id = 0.
<<struct>>
FeatureList
+ feature_id:
+ block_position:
unsigned int
unsigned short*
<<struct>>
InvertedIndex
unsigned int
unsigned short*
unsigned int*
FeatureList*
+ n_molecules:   
+ n_features:    
+ parent_clusters: 
+ feature_skip_list:
1..*
Figure 3.3: UML diagram of inverted index core data structure.
Fig. 3.2D finally shows, how these data structures enable the efficient calculation of shared
feature counts c between all pairs of molecules of a processed block pair {bi , b j}. As an
important consequence, the time complexity of our algorithm is O(m2) as opposed to O(n2)
for a naïve pairwise Tanimoto calculation.
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Listing 3.1: C++ implementation of shared feature count calculation between two sets
of fingerprints represented as iiDS. For clarity, braces were skipped.
1 void sharedFeatureCounts ( Inver tedIndex ∗ i i 1 , Inver tedIndex ∗ i i 2 ,
2 unsigned short ∗∗ cc_matr ix )
3
4 F e a t u r e L i s t ∗ f1 = i i 1−>f e a t u r e _ s k i p _ l i s t ;
5 F e a t u r e L i s t ∗ f2 = i i 2−>f e a t u r e _ s k i p _ l i s t ;
6
7 unsigned short ∗ i i 1 _ p o s i t i o n , ∗ i i 2 _ p o s i t i o n , ∗ cc_matr ix_ f1 ;
8
9 while ( f1−>f e a t u r e _ i d != f2−>f e a t u r e _ i d )
10 i f ( f1−>f e a t u r e _ i d > f2−>f e a t u r e _ i d )
11 ++f1 ;
12 else
13 ++f2 ;
14
15 while ( f1−>f e a t u r e _ i d && f2−>f e a t u r e _ i d )
16 i i 1 _ p o s i t i o n = f1−>b l o c k _ p o s i t i o n s ;
17
18 while (∗ i i 1 _ p o s i t i o n )
19 cc_matr ix_ f1 = cc_matr ix [∗ i i 1 _ p o s i t i o n ] ;
20 i i 2 _ p o s i t i o n = f2−>b l o c k _ p o s i t i o n s ;
21
22 while (∗ i i 2 _ p o s i t i o n )
23 ++∗ ( cc_matr ix_ f1 + ∗ i i 2 _ p o s i t i o n ) ;
24 ++i i 2 _ p o s i t i o n ;
25
26 ++i i 1 _ p o s i t i o n ;
27
28 ++f1 ;
29 ++f2 ;
30
31 while ( f1−>f e a t u r e _ i d != f2−>f e a t u r e _ i d )
32 i f ( f1−>f e a t u r e _ i d > f2−>f e a t u r e _ i d )
33 ++f1 ;
34 else
35 ++f2 ;
The core part of the shared feature count calculation is shown in Listing 3.1 and described
in the following. The function takes as input pointers to both InvertedIndex structs to be
processed and a pointer to a zero-initialized shared feature counts matrix, First, pointers to
the first element (FeatureList) of the feature_skip_lists are initialized (lines: 4-5). Furthermore,
pointers for later use to iterate the block_position arrays and to point to a certain matrix row are
declared. The next step iterates over both feature_skip_lists until the underlying FeatureLists
have the same or the default feature_id. The latter case indicates that no molecules between
the processed blocks possess common features (lines: 9-13). The outer loop spanning lines 15
to 35 iterates both feature_skip_lists as long as there are FeatureLists with same feature_id. Two
39
3. Deterministic Clustering of Large Chemical Spaces
FeatureLists with same feature_id contain the block_positions of all molecules in the processed
blocks, which possess this feature. Now, the previously initialized block_position pointers are
used to iterate over the corresponding arrays (lines: 16, 20). Thereby, all pairs of molecules
between the processed blocks sharing this fingerprint feature are visited in the first inner loop
(lines: 18-26). The dereferenced block_positions are used to address the matrix cell of the
visited molecule pair, which is then incremented (line: 23). When the end of one or both
block_position arrays is reached the function steps ahead to the next FeatureList (lines: 28, 29).
The second inner loop again tries to find the next FeatureList pair with same feature_id. If one
feature_skip_list reaches the default FeatureList, the outer loop exits and the function returns.
Using the calculated shared feature counts matrix and the total feature counts of every
fingerprint, which can also be accessed via the iiDS, immediate calculation of STan is possible
using Eq. 2.2. To exploit the full power of modern shared memory multi-core architectures, we
implemented this algorithm in a thread-parallel fashion. For this purpose we used the BOOST
thread library.
Clustering Step 1: Duplicate Fingerprint Detection
For the unique fingerprints filter, feature lists are hashed using the collate class of the C++
standard library. Duplicates are detected on the basis of the calculated hash values. The first
occurrence of every molecule is used for further processing and the remaining occurrences are
temporarily stored.
Clustering Step 2: Connected Components Decomposition
Using the described bII method, all pairwise similarities (STan) are calculated for the unique
fingerprint set. As we are solely interested in the final CC decomposition and do not need the
complete similarity network topology, we do not store the edges exceeding the similarity cutoff.
This proceeding enables the application of the union-find based CC algorithm introduced in
Chapter 2.1. This method starts with an empty set of edges and dynamically generates the
CCs by inserting new edges into the graph. For this purpose we use the BOOST graph library,
which provides incremental CC functionality.135 This implementation uses union-find with
path-compression and has a time complexity of O(V + αE), where α is the extremely slow
growing inverse Ackerman function.
In the following clustering step we need the nearest neighbor of every molecule. Instead of
recalculating these similarities, we immediately store the nearest neighbor information while
calculating all pairwise similarities.
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Clustering Step 3: Hierarchical Clustering
The agglomerative average linkage method is used to cluster CCs exceeding a predefined size.
As mentioned in this chapter’s introduction, efficient methods have been described for this
clustering methodology on the basis of so-called reciprocal nearest neighbors (RNN).136,137
RNNs are cluster pairs which are mutual nearest neighbors and have the property that they can
immediately be merged to create a new cluster. Murtagh described two RNN-based algorithms.
First, an iterative parallel approach where a nearest neighbor is calculated for every element
with subsequent determination and merging of all RNN pairs at once. The second algorithm
constructs a chain of subsequent nearest neighbors. At a certain point the chain ends up with
an RNN pair, which has to be merged and the algorithm continues from the last but two chain
link. As already mentioned, we calculated the nearest neighbor information for every molecule
during similarity graph construction. Thus we decided to start the hierarchical clustering using
the parallel RNN version until the entire similarity matrix for the remaining clusters fits into
the main memory. At this point we calculate the similarity matrix for the remaining clusters
and switch to the nearest neighbor chain algorithm to finish the clustering.
Clustering Step 4: Cluster-level Selection
For cluster-level selection we implemented the method developed by Kelley et al..138 The
method is often termed as the Kelley criterion. In their work, the authors also used average
linkage to generate a clustering on their data set. A penalty value is calculated for every
internal node of the dendrogram. The node with minimum penalty value is chosen to cut the
dendrogram yielding a final cluster selection with maximally populated clusters and minimal
internal spread. The spread of a cluster is an information about the similarity of its members.
In our case, small spread values indicate high similarities of the molecules in a cluster. As
the calculation of a clusters spread has to sum up the pairwise similarities of its members, we
calculate this sum during clustering and store it for every internal node when it is created.
Clustering Step 5: Calculation of Cluster Representative
To select a representative molecule for every cluster Ci we calculate its medoid. The latter
is the molecule mi ∈ Ci with the highest mean Tanimoto similarity to all other molecules
in Ci. If multiple molecules share the maximum mean similarity, all of them are marked
as representatives. Additionally, if the fingerprint of a medoid is shared by multiple input
molecules all of them are marked as representatives in the output, too. This step also uses our
bII algorithm to efficiently calculate all pairwise similarities within all clusters.
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3.2.2 Data Sets
As a virtual compound library we used the all purchasable subset of the ZINC database (version
12, accessed 20/6/2012) comprising 17,833,934 compounds at that time.127 The library was
prepared using Pipeline Pilot and OpenEye.139,140 Salts were removed and canonical SMILES
were calculated. Two commonly used types of binary fingerprints were calculated using tools
from ChemAxon’s JChem Base (GenerateMD).141 The first type was extended connectivity
fingerprints (ECFP), which generates higher order features based on radial substructures of
increasing radii.37 We used a maximum radius of four bonds. The second type was ChemAxon’s
default path-based chemical fingerprints (PBFP), which also generates higher order features
on the basis of linear paths of a predefined length. Here we used the default maximum path
length of seven bonds. ECFPs are used as an example for sparse fingerprint types and PBFP
as an example for fingerprints with high density. To benchmark the similarity calculation
methods, we used a random subset selected with Pipeline Pilot.
3.2.3 Hardware and Software
The popcount versions for similarity matrix construction of Haque et al. were compiled as
provided in their supporting information using CUDA toolkit version 4.2.9. For runtime
comparison of our clustering method to Ward and Jarvis-Patrick, we used the implementations
provided by ChemAxon JChem Base (Ward, Jarp).141 For performance evaluation of these
methods, we used a current desktop computer equipped with an Intel Core™ i7-2600 processor
(4 cores, 3.8 GHz) and 8 GB main memory. For clustering of the entire ZINC all purchasable
subset we used a compute server equipped with 4 AMD Opteron™ 6274 processors (64 cores,
2.2 GHz) and 512 GB main memory.
We used the C++ compiler from the GNU Compiler Collection (versions: Intel system
4.6.2, AMD system 4.4.7). Cache analysis were performed using Cachegrind from the Valgrind
Tool Suite (version 3.7.0). Additionally, we used the thread and graph libraries from BOOST
(versions: Intel system 1.49.0, AMD system 1.46.1).
3.3 Results
In this section, we first show the benchmarking results of our bII similarity calculation method
in comparison to state-of-the-art tools to solve this task. We then show the results of block
size and parallel execution analysis. Next, we show the clustering method comparison results.
Finally, we demonstrate the performance of the method to process the currently available
chemical space.
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Figure 3.4: Performance of similarity calculation. The bars show maximum Tps values for
our bII method (green bars) in comparison to naïve SSE4 implementation (red bars) and
to the cache-efficient SSE4 implementation (orange bars) for ECFP and PBFP fingerprint
types folded to different lengths. Additionally, we compared our bII implementation to
the inverted index implementation for LINGO similarity calculations (blue bar).
3.3.1 Blocked Inverted Index Performance
To evaluate the maximum performance of our blocked inverted index algorithm we conducted
threshold searches for ECFP and PBFB fingerprints folded to different lengths (1,024, 2,048,
and 4,096 bits). We used a scenario as described in the study of Haque and compared the
results to their popcount-based implementations.130 In brief, we calculated all pairwise similar-
ities of an input library and reported all molecule pairs with a similarity exceeding a similarity
of STan > 0.8. The results are displayed as a bar chart in Fig. 3.4. For these benchmark runs,
we set the block size parameter for our bII algorithm to sb = 480 molecules per block. For the
best performing settings with ECFPs folded to 4,096 bit, our bII algorithm achieved the equiva-
lent of 365 million Tanimoto calculations per second (Tps). These results demonstrate that our
bII algorithm performs as well as the popcount implementations and for several cases it is even
better. This is particularly remarkable because our method is a purely algorithmic solution for
this problem. These results point out two important characteristics of the compared methods.
First, the performance of inverted index algorithms is rather independent of the fingerprint
size whereas the performance of popcount-based algorithms decreases linearly with finger-
print length. Second, the performance of inverted index algorithms is output-sensitive with
respect to the final shared feature counts whereas the performance of popcount algorithms is
independent thereof. This is shown by the throughput of the bII for the dense PBFPs, which is
approximately an order of magnitude lower than for the ECFPs.
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Figure 3.5: Block size dependency of the bII algorithm. (A) The primary vertical axis
shows the performance in million Tps (green line). Cache write misses in percent are
shown on the secondary vertical axis for the L1 data cache (dashed blue line) and the L3
data cache (dashed red line). (B) The chart shows the bII performance for 1-8 parallel
threads and increasing block sizes.
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3.3.2 Block Size and Hardware Scalability
As we were interested to gain knowledge on the influence of the block size parameter sb,
we evaluated the performance of the bII algorithm for varying block sizes. This parameter
affects three important aspects. First, the number of pairwise block comparisons decreases.
Second, the size of a single iiDS increases and third, the size of the matrix to store the
shared feature counts grows quadratic with the block size. Fig. 3.5A shows the Tanimoto
throughput depending on the block size using a single threaded version of our algorithm.
Starting with a block size of one, which corresponds to an iiDS for every input molecule, the
minimal throughput of our algorithm is about 2×106 Tps. This can be regarded as an efficient
implementation of naïve Tanimoto calculation. Increasing the block size up to 500 molecules
leads to a hyperbolic performance gain and reaches a maximum throughput of about 75×106
Tps. This throughput remains nearly constant up to a block size of about 900. Further increase
leads to an asymptotic performance loss tending to a throughput of ∼56×106 Tps for a block
size of 50,048 molecules. In this extreme case, a single iiDS is created including all input
molecules. To explain this effect, we analyzed the processor cache behavior. Fig. 3.5A thus
also shows the relative cachemissrates for L1 and L3 data cache writes. The initial performance
gain seems to decelerate due to an increasing miss rate of the L1 data cache. The performance
decrease following the plateau phase seems to be an additive effect of increasing miss rates
of both, the L1 and the L3 data caches. However, the dominating effect is supposed to be
the L3 behavior because cache misses of the latter are typically an order of magnitude more
expensive than L1 cache misses.
Fig. 3.5B shows the hardware scalability of the bII algorithm with increasing number of
parallel threads. The results demonstrate that the implementation scales almost linearly up
to a number of four threads. Interestingly, the use of more than four threads does not scale
linearly any more. The increase in Tps is less than 25 % for every single thread compared to
the first four threads. The reason therefor is most probably also the cache limitations because
the employed Intel processor provides four physical and eight virtual cores. Thus, using more
than four threads has the consequence that physical cores and their dedicated cache have to
be shared by multiple threads.
3.3.3 Comparison to Standard Clustering Methods
The chart in Fig. 3.6 shows the runtimes of our clustering method and ChemAxon’s Ward and
Jarvis-Patrick implementation evaluated on a desktop computer. Our method was tested with
the ECFP and PBFP fingerprints folded to 2,048 bits. The ChemAxon methods were run
with ChemAxons standard fingerprint settings (PBFP, 512 bit). The similarity cutoffs for CC
decomposition were separately chosen for the different fingerprint types. To yield reasonable
and comparable sizes of the largest CCs, we set the similarity cutoffs to SCutTan = 0.6 for ECFPs
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Figure 3.6: Clustering runtime comparison. We compared Ward (blue marks), Jarvis-
Patrick (orange marks) and our clustering method. We evaluated the latter on PBFPs
(green marks) and ECFPs (red marks).
and to SCutTan = 0.7 for PBFPs. The lower cutoff for hierarchical clustering of CCs was set to
1,000 molecules per CC for all library sizes. Our method clearly outperforms the runtime
of the Ward method. As expected, the Jarvis-Patrick implementation is much faster than
the Ward method due to the use of heuristic algorithms.141 The runtimes of our clustering
method lie in the range of the performance of Jarvis-Patrick. For the ECFP fingerprint type,
our method is even faster than Jarvis-Patrick. These observations show that the runtimes of
chemoinformatics clustering methods are also highly dominated by the speed of the similarity
calculation. Thus, the latter forms a bottleneck and optimizations can lead to significant
runtime improvements of clustering applications.
3.3.4 Clustering the Available Chemical Space
The input database contained 17,833,934 compounds, which were represented as ECFPs
folded to 2,048 bit length. The duplicate fingerprints filter step reduced this input library
down to 12,976,486 unique fingerprints. To choose appropriate values for SCutTan to generate
the similarity network and the minimum CC size for hierarchical clustering, we performed
a pre-analysis step. For this purpose, we calculated all CC decompositions in a Tanimoto
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Figure 3.7: Similarity network analysis of the ZINC all purchasable subset. The finally
selected similarity cutoff SCutTan = 0.76 is marked by dotted vertical lines. (A) The plot
shows the number of edges exceeding SCutTan (blue line), the size of the largest CC (green
line), the total number of CCs (red line) and the number of singletons (yellow line). (B)
The second and third largest CCs are shown (red and green line, respectively) as well as
the number of CCs with more than 1,000 members (blue line).
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range from 0.52 to 1.0 using a step width of 0.02. The resulting graph is shown in Fig. 3.7A.
It reveals similar results as previously calculated for three different and small compound
datasets reported by Lepp et al..142 They also recognized a single dominating CC, which
gradually decomposes in a Tanimoto range of 0.5 to 0.8. The second and third largest CCs are
an order of magnitude smaller than the largest CC, which is shown in Fig. 3.7B. Additionally,
this graph shows the number of CCs with more than 1,000 members.
Based on these results, we decided to set the cutoff for similarity network generation to
SCutTan = 0.76 and the CC size exclusion cutoff for hierarchical clustering to 1,000 members.
Thus, CCs with less than 1,000 members were not directed to hierarchical clustering. Using
these parameters we executed our method on the described Opteron compute server using all
cores and 100 GB of main memory, which took 64 hours to complete.
3.4 Discussion
In the present study we describe the development of a deterministic clustering method, which
is capable of processing extremely large chemical spaces represented as 2D fingerprints within
days on current standard hardware. As described in this chapter, one critical bottleneck of
chemoinformatics clustering methods is the speed and efficiency of the underlying similarity
calculation method. Thus, we developed and implemented an extremely fast and flexible
algorithm for the calculation of binary 2D fingerprint similarities especially for this purpose.
This algorithm is highly optimized to compute all pairwise similarities within a given dataset.
It is based on inverted index data structures, which is an efficient representation of binary
fingerprints and enables extremely fast calculation of shared feature counts between finger-
prints. We have modified this data structure by dividing the input molecules into equally sized
blocks, which enables the choice of an optimal block size to maximize the number of similarity
calculations per second. Recently introduced methods to calculate fingerprint similarities use
specialized instruction set extensions on hardware level or specialized hardware itself, like
GPUs. In contrast, the presented bII algorithm is purely algorithmic and can be run on every
standard CPU.
We compared our bII algorithm to popcount-based methods and the results demonstrate
that our algorithm can perform equally well and for several cases even better. Furthermore,
these results nicely highlight the advantages and disadvantages of the compared methods
for different fingerprint types. The bII method performs better for sparse fingerprints and is
insensitive to fingerprint length, whereas popcount-based methods perform better on short
fingerprints and are insensitive to fingerprint density. Additionally, we have analyzed the
block size dependence of our algorithm which points out that splitting of molecules influ-
ences the cache performance and an optimal choice of this parameter is critical to the overall
performance.
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Using this algorithm, we implemented our deterministic clustering method to process very
large compound libraries. The method combines different techniques to decompose an input
library in three consecutive steps. These steps comprise a unique fingerprint filtering, the
graph theoretic concept of CC decomposition and standard hierarchical clustering. By runtime
comparison of our clustering method to the frequently used methods Ward and Jarvis-Patrick,
we could demonstrate that our method is faster or at least competitive for commonly used
2D fingerprint types. To finally show the power of our clustering method, we processed the
commercially available chemical space comprising more than 17 million compounds on a
compute server which took 2.5 days of computation time. For the clustering of such large
chemical spaces, normally the non-deterministic k-Means or Jarvis-Patrick approaches are used.
Deterministic hierarchical methods like Ward cannot be used for data sets of these dimensions
because their runtime complexity is too bad.
Our blocked inverted index method and the exact clustering are currently integrated into
the free chemical structure database ChemSpider, which is provided by the Royal Society of
Chemistry (http://www.chemspider.com/).143 The methods are used to generate similar-
ity networks for their newly developed webservices in order to speed up similarity searching.
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Chapter 4
Scaffold Families
4.1 Introduction
The concept of small molecule scaffolds was briefly introduced in Section 2.2.1. Scaffolds
are frequently used for various chemoinformatics tasks, which comprises amongst others the
design and the analysis of compound libraries,144 scaffold hopping,145 or rational and scaffold-
driven drug design approaches.146 As already described, different definitions of molecular
scaffolds exist and the opinions on how to define a molecule’s scaffold diverge. However,
in general it is reasonable to use data set-independent scaffold definitions like Murcko scaf-
folds or Scaffold Trees.49,51,147 This is for example not true if maximum common substructure
approaches are employed to dynamically calculate the minimal scaffold within a data set.148
In the case of compound library analysis the distribution and occurrence of scaffolds
can yield useful information on the composition of a library. These can possibly be used
to specifically expand the library by adding novel scaffolds. However, depending on the
employed scaffold definition the results of such analysis differ vastly.150 Using scaffolds reduces
compound complexity and can help to rationalize chemical space by grouping structurally
related compounds. This procedure is static in a sense that it does not allow for structural
variations in the scaffolds and the created groups. Nevertheless, allowing limited structural
variations is common practice when medicinal chemists explore structure-activity of identified
hits. An example is illustrated in Fig. 4.1. It shows two dihydrofolate reductase (DHFR)
inhibitors as well as their corresponding Murcko scaffolds.149 Despite slightly different Murcko
scaffolds, their receptor-bound 3D conformations are highly similar. As both compounds are
thus closely related by their biological activity, it would makes sense to group them together
from a drug design perspective.
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Figure 4.1: Scaffold family example. Compound A and B are chromene-derived antibi-
otics, which inhibit the enzyme DHFR. Compound A is the drug candidate Iclaprim and
its conformation is taken from PDB entry 3fra.149 Compound B is ligand XCF taken from
PDB entry 3frf.149 The binding mode of both inhibitors is conserved as can be seen from
their superposed conformations. However, their Murcko scaffolds are not equal but the
fingerprint-based 2D similarity between A and B indicates a highly related scaffold. Thus,
A and B can be classified into the same scaffold family.
Goals of the Project
In this project, we introduce a fast method to abstract molecule scaffolds in order to create
so-called scaffold families with improved information content when referring to medicinal
chemistry aspects. As described in the introductory DHFR inhibitor example, scaffold fami-
lies are intended to group compounds together that show closely related activity on a single
target but do not share the same scaffold. In structure-activity relationship (SAR) studies, the
exploration of related scaffolds is part of a medicinal chemist’s core competencies, but for
these experts it is not feasible to manually classify larger compound data sets or even libraries
according to related scaffolds. Thus, an automatic method to generate scaffold families is
desirable. We quantitatively evaluate the method on selected target specific data sets and a
large virtual compound library. Furthermore, we show selected scaffold families generated by
our method to highlight the advantages of this approach.
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Related Work
Previous research projects to analyze the scaffold diversity of compound libraries mainly
focused on assessing the number of unique scaffolds and their population sizes.144 Langdon et
al. performed a similar study.150 However, they were especially interested in the comparison
of compound libraries’ scaffold compositions for different scaffold definitions. As a result, they
recommend level 1 scaffold tree scaffolds as a useful abstraction method to analyze compound
libraries. Additionally, they used 2D fingerprints to hierarchically cluster level 1 scaffolds to
enable data visualization using tree maps for diversity and population analysis.
4.2 Materials and Methods
This section describes our method to calculate scaffold families for a given compound collection,
the analyzed data sets and their preparation. The latter was performed using standard compo-
nents from Pipeline Pilot using tools from its Chemistry package.151 To calculate the scaffold
similarity network of all data sets we used the software that we presented in Chapter 3.
4.2.1 Scaffold Family Calculation
Fig. 4.2 gives an overview of our method to calculate scaffold families from a compound library.
First, we generate the Murcko scaffold for every molecule. We decided to use the Murcko
scaffold definition because resulting scaffolds are closest to the original molecule. Additionally,
these scaffolds are represented by at least one molecule in the library, which is not necessarily
given for lower level scaffold tree scaffolds. We group the library according to their scaffolds,
yielding a set of unique scaffolds.
Second, we calculate 2D binary fingerprints from the unique Murcko scaffolds. As a binary
fingerprint type we employ ECFPs with a maximum radius of four bonds and pharmacophore
atom abstraction (Pipeline Pilot fingerprint abbreviation: FCFP_4).
In the third step, we calculate the scaffold families on the basis of all pairwise fingerprint
similarities using the Tanimoto coefficient as similarity measure. Using our presented methods
for fast similarity calculation (Chapter 3), we generate the scaffold similarity network at a
predefined Tanimoto cutoff. From this scaffold network we extract the CCs, which finally
represent the scaffold families.
4.2.2 Data Sets
We used 13 target specific data sets extracted from the ChEMBL database (release 17) to
analyze the classification characteristics of our scaffold families.152 ChEMBL is one of the most
comprehensive and freely availably databases containing bioactivity data for small molecule
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ligands on various targets. Compound structures of the data sets were downloaded from the
ChEMBL website in SMILES format. All data sets are protein targets of varying sizes and
comprise four organisms. Additionally, we analyzed a manually curated compound database,
which contains all immediately available compounds from selected and representative chemi-
cal suppliers.
Compound Library
Scaﬀolds
Scaﬀold Families
1. Generate Murcko Scaﬀolds
2. Group by Murcko Scaﬀolds 
1. 2D Fingerprints of Scaﬀolds
2. Calculate Pairwise Similarities
3. Similarity Network Generation
4. Calculate Connected Components
A
B
Figure 4.2: Scaffold family generation schema. (A) First, Murcko scaffolds are generated
for every molecule in a virtual library. Second, duplicate removal yields the virtual scaffold
library. (B) Scaffold families are obtained by calculating the 2D fingerprint-based similarity
network at a defined similarity cutoff and subsequent CCs decomposition. The resulting
CCs form the scaffold families.
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Data Set Preparation
The data sets we selected and the resulting compound numbers are listed in Table 4.1. Du-
plicate compounds in the single subsets were removed. Subsequently, we analyzed the com-
pounds’ scaffold fractions and discarded all compounds with less than 50 % non-hydrogen
scaffold atoms as compared to the decoration. The remaining compounds were used for the
generation and analysis of Murcko scaffolds and scaffold families.
The custom compound library was compiled from the supplier catalogues using the fol-
lowing procedure. First, salts and counter ions were removed, charges and stereo information
was standardized and canonical SMILES were generated. Based on the latter we started with
the largest supplier data set to select compounds for our library. The other suppliers were
sequentially added by decreasing size and duplicates were skipped. In total, this data set
finally comprised 6,494,794 compounds. The sizes of the single supplier subsets are also listed
in the appendix (Table E.1).
Table 4.1: Target-specific compound data sets extracted from ChEMBL database. M:
redundancy-reduced (unique) compounds. N: number of compounds with sufficient
scaffold fraction used for further analysis.
Target Abbr. Organism UniProt ID M N
Neuraminidase Influenza A P03468 405 160
Beta lactamase P. aeruginosa Q932Y6 658 628
Angiotensin-converting enzyme ACE H. sapiens P12821 668 431
Aldose reductase AR H. sapiens P15121 748 680
Dihydrofolate reductase DHFR H. sapiens P00374 1,147 1,091
Urokinase H. sapiens P00749 1,230 1,110
Heat shock protein 90-α HSP90 H. sapiens P07900 1,316 1,247
Reverse transcriptase HIV-RT HIV 1 Q72547 3,284 2,781
Histamin H3 receptor H3R H. sapiens Q9Y5N1 3,350 3,238
Cylcooxygenase 1 COX-1 H. sapiens P23219 3,836 3,417
Acetylcholinesterase AChE H. sapiens P22303 4,134 3,554
SRC kinase H. sapiens P12931 5,311 5,039
Thrombin H. sapiens P00734 7,322 6,497
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4.3 Results
This section first shows the quantitative results for the analysis of Murcko scaffolds and scaffold
families from the ChEMBL data sets. Additionally, the scaffold family decomposition of our
custom compound library is presented. Second, we highlight two scaffold families generated
from the ChEMBL data sets to demonstrate the beneficial properties of this method.
4.3.1 Quantitative Analysis of Scaffold Fingerprints
The fractions of unique Murcko scaffolds and scaffold families are shown in the bar chart of
Fig. 4.3. The scaffold families were calculated using a Tanimoto cutoff STan = 0.7. Various
cutoffs were tested and the latter was chosen because it leads to a significant size reduction
of all analyzed data sets. Light-colored base parts of the bars indicate the fraction of resulting
singletons for every type. Here, singletons are scaffolds or scaffold families that cover only one
original compound in the analyzed data set.
0.0
0.2
0.4
0.6
0.8
1.0
Ur
ok
ina
se
HI
V-R
T
H3
R
Th
ro
mb
in AR
CO
X-1
DH
FR
AC
hE
Ne
ur
am
ini
da
se
SR
C k
ina
se AC
E
HS
P9
0
Be
ta 
lac
tam
as
e
Scaﬀolds
Scaﬀold families
Fr
ac
tio
n
Figure 4.3: Fractions of Murcko scaffolds (red bars) and scaffold families (green bars)
for the ChEMBL data sets. Scaffold families were calculated using a Tanimoto cutoff of
0.7. The light coloured base parts of the bars show the singleton percentages of the
corresponding types. The data sets are sorted by increasing scaffold family fraction.
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The calculation of scaffold families from Murcko scaffolds reduces the fraction of represen-
tative groups to various extents. The least difference can be observed for the COX-1 inhibitor
data set. Here, the number of scaffold families is only ∼ 5 % smaller than the number of unique
Murcko scaffolds. The maximum difference can be observed for the H3R inhibitor data set.
Here, the fraction of scaffold families is less than half the fraction of unique Murcko scaffolds.
This large reduction points out that the actually explored scaffold space is much smaller than
the number of unique Murcko scaffolds present in this data set. In contrast, a small reduction
as in case of the COX-1 data set indicates that the explored scaffold space indeed equals the
number of Murcko scaffolds.
The comparison of singleton fractions also yields interesting insights. In all analyzed data
sets, the magnitude of Murcko scaffold reduction by scaffold family generation is correlated to
the reduction of singletons.
Custom Compound Library
From the 6,494,794 unique members in our custom compound library 6,480,058 compounds
possess a valid Murcko scaffold. Application of the minimum scaffold fraction filter to skip
compounds with > 50 % decoration leaves 6,085,875 compounds. The number of Murcko
scaffolds and scaffold families are listed in Table 4.2. The library comprises 1, 259, 875 unique
Murcko scaffolds whereof ∼ 62 % are singleton scaffolds.
The scaffold families were calculated using a Tanimoto cutoff of 0.85. We have evaluated
various cutoffs in the range of 0.6 to 0.9 in order to choose this final cutoff because it yields
a homogeneous library decomposition where the single huge CC is broken up and no single
CC is dominating. The number of scaffold families using this similarity cutoff yields 626,257
scaffold families from which only ∼ 51 % are singletons.
Table 4.2: Fraction of Murcko scaffolds and scaffold families in the custom library.
Type N Singletons
Murcko scaffolds 1,259,875 789,122
Scaffold families 626,257 324,322
4.3.2 Qualitative Analysis of Scaffold Fingerprints
To demonstrate properties of scaffold family classification we selected two interesting examples
from the analyzed ChEMBL data sets. They illustrate how scaffold families can be utilized to
generate a classification of chemical spaces with improved medicinal chemistry information
content.
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Aldose Reductase Inhibitors
Fig. 4.4 shows a group of phtalazinone-based inhibitors of the human aldose reductase (AR).
This enzyme catalyzes the reduction of glucose into sorbitol. It is one of the most important
targets for the treatment of hyperglycemic states in patients suffering from type 2 diabetes to
prevent long-term consequences.153 The selected compounds were optimized in a typical SAR
study by Mylari et al..154 Starting from the lead structure zopolrestat, the authors explored
various oxodiazole and thiadiazole derivatives with AR inhibitory activity. The visualized
example shows one scaffold family that merges four different Murcko scaffolds representing
both chemotypes. The latter demonstrates the benefits of using pharmacophore feature atom
encoding for 2D fingerprint generation.
Scaﬀold Family1
2
3
4
Figure 4.4: A scaffold family from AR inhibitors data set. This scaffold family comprises
four different Murcko scaffolds, which represent 16 inhibitors in total. The grouping of
oxodiazole and thiadiazole derivatives exemplifies the benefits of pharmacophore feature
atom type encoding.
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Serine Protease Inhibitors
The second example is shown in Fig. 4.5 and highlights serine protease inhibitors, which were
synthesized in an effort to identify selective Factor Xa (FXa) modulators. FXa is one of the
key enzymes in the early blood clotting cascade and an important anticoagulant target.155
The selected compounds were all identified in a SAR study exploring amidine-substituted
(bis)benzylidene-cycloketone olefines as candidates for non-peptidic FXa inhibitors.156 The
presented scaffold family is formed by five different Murcko scaffolds. Here, the variant key
feature is the central cycloketone. This central aliphatic ring spans all sizes from cyclohexanone
up to cyclodecanone.
Scaﬀold Family
1
2
3
4
5
Figure 4.5: A scaffold family from thrombin serine protease inhibitors data set. This
scaffold family comprises five different Murcko scaffolds, which represent 36 inhibitors in
total.
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4.4 Discussion
A meaningful classification of compounds in a way that reflects medicinal chemistry notions is
of great interest and chemoinformatics tools to perform this task are of great value. Possibly
the most important approach is the calculation and distribution of molecule scaffolds, which
splits up a molecule into a functional framework and its decoration. Different scaffolding
definitions have been proposed and evaluated and lead to quite different outcomes. However,
a common substructure is a property of all scaffold definitions. This implies that a scaffold
shared by a set of molecules is an invariant common substructure of them. On the one hand,
this invariant representation is very useful to analyze the precise scaffold diversity within
compound libraries. On the other hand, this view does not embrace the multifaceted kinds of
structural relationships from a medicinal chemistry and structure-activity point of view.
In this chapter, we introduced scaffold families as a computational approach to push the
rather static scaffold definitions towards a more medicinal chemistry meaningful way of rep-
resenting compound framework relationships. scaffold families are generated by CC decom-
position of a similarity network calculated using 2D fingerprints from Murcko scaffolds. In
combination with the tools for fast fingerprint similarity calculations presented in the previous
chapter, scaffold families can efficiently be calculated, even for huge virtual compound libraries.
Our results demonstrate, that the use of scaffold families instead of Murcko scaffolds can reduce
the number of representative groups and especially the number of singletons. The examples
of AR and FXa nicely point out the benefits of our approach. Both cases show the successful
co-classification of compounds from typical SAR studies. In summary, scaffold family oriented
compound classification is extremely useful to rationalize scaffold and chemical space. Addi-
tionally, it is only marginally more computationally demanding than the generation of scaffolds
alone.
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Chapter 5
In Silico Analysis of Protein-Protein
Interaction Stabilization
The content of this chapter is in parts published in the review article:
Small-molecule stabilization of protein-protein interactions:
an underestimated concept in drug discovery?22
5.1 Introduction
The number of publications on the inhibition of PPIs by small molecules has been continuously
growing over the last two decades.17,18,20 This has also inspired theoretical investigation of PPI
inhibition and a lot of effort has already been spent on gaining knowledge for the development
of tools for in silico discovery of small molecule PPI inhibitors. A recent summary is given in
the review of Villoutreix et al..70
In contrast, only one publication is available yet reviewing the stabilization of PPIs by small
molecules.22 The work describes the currently known and structurally characterized examples
for this fascinating molecular mechanism. Interestingly, without being aware of the underlying
mechanism, the stabilization of PPIs has been one of the most successful industrial strategies
for herbicide development since the early 1940s.157 Today, assays to monitor PPI stability in
vitro are available and feasible for HTS as demonstrated by Rose et al..25 Nevertheless, costs
for HTS campaigns remain high and get even more expensive due to increasingly elaborate
technology. Computational techniques are nowadays routinely used to support drug discovery
campaigns because they are more cost effective.
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Thus, it is of great importance to promote in silico research in the field of small molecule
stabilization of PPIs. As a consequence of the novelty of this research field, no work has
as yet been spent on analyzing the properties of small molecule binding to such complexes
and to turn this knowledge into the development of in silico tools to screen specifically for
PPI stabilizers. However, a couple of straightforward screens for PPI stabilization have been
reported and will be discussed briefly in the following.
Goals of the Project
The first goal of this work is to analyze the ligand-bound stabilized PPIs, which are listed in
Thiel et al. to infer structural principles of this mode of action.22 Based on this knowledge we
want to develop tools to identify PPIs which are stabilized by small molecule ligands.
The second goal is to use these tools for screening the PDB in order to identify as yet over-
looked candidate PPIs that are possibly stabilized by a bound ligand. The latter is particularly
promising because PPI stabilization by small molecules is not yet a well established mechanism
and the description of it in the literature is heterogeneous and inconsistent. Additionally, the
identification of further stabilized complexes will serve as a positive control for the developed
tools and the conclusions we will draw from known cases.
The third goal is to use the resulting set of stabilized PPI complexes to evaluate the ability
of current protein-ligand docking tools to correctly predict the binding pose of stabilizing
ligands into their rim-exposed pockets.
Finally, we will use the obtained knowledge from the above and the developed tools to set
up a VS approach to predict small molecule stabilizers of a selected PPI target. A set of final
candidates will be experimentally evaluated for their potency to stabilize the target PPI and
– in case of success – we will try to elucidate the binding mode of validated hits by means of
X-ray crystallography.
Related Work
Efforts to find stabilizers of PPIs by means of in silico techniques are sparse but three projects
have already been described in the literature. The first one published was performed by Ray
et al. who tried to find small molecule ligands that stabilize the homodimer of superoxide
dismutase 1 (SOD1).158 SOD1 is a key player in familial amyotrophic lateral sclerosis (fALS),
a severe degenerative motor neuron disease.159 Here, point mutations in SOD1 lead to its
aggregation, which is suspected to play an important role in disease progression. A prerequisite
of aggregation is the dissociation of the SOD1 homodimer. The latter served as a model system
for a standard protein-ligand docking approach that yielded stabilizers active in vitro.
The second VS for PPI stabilizers was reported by Block et al..23 As a target they used the
interaction of plant 14-3-3 like protein C and PMA2, which is stabilized by the natural product
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FSC (see also Section 2.4.3). Using a combination of ligand-based and structure-based VS, the
authors’ aim was to demonstrate the feasibility of PPI stabilizer screening in silico. However,
the study revealed no active stabilizers for this interaction. A possible reason for this could
have been the strong emphasis the authors put on the reference ligand FSC for the ligand-based
step because the scaffold of this natural product is highly singular and similar compounds in
public databases are limited to structurally close derivatives.160
The third and most recent report in VS for PPI stabilizers was presented by Jiang et al..161
In this study, the PPI of interest was the homodimer of myc-associated factor X (Max) as a
promising target in various human cancer types. In brief, the transcription factor c-Myc has
been shown to be overexpressed in many tumors and many of its biological activity depends
on the heterodimerization with Max.162 Thus, the c-Myc◦Max complex has been subjected to
various PPI inhibitor discovery campaigns. As an interesting alternative, the authors proposed
Max◦Max homodimer stabilization as a way to reduce available Max for heterodimerization
with c-Myc. By means of standard protein-ligand docking they selected 68 compounds for
experimental testing and reported 13 active stabilizers.
The described studies applied standard protein-ligand docking tools for structure-based VS,
which have all been developed for the prediction of small molecule binders to enzymatic active
sites. None of these works tried to include knowledge of already known PPI complexes, which
are stabilized by small molecule ligands. However, Block et al. also performed a quantitative
and qualitative analysis of rim-exposed interface PPI pockets to assess their frequency and
potential druggability.23 To get an estimate on the number of such pockets they analyzed 198
transient protein complex structures for the occurrence of rim-exposed interface pockets. In
total they identified 380 pockets. Thus, a transient complex features on average two pockets.
To assess the druggability of the identified rim-exposed interface pockets they calculated
typical descriptors for druggability estimation and compared the results to 636 ligand-bound
pockets of 243 enzymes. The results revealed considerable similarities with enzymatic binding
pockets in terms of hydrophilicity, cavity volume, and burial suggesting a reasonable chance
to successfully address PPI pockets with small molecules.
Recently, Gao et al. performed a more comprehensive analysis of PPIs in the PDB on the
occurrence of rim-exposed interface pockets.24 They analyzed 1,611 transient PPIs for pockets
at the rim of the corresponding PPI interface. They identified 3,045 pockets at the PPI interface
whereof 30 % exclusively exist in the formed protein complexes. Additionally, they reported
782 ligands with more than five heavy atoms that bind in proximity of these pockets. However,
the authors drew no further conclusions from their work regarding the possibilities to stabilize
PPIs with small molecules.
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5.2 Materials and Methods
All materials, which were used for wet lab experiments and which are not directly described
in the following sections are listed in the appendix (Table E.6). We refer to small molecule
ligands of crystal structures by their chemical component identifier from the PDB. In the
analysis of crystal structures only parts relevant to this work on the concept of PPI stabilization
are introduced and discussed.
5.2.1 Principles Underlying known PPI Stabilizers
To gain information on structural principles of PPI stabilization we analyzed nine protein
complexes, which have been found to be directly stabilized by a small molecule and for which
the trimeric crystal structures are available. The PPIs stabilizes by AFB (PDB ID: 1s9d), FOK
(PDB ID: 1cs4), and FSC (PDB ID: 2o98) were introduced in Section 2.4.3 and are visualized
in Fig. 2.10. The remaining structures are shown in Fig. 5.1 and described in the following.
The PDB entry 3p1o contains a trimeric complex of 14-3-3σ, a mode III phosphopeptide
from the human TWIK-related acid-sensitive potassium (K+) channel 3 (Task3) and the fungal
toxin FSC.163 The C-terminal end of Task3 can be phosphorylated, which enables its binding to
14-3-3σ with an KD of 1.5 µM. The corresponding structure is analog to the stabilized complex
of 14-3-3 like protein C and PMA2, which is shown in Fig. 2.10A-B. The binary complex of
14-3-3 and Task3 reveals a large cavity at the interface rim. This cavity is the binding pocket
for FSC, which contacts both chains and thereby decreases the affinity to an apparent KD of
50 nM. The protein-ligand interaction is mainly hydrophobic in nature. Only one deeply buried
hydrogen bond is formed between the conserved Lys129 and FSC’s methoxy group.
Three complex structures are related to 14-3-3◦PMA2 (PDB ID: 2o98). They all contain
a stabilized protein complex consisting of a plant 14-3-3-like protein C or E and a C-terminal
construct of phosphorylated PMA2. Again, the binary complexes reveal large cavities at
the interface rim, which are occupied by stabilizing ligands. In crystal structure 3m51 the
ligand is a pyrrolidone derivative (YR1) and in 4dx0 a pyrazole derivative (OMT).25,164 Both
compounds occupy a similar pocket as FSC and increase the affinity of the proteins. The
structure of YR1 is shown in Fig. 5.1F. The binding mode of OMT is comparable. Epibestatin
(EBT) is the stabilizing ligand in PDB entry 3m50 but binds to a different pocket in the interface
rim (Fig. 5.1D).25
Crystal structure 2p1q, shown in Fig. 5.1A-C, contains a trimeric complex of the F-box pro-
tein TIR1, a peptide from the auxin-responsive protein IAA (Aux/IAA) and the phytohormone
auxin (IAC).165 IAC binds into a deep cavity formed at the interface rim of TIR1◦Aux/IAA.
The indole part occupies a mainly hydrophobic pocket inside a leucine-rich repeat of TIR1 and
is stabilized by a hydrogen bond to its nitrogen. The carboxy group contacts polar residues of
TIR1. The Aux/IAA peptide pi-stacks with a tryptophan side-chain onto the aromatic indole.
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A comparable mechanism to TIR1◦Aux/IAA stabilization by IAC is found in structure
3ogk.166 The binary receptor for ligand OGK is formed by the F-box protein coronatine insensi-
tive 1 (COI1) and the transcriptional repressor JAZ1. The ligand OGK is also a phytohormone
from the family of jasmonates. OGK is deeply buried in a hydrophobic pocket in the inner side
of the COI1 leucine-rich repeat. Additionally, OGK is coordinated via four hydrogen bonds to
COI1 side-chains. The contacts to JAZ1 are rather small but the ligand increases the affinity of
this complex.
5.2.2 Analysis of PPI Stabilization
To describe the structural characteristics of PPI stabilization by small molecule ligands in a
quantitative manner, we analyzed the selected ternary complex structures in two different
ways: First, we analyzed the contact sizes of all interacting molecules. Second, we analyzed
selected physicochemical properties of the stabilizing ligands.
BA
D
A B
L
A B
L
C
A B
L
L
Figure 5.2: Evaluated surface areas of stabilized PPI complexes. Calculated BSAs are
differently colored. (A) Contact surface between ligand and protein A (BSAAL , red). (B)
Contact surface between ligand and protein B (BSABL , orange). (C) Contact surface
between ligand and the entire protein complex (BSAABL , red + orange). (D) Surface area
of unbound ligand (red + orange + yellow), which is used to calculate F racBSAL .
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Ligand Analysis
To analyze the eight stabilizing small molecules we used the isomeric SMILES provided by the
Chemical Component Dictionary of the PDB. These were used as input for physicochemical
property calculation with Pipeline Pilot.151 Molecules were generated from SMILES using
standard parameters. Property calculators from the Chemistry package were used to calculate
the number of hydrogen bond donors and acceptors, the MW, and the AlogP.167–169 The latter
is an estimate for the experimentally determined partition coefficient of octanol in water, logP.
Contact Size Analysis
In the following, we use A and B to denote the participating proteins and L to denote the
stabilizing ligand of an analyzed PPI. We describe the interaction properties of a stabilized PPI
A◦B◦L by three parameters. To calculate them, we implemented a tool called MultivalentInter-
actionAnalyzer. It is built on top of the biochemical algorithms library BALL.2
Fig. 5.2 gives a schematic overview of the following parameters. The first parameter –
BSAAL – is the BSA size between protein A and ligand L in Å
2. The corresponding contact
surface is highlighted in Fig. 5.2A. The second parameter – BSABL – is the BSA size between
protein B and ligand L in Å2. The corresponding contact surface is highlighted in Fig. 5.2B.
The third parameter – F racBSAL – is the fraction of ligand surface area, which is buried upon
binding to the rim-exposed surface pocket. To calculate the latter, we need BSAABL, which is
the contact size between protein complex A◦B and ligand L as well as the total ligand surface
area. Fig. 5.2C and 5.2D highlight these surfaces.
The MultivalentInteractionAnalyzer uses the Numerical Solvent-Accessible Surface (Numer-
icalSAS) class of BALL to calculate these parameters. However, this class does not calculate
BSAs directly but it provides functionality to calculate the solvent-accessible surface areas
(SASA) of individual atoms in a structural assembly. The class uses a probe sphere of prede-
fined size to calculate accessible surface points. We set the probe radius to 1.4 Å, which is
commonly used for water molecules as solvent.170 To retrieve the described BSA parameters,
we calculate SASAs for L and for the subcomplexes A◦L, B◦L and A◦B◦L. Using these values,
the BSA parameters are calculated as follows:
BSAAL =
|LigandAtoms|∑
i=1
SASAL(atomL,i)− SASAAL(atomL,i) (5.1)
BSABL =
|LigandAtoms|∑
i=1
SASAL(atomL,i)− SASABL(atomL,i) (5.2)
BSAABL =
|LigandAtoms|∑
i=1
SASAL(atomL,i)− SASAABL(atomL,i) (5.3)
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The four functions SASAABL , SASAAL , SASABL and SASAL return the SASA of ligand atom
i using the complexes A◦B◦L, A◦L, B◦L and unbound ligand as input, respectively. Parameter
F racBSAL is calculated by the following equation:
F racBSAL =
BSAABL
|LigandAtoms|∑
i=1
SASAL(atomL,i)
(5.4)
5.2.3 Screening the Protein Data Bank for Stabilizer Candidates
Based on the properties which we inferred from analyzing currently described stabilized PPI
complexes, we set up a screening for potentially ovelooked stabilized complexes within the
PDB. Therefore, we implemented a workflow to filter the PDB to select possible candidate PPIs,
which are possibly stabilized by a small molecule ligand. This workflow is shown in Fig. 5.3.
Organic Compound
# PDB Occurrences
Ligand Filter
Molecular Weight
MinContactAll
MinContactSingle
Minimal FracLigBSA
Complex Structure Filter
# Contact Chains
Protein Data Bank
Chemical Components
Dictionary
Protein Structures
Separate Receptor & Ligand
Extract Ligand Binding Pocket
Preparation & Analysis
Group Homo- & Heterooligomers
Group PPI Pockets by 
Spatial Backbone Similarity
Binding Pocket Grouping
HeteroStab Candidates HomoStab Candidates
Figure 5.3: Filtering the PDB for candidates of small molecule stabilized PPIs.
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Ligand-guided Preselection
The first workflow step is a filtering of the PDB Chemical Component Dictionary. This dic-
tionary contains all non-peptidic ligands occurring in the PDB. The workflow was set up in
Pipeline Pilot.151 We obtained the dictionary in SD format and started by removing all inor-
ganic compounds. This filter rejects compounds containing other atom types than H, C, N, O,
P, S, F, Cl, Br, or I. Thereby compounds like metal clusters were removed, in which we were
not interested. The second step was an MW filter. Here, we used the lowest and highest MW
from the previously discussed stabilizer analysis as a lower and an upper threshold. Finally, we
rejected all compounds that were present in more than 15 PDB entries. This value has been
arbitrarily chosen in order to include the most frequent PPI stabilizer FOK. We included this
constraint because various chemical components are frequently found in crystallization buffers
and can be regarded as promiscuous binders. For example, glycerol is present in more than
8,000 PDB entries. For the remaining chemical components we obtained the corresponding
PDB entries for subsequent structure-based analysis.
Preparation of Preselected Candidate Structures
For further analysis, we split every PDB file into a receptor and a ligand file. We exclusively
extracted the ligand binding pocket from the receptor part. As a simple criterion to define the
ligand binding pocket, we selected all residues containing at least one atom with a maximum
distance of 17.0 Å to the ligand’s geometric center. This value has been arbitrarily chosen based
on the observation that for the known stabilizer-bound structures a sufficiently large pocket
was extracted. We only kept receptors and corresponding ligands if the receptor consisted of
at least two protein chains to ensure that only PPI complexes were selected.
Additionally, we extracted information of the receptor chains to group the candidates into
homo- and heterooligomeric PPIs. The latter is not a straightforward procedure because the
necessary information in PDB file headers are rather inconsistent. However, a substantial part
can be captured by checking for the occurrence of a single COMPND entry listing multiple
chain identifiers. This uniquely identifies homooligomers. In the case of multiple COMPND
entries, we checked if they contain the same molecules by comparing their names, which can
also be used to distinguish between homo- and heterooligomers.
PPI Analysis of Preselected Candidate Structures
We used the MultivalentInteractionAnalyzer to calculate the contact properties of the prepared
structures in order to filter for stabilized PPI candidates. For this purpose, we used the BSA
parameter values we retrieved from the known stabilized PPIs to define three filter criteria.
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F racBSAMinL : Criteria to reject candidate structures with too few contacts between ligand
and complex. As lower cutoff we used the minimum observed F racBSAL within the set of
known PPI stabilizers.
BSAMinorC L : Criteria to reject candidate structures where at least one protein-ligand contact
is too small. As lower cutoff we applied the smallest observed BSAC L between ligand and any
single protein contact chain C within the set of known PPI stabilizers.
BSAMa jorC L : Criteria to reject candidate structures where no protein-ligand contact is large
enough. This is also a lower cutoff and was chosen as the smallest BSAC L, where L is again
the stabilizing ligand and C are those contact chains from every analyzed PPI that form the
larger contact area with the ligand.
Pocket-guided Grouping of PPI Stabilizing Candidates
Finally, we grouped the remaining binding pockets by their 3D structural conservation. For
this purpose we implemented the BALL tool PPIReceptorMapper. This tool takes as input two
extracted PPI receptors and calculates an optimal mapping of their Cα backbone using BALL’s
StructureMapper class with default parameters. Our tool provides the optional parameters
CAmin and RMSDmax , which can be used to control if the mapping of a receptor pair is
accepted, that is if they are structurally conserved. Parameter CAmin is a lower cutoff for the
number of Cα atoms that must be aligned to accept a receptor pair. RMSDmax is an upper cutoff
that receptor pairs mustn’t exceed in order to be an accepted match. Using a straightforward
procedure, we iterated over all PPI receptor candidates and grouped successfully superposed
receptor pairs and the corresponding ligands. For every evaluated receptor, we first searched
for matching pocket in already existing groups. In case of a group match, the receptor was
added to it. Otherwise, it was compared to all ungrouped receptors and in case of an accepted
matching a new group was formed.
5.2.4 Redocking of Known PPI Stabilizers
To test the ability of protein-ligand docking software to correctly reproduce and rank the
binding poses of small molecule PPI stabilizers, we performed redocking experiments of a
subset of the known and newly identified stabilizing ligands. As an exemplary protein-ligand
docking software we evaluated Glide from the Schrödinger Small-Molecule Drug Discovery
Suite.171
Structure Preparation
Protein-ligand structures from the PDB were analyzed and prepared using Schrödinger Mae-
stro.172 First, we deleted all waters as well as other organic compounds. Additionally, all ions
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without contact to the ligand were deleted. To prepare the PPI receptors we also removed
the ligands from their binding pockets. Preparation was performed according to the Protein
Preparation Wizard protocol with slightly modified settings: In case of alternative side-chain
conformations, we kept the candidate with highest occupancy. We further checked if all side-
chains in the binding pocket and adjacent to it were complete. We included sampling of water
orientations in the hydrogen bond refinement step. Finally, we applied restrained energy
minimization to the entire protein.
Suitable ligand conformations for docking were generated using LigPrep.173 As input
structures we used the crystallized ligands. Possible protonation states were generated in
a pH range from 5.0 to 9.0. We disabled the option to generate tautomers and forced the
software to determine ligand chiralities from the input 3D structures. A single low energy ring
conformation was calculated for every ligand.
Receptor Grid Calculation and Protein-Ligand Docking
The rectangular grid boxes capturing the PPI receptor were centered at the ligand centers.
The dimensions of the inner box were kept at the default size of 10 Å. The dimensions of the
outer boxes were adjusted for the docking of ligands with similar size as the reference ligand.
Calculation of receptor grids was performed without constraints using Glide.171
Flexible docking of the prepared ligands into the PPI receptor grid was also performed
using the Glide single precision (SP) scoring function. Default parameters were used with two
exceptions: The number of poses included for post-docking minimization was increased to 20
for every ligand and ten poses per ligand were written to the output.
Analysis of Docking Accuracy
To assess the accuracy of the employed docking software to reproduce and to rank PPI-ligand
complexes, we calculated the RMSD between the top-ranked docking pose according to the
glide docking score and the crystallized ligand conformation. Additionally, we calculated the
RMSDs of the docking ranks 2-5 and the native ligand conformation to evaluate if better or
possibly correct solutions are found on lower ranks.
5.2.5 Virtual Screening for 14-3-3◦Task3 Stabilizers
To translate the insights we gained from analyzing PPI stabilization by small molecules, we
integrated this knowledge into a VS for ligands with the potency to stabilize the interaction of
14-3-3σ and the previously described potassium channel Task3 (Section 5.2.1). We decided
to use this target as our model system because we had access to in vitro assays for validation
as well as to materials and methods for crystallization of this target. Furthermore, Task3 has
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been shown to be overexpressed in several types of cancer and it is linked to neuropathological
disorders like ischemia or epilepsy.174,175 Thus, small molecule stabilizers for this PPI would
form useful tools in chemical biology research or even could serve as candidates for drug
development. In a previous study, we evaluated the druggability of a comparable complex of
14-3-3 and PMA2 using the prediction method SCREEN developed by Nayal and Honig.176
Here, this complex achieved a druggability index DI > 0.8 and is thus classified as highly
druggable.110
Structure Analysis
Various high-resolution structures of 14-3-3σ in complex with mode III phosphopeptides are
available from the PDB as well as currently unpublished data. We took a subset of these
structures for further analysis and to select an appropriate model for structure-based VS. The
analyzed structures are listed in the appendix (Tables E.2 and E.3).
All structures possess a single monomer of 14-3-3σ in the asymmetric unit. To perform
further analysis we superposed these complexes using the macromolecular modeling tool
Coot.177,178 Superposition was performed using Coot’s implementation of the Secondary Struc-
ture Matching (SSM) algorithm developed by Krissinel and Henrick.179 As reference structure
for superposition we used 14-3-3 chain A from PDB entry 3p1n without bound peptide.
Analysing Conserved Waters
Due to the availability of high-quality structures for 14-3-3σ in complex with naturally oc-
curring and artificial mode III phosphopeptides, we performed an in-depth-analysis of the
crystallographically resolved waters. We were especially interested in their spatial conser-
vation throughout all analyzed structures to get hints which waters might to be kept for
structure-based VS.
For this purpose, we implemented the tool ConservedWaterFinder using BALL. The tool
requires a set of superposed PDB structures for water analysis. In the first step the distribution
of water B-factors is analyzed for every input structure separately. Due to the dependence of
the atomic B-factor on crystallographic resolution we performed a z-score normalization of
the water B-factors using Eq. 5.5. As robust estimates for mean and standard deviation we
used median and median absolute deviation (MAD), respectively.
z(wi) =
Median([b(w1), b(wn)])− b(wi)
MAD([b(w1), b(wn)])
(5.5)
Here, n is the number of waters and b(wi) is the B-factor of water i. Median([b(w1), b(wn)])
is the B-factor median of all waters. The MAD is calculated equivalently. As we were interested
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in positive z for waters with low temperature factors, we substracted b(wi) from the median
in the numerator. The calculated z-scores can be used to filter for spatially highly conserved
crystallographic waters with respect to the considered crystal structure. The ConservedWa-
terFinder thus provides a parameter zcut , which is used as a filter criterion to delete waters wi
with z(b(wi))< zcut .
In the next step, the waters of all input structures are inserted into a global water map.
This water map is then hierarchically clustered using Ward’s minimum variance method with
pairwise water distances as dissimilarity measure.46 Again, the ConservedWaterFinder provides
a cluster selection parameter cs to cut the cluster hierarchy. Additionally, an optional parameter
smin can be specified to delete clusters ci with |ci| < smin. Finally, all waters that are part of a
remaining conserved water cluster are written into a PDB file for visual inspection.
Compound Library for Virtual Screening
As compound library for virtual screening we used a subset of the custom vendor library
introduced in Section 4.2. All compounds and their Murcko scaffolds were encoded as ECFPs
using pharmacophore feature atom typing. To select this subset we clustered the vendor library
using the previously introduced chemoinformatics tools with some modifications.
In brief, we used scaffold fingerprints as input and skipped CC decomposition. We directly
used the parallel RNN clustering method to merge RNN scaffold families up to a lower similarity
cutoff STan = 0.6. The resulting clusters were then hierarchically clustered using the complete
molecule fingerprints if their size exceeded 1,000 compounds. The medoid selection procedure
was applied to select cluster representatives, which were included into the virtual screening
library. The latter finally comprised 197,062 compounds.
Protein-Ligand Docking
The virtual screening library was prepared with LigPrep using default parameters except using
Ionizer instead of Epik for ionization (option: –i 2).173 This produced 513,900 conformers as
input for protein-ligand docking.
The PPI receptor preparation was performed using the Protein Preparation Wizard of
Schrödinger Maestro with slightly modified settings:172 We kept the entire ternary complex
and the waters surrounding reference ligand FSC for optimization of hydrogen bond net-
works. We restricted the energy minimization to hydrogens only. Finally, we removed all
water molecules with the exception of those waters that were defined as conserved on the
basis of the previously described conserved water analysis. The receptor grid generation was
performed with Glide using default settings.180 The grid center was defined by selecting FSC
as the reference ligand. The cubic grid box had the outer dimensions of x = y = z = 27.71 Å.
73
5. In Silico Analysis of Protein-Protein Interaction Stabilization
The prepared ligand conformers were docked into the 14-3-3σ◦Task3 receptor grid using
Glide in SP mode.54,171,181 We set the maximum number of reported poses to 200,000 com-
pounds and used default settings for all other options. For further processing, the docked
compound poses were sorted according to decreasing docking score.
In order to choose an appropriate upper docking score cutoff to select solutions for further
analysis, we also calculated the docking score of the reference ligand in place. Here, we used
the FSC conformation from protein preparation as input ligand and calculated the docking
score using the Glide SP scoring function.
PPI Contact Filter
To tailor the structure-based VS approach to the discovery of PPI stabilizing ligands, we filtered
all generated docking poses using our MultivalentInteractionAnalyzer. Here, we again used the
filtering criteria F racBSAMinL , BSA
Minor
C L , and BSA
Ma jor
C L , which were introduced earlier in this
section. In this way, we rejected all docking poses that did not match the PPI stabilizer criteria
we derived from structure analysis described in Section 5.2.2.
Reference Ligand Filter
As a final step, we exploited the availability of the co-crystallized reference ligand FSC, which
was not incorporated up to this point. However, none of the available studies yields information
on SAR, which we could have used to define constraints on the docking poses. Thus, we
decided to score the volume overlap of the filtered docking poses and the reference ligand
FSC and to rank the remaining poses accordingly. For this step, we used the free software
tool Shape-it from Silicos-it.182 This software uses a method to align molecules described by
Gaussian atom descriptions.183 Shape-it calculates a Tanimoto-based volume overlap score
which we used for final docking pose ranking.
Compound Selection
Based on this final ranking, we selected compounds for experimental validation. Selected can-
didates were acquired from MolPort (http://www.molport.com/). Compounds were delivered
in solid form. We dissolved the compounds in dimethyl sulfoxide (DMSO) and stored them as
20 mM stock solutions at -20 °C.
In Vitro Validation of Selected Compounds
To assess the compounds’ potential to stabilize the protein interaction of a Histidin-tagged
14-3-3σ and FAM-labeled phosphopeptide from Task3 in vitro, an fluorescence polarization
(FP)-based assay was performed (Maria Bartel, TU Eindhoven).184 An initial validation screen
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was performed to identify potential candidates, which were analyzed in more detail to deter-
mine the compounds’ EC50.
Additionally, three control experiments were conducted. First, the assay was performed
without peptide to test if the compounds themselves interfere with the assay. Second, the
Task3 phosphopeptide was replaced by a peptide from C-Raf (residues 252-264) surrounding
phosphorylated Ser259. This C-Raf peptide is no mode III motif and the sequence exceeds
the +1 position following the phosphorylated residue. This markedly reduces the size of
the binding pocket in the 14-3-3◦C-Raf complex and prevents FSC binding and complex
stabilization. Finally, the compounds were tested on an entirely different PPI using the same
assay. This target complex consisted of retinoid X receptor with a co-repressor and a known
ligand as a negative control.
Protein Crystallization
To verify our structure-based VS approach we also tried to obtain ligand-bound crystal struc-
tures of the validated 14-3-3σ◦Task3 stabilizers. 14-3-3σ was used as a C-terminally shortened
construct (14-3-3σ∆C), which was truncated after Thr231. Cloning, expression and purifica-
tion of 14-3-3σ∆C was performed as described by Schumacher et al..185 Protein was provided
by the Ottmann lab. Task3 peptides were synthesized by Biosyntan (Berlin) and re-suspended
in Millipore water. Complexation solution was mixed from 14-3-3σ and peptide at a molar
ratio of 1:2 and diluted using the complexation buffer listed in the appendix (Table E.7) to
reach a final 14-3-3σ∆C concentration of 14 mg/ml.
Crystallization buffers were created as a 2D grid variation consisting of 24 different condi-
tions (C1-C24), which is based on a successful crystallization buffer for complexes of 14-3-3σ
with a phosphopeptide from YAP. The original condition and the derived grid variations are
listed in the appendix (Table E.8). The pH values of the Na-HEPES buffers were pre-adjusted
and these solutions were used to set up the crystallization conditions with a final concentration
of 95 mM Na-HEPES. This procedure has been performed in accordance to the production
report of the original crystallization buffer (JCSG Core I, Qiagen®).
For soaking experiments, we performed hanging-drop crystallization experiments at 4 °C.
For this purpose, reservoirs from a 24-well plate were filled with 500 µl of crystallization buffer.
Hanging-drops were mixed from 2 µl complex solution with 2 µl crystallization buffer from
the reservoir and placed on a cover glass, which was used to seal the well. Diffracting crystals
grew within a week. We then soaked these crystals with candidate compounds. Therefore, we
injected compound DMSO stock solution directly into the hanging-drops and incubated them
four days. As the mother liquors in the hanging-drops were cryogenic, we directly flash-froze
the crystals in liquid nitrogen for subsequent diffraction experiments.
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Data Collection and Structure Elucidation
Diffraction experiments were performed in-house using a rotating copper anode from Rigaku
(MicroMAX-007 HF) as an X-ray source. This beamline was equipped with a MAR345 image
plate. Data processing was carried out using the software package XDS.186 During this step,
choice of the lowest resolution to trim the data sets was based on three parameter values of
the outermost shells. First, we required a minimum signal to noise ratio of 4.0. Second, we
required a minimum completeness of 90.0 %. Third, we required the redundancy independent
R-factor (Rmeas) to be lower than 40.0 %. Crystal parameters and data collection statistics are
listed in the appendix (Table E.9).
The CCP4 software collection for macromolecular X-ray crystallography was used for
phase determination and automatic refinement.187 MR was carried out with PHASER (version
2.1.4).188 PDB entry 3p1n without waters was used as a search model. This model contains an
identical complex of 14-3-3σ and Task3 phosphopeptide. MR solutions were used as starting
data for iterative cycles of manual and automatic refinement with REFMAC (version 5.5) and
COOT (version 0.6), respectively.178,189 Final refinement statistics are listed in the appendix
(Table E.9). Corresponding Ramachandran plots were generated with RAMPAGE and are
shown in the appendix (Fig. D.4).
5.3 Results
The first part of this section shows the characteristics for small molecule stabilizers of PPIs and
the analyzed determinants that we have drawn from the interaction properties with their PPI
receptors. Next, we present the results of screening the PDB for unrecognized small molecule
stabilized PPIs and the outcome of our stabilized redocking experiments. Finally, we present
the results of our VS approach for the discovery of small molecule PPI stabilizers for the
14-3-3σ◦Task3 PPI.
5.3.1 Structural Characterization of PPI Stabilization
Table 5.1 lists the calculated structural and physicochemical properties of the eight evaluated
small molecule PPI stabilizers. Additionally, it shows the Ro5 thresholds for these properties.
With the exception of FSC, all analyzed small molecules lie within the Ro5 limits and thus are
typical druglike compounds. However, the fungal metabolite FSC is a plant toxin and thus not
expected to be Ro5 compliant.
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Table 5.1: Structural and physicochemical properties of small molecule PPI stabilizers.
These properties form the Ro5 and are commonly used to describe the oral bioavailability.
The Ro5 limits are listed in the bottom row.
Hydrogen bond
Ligand ID MW Donors Acceptors AlogP
AFB 280.4 2 4 2.2
EBT 308.4 4 5 -1.3
FOK 410.5 3 7 0.8
FSC 680.8 4 12 1.9
IAC 175.1 2 2 1.8
0MT 440.4 2 6 4.4
OGK 321.4 2 4 2.4
YR1 460.4 3 8 3.2
Ro5 < 500.0 < 5 < 10 < 5.0
Contact Analysis of Stabilized PPIs
The initial properties we analyzed were the contact surface sizes, BSAAL and BSABL, of the
ligands to every single protein chain of the stabilized PPI, which is shown in Fig. 5.4. Subfigure
A shows the measured BSAs in Å2. Fig. 5.4B displays the ratios of the smaller and the larger
BSAs. A contact ratio of 1.0 would indicate equally sized contact surface sizes of the ligand to
both PPI receptor chains.
Interestingly, these contact ratios span an extremely wide range. The smallest ratio is < 0.1
and it is observed for the phytohormone OGK binding to its PPI receptor. This is due to a very
small surface contact between OGK and the minor contact chain as can be seen in Fig. 5.4A.
In fact, it is the smallest contact size observed for all analyzed PPI complexes. In contrast,
the ratios for EBT and FOK are 0.96 and 0.99, respectively. Both ligands share nearly equally
sized contacts with both of the PPI receptor chains. In general, the apparent trend seems to be
either the occurrence of one chain with large ligand contacts and one chain with small ligand
contacts or complexes with equally distributed protein-ligand contacts.
Fig. 5.4C shows the results of evaluating the fraction of surface area that a stabilizing
ligand looses upon binding to a rim-exposed PPI pocket (F racBSAL). The result values span
from 0.66 for FSC binding to 14-3-3σ◦Task3 up to 0.98 for IAC binding to AuxIAA◦TIR1.
Interestingly, the lowest five F racBSAL values are observed for the complexes involving
14-3-3 proteins.
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Figure 5.4: Surface contact analysis. The analyzed PPI complexes are identified by their
PDB ID and the Ligand ID in the format <PDB_ID.Ligand_ID>. (A) Contact sizes between
ligand and receptor chains (BSAAL and BSABL). Light grey bars represent smaller ligand-
chain contact sizes and dark grey bars the larger ones, respectively. Inferred lower cutoffs
for filter criteria are indicated: BSAMinorC L (dashed green line) and BSA
Ma jor
C L (dashed red
line). (B) Contact ratios of BSAAL and BSABL . (C) F racBSAL of the analyzed stabilizing
ligands. The inferred lower cutoff for our filter criteria F racBSAMinL is indicated by a
dashed line.
5.3.2 Stabilizer Candidates in the Protein Data Bank
The workflow for our PDB screening is shown in Fig. 5.3. The Chemical Components Dictionary
of the PDB comprised 16,727 compounds at that time (accessed 8/8/2013). The results of
the initial ligand-based filtering are listed in Table 5.2. As upper and lower MW cutoffs we
used 700 Da and 170 Da, respectively. These values were chosen on the basis of the MW
range of known PPI stabilizers listed in Table 5.1. Besides these MW filters we applied no
further Ro5 filter criteria because they rather reflect pharmacokinetic and -dynamic properties
of compounds, which is of minor interest to this study. The applied filters reduced the number
of candidate ligands down to 12,032 compounds.
Next, we analyzed the entire PDB structure of every candidate ligand. Based on the ob-
served PPI contact sizes described in the last subsection we set our PPI stabilizer filter criteria
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Table 5.2: PDB ligand filtering results.
Filter Limit Compounds
Organic 15,977
MW lower ≥ 170 13,694
MW upper ≤ 700 12,946
PDB occurrence ≤ 15 12,032
as listed in Table 5.3a. The corresponding cutoffs are highlighted in Fig. 5.4A and 5.4C. We
have not taken the contact ratio into account because we subsume that the real ligand-chain
contact sizes are more important than their ratio. Additionally, the contact ratios span such
a wide range that a filter criterion most probably would not be discriminative. As listed in
Table 5.3b, these settings finally yielded 2,045 candidate PPIs, whereof 412 were classified as
heterooligomers and 1,633 as homooligomers. To reduce these candidates to a non-redundant
set, we grouped them by receptor conservation using the introduced PPIReceptorMapper. Map-
ping parameters were set to CAmin ≥ 35 and RMSDmax ≤ 1.0 Å. These settings finally yielded
86 unique heterooligomeric PPI candidates and 333 unique homooligomeric PPI candidates.
Table 5.3: Filter criteria and results of the structure-based screening for potentially
overlooked stabilized PPIs in the PDB.
(a) Applied filtering criteria
Filter criteria Unit Cutoff
F racBSAMinL 0.66
BSAMinorC L Å
2 34.0
BSAMa jorC L Å
2 207.0
(b) Resulting stabilized PPI candidates
Heterooligomer Homooligomer
Total 412 1,633
Mapped 49 175
Unmapped 37 158
Manual Validation of True PPI Stabilizers
As we were interested to know if the selected candidates contained true stabilizers we manually
inspected the 86 heterooligomeric PPI-ligand complexes. For this purpose, we searched in the
corresponding PDB entries and the original literature for reports on a stabilizing effect of these
ligands on the PPIs. Indeed, we found such information for six of these complexes, which are
listed in Table 5.4 and briefly described in the following.
The structure of the enzyme histone deacetylase 3 (HDAC3) in complex with a co-repressor
domain was recently reported by Watson et al..190 Binding of co-repressors to HDAC3 can
regulate their enzymatic activity. In this work, the structure reveals an inositol tetraphosphate
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molecule which acts as a molecular glue between the proteins. In the recent past, histone
deacetylases moved into the focus as anticancer targets and this mechanism possibly hints at
a strategy to modulate these enzymes.
N-methyl-D-aspartate (NMDA) receptors are transmembrane protein complexes, whose
natural ligand is glutamate.191 These receptors form heteromeric ion-channels and some
family members contain the protein subunits GluN1 and GluN2B. The ion-channel activity
of these subtypes can be modulated in an allosteric way by phenylethanolamine derivatives
like the inhibitor Ifenprodil, which has neuroprotective activity.192 The mechanism of these
compounds has recently been identified by Karakas et al..193 They solved a crystal structure
where the compound binds into a rim-exposed pocket in the interface of GluN1 and GluN2B.
Binding leads to a stabilization of the heterodimer and establishes an interesting approach to
modulate this important target class.
The actin-related protein (Arp) 2/3 protein complex is a heteromeric ATPase, which at-
taches to existing actin filaments and triggers the nucleation of new branches.194 Small
molecule inhibitors of this function have been described and their mode of action was re-
vealed by crystal structures reported by Nolen et al..195 Some of these compounds bind into
a rim-exposed pocket in the heterodimer interface of Arp2◦Arp3. The described mechanism
is a blocked movement of these subunits into their active conformations, which can also be
considered as a stabilization of a protein interaction.
We found several examples for related nuclear receptors whose regulatory effect on target-
gene expression is physiologically modulated by binding to specific co-repressor proteins. An
example is the retinoic acid receptor alpha (RARα), whose activity can be silenced by binding
of nuclear receptor co-repressor 1. Le Maire et al. recently reported on a small molecule that
strengthens this interaction and supports silencing.196 Again, the crystal structure shows that
the small molecule contacts both interacting proteins.
A well known example for an allosterically stabilized PPI is the α◦β heterodimer in poly-
merized tubulin, which has been described in Section 2.4.3. In addition to the allosteric
stabilizers we found direct stabilizers like the alkaloid colchicin. This molecule binds to the
interface of the α and β subunits.197
Finally, we identified multiple PDB entries containing viral capsids, which are composed
of different subunits. One example is a capsid from a human rhenovirus containing the coat
proteins VP1 and VP2 as subunits. Here, a small molecule binds to an interface pocket of
VP1◦VP2.198 Binding of these compounds stabilizes the capsid and hinders uncoating of the
virus, which forms an interesting starting point for antiviral drug development.
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5.3.3 Redocking of Known PPI Stabilizers
For redocking experiments, we selected one representative PPI-ligand complex from every
identified target group listed in Table 5.4. If a target group comprised more than one PPI-
ligand complex, we have chosen the entry with best crystallographic resolution.
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Figure 5.5: Redocking of a representative subset of PPI stabilizing small molecules
(nomenclature: <PDB_ID.Ligand_ID>). The light grey bars indicate the RMSD between
the stabilizers’ experimental geometry to the top-ranked docking pose. The dark grey
bars indicate the lowest RMSD observed between the stabilizers’ experimental geometry
and the five highest scoring docking poses.
For HDAC3 in complex with a co-repressor we only found one example in the PDB (4a69).
The crystal structure shows HDAC3 in complex with a co-repressor, which is described to
be stabilized by an inositol tetraphosphate (IP4) molecule. In addition to IP4, two glycerol
molecules are located in the same binding pocket, which extensively contact the ligand. These
contacts bridge the space between IP4 and the HDAC3◦co-repressor complex. In principle, it is
possible to treat these glycerol molecules as part of the receptor, but we have decided to skip
this PPI because this arrangement appeared too artificial as to be included in this study.
All redocking experiments were performed as described in Section 5.2.4. For PDB entry
1ncq manual intervention was necessary because assigned bond orders of ligand W11 were
wrong. Bond orders were corrected based on the chemical component description of W11.
Fig. 5.5 summarizes the redocking results. The bar chart shows RMSD values for non-
hydrogen atoms between crystallized ligand conformation and docked ligand poses. The
light-grey bars were calculated for the top-ranked docking pose according to the Glide SP
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docking score. Dark-grey bars represent the pose within the five highest ranking docking poses
that has the lowest RMSD to the crystal ligand conformation. Thus, if both bars have the
same height, the top-ranked ligand is also closest to the native pose. The RMSD threshold of
2.0 Å is highlighted as a dashed grey line, which has frequently been used to evaluate the
accuracy of docking algorithms and it is a commonly accepted cutoff to classify docking poses
into correctly predicted (≤ 2.0 Å) and false predicted (> 2.0 Å).199–201
The docking software predicted correctly ranked docking poses for nine out of ten sta-
bilizing ligands when docked into their native PPI complexes. For the stabilizers IAC, AFB,
FOK, W11 and FSC the lowest RMSD pose is also the one with lowest Glide SP score. A
more accurate ligand pose is found for the stabilizers EQO, CKH and LOC within the docking
ranks 2-5. However, the difference between these conformations and the top-ranked pose
is only 0.57 Å on average. For these cases, a pose clustering of the docking conformations
would group these solutions together. The largest deviation is found for stabilizer CKH with
an RMSD of 1.06 Å. This is due to the freely rotatable para-fluorobenzene ring of the ligands
2-fluorobenzamide moiety, which is flipped by 180° as shown in Fig. 5.6.
Only the docking of ligand QEL into the complex of GluN1 and GluN2B failed to rank
a correct ligand conformation best. As indicated by the dark grey bar for this complex, the
docking algorithm samples a correct ligand pose but the scoring function failed to correctly
score this pose best.
Figure 5.6: Binding pocket of PPI stabilizer CKH in the interface rim of the Arp2◦Arp3
complex (PDB ID: 3ukr). The protein is shown as cartoon and semi-transparent SES
colored by chain (green: Arp3; gold: Arp2). The crystallized ligand conformation of CKH
is shown as ball-and-stick model with grey carbons. The top-ranked docking pose of CKH
is also shown as ball-and-stick model with yellow carbons. The major difference for CKH
is the 180° flip of its para-fluorobenzene moiety.
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5.3.4 Virtual Screening for 14-3-3◦Task3 Stabilizers
To select an appropriate structure of 14-3-3σ in complex with a mode III phosphopeptide for
VS we analyzed 11 candidates from the PDB and unpublished in-house date sets, which are
listed in the appendix (Tables E.2 and E.3). The collection comprises mammalian and plant
14-3-3 homologs and targets that were crystallized under different conditions.
Superposition of these structures yields an average RMSD of 0.87 Å for 14-3-3 monomers.
This confirms the high structural conservation of this protein. However, visual inspection of
the superposed proteins revealed the occurrence of two pronounced conformations of helix 9.
Backbone models of two representative structures are shown in Fig. 5.7 where the two distinct
conformations of helix 9 are highlighted in green and red, respectively. FSC (stick-model and
yellow SES) is shown in the rim-exposed binding pocket formed by 14-3-3 and Task3 peptide.
As helix 9 is part of this pocket, the selection of one conformer for protein-ligand docking will
significantly affect its outcome.
Tyr213
*Glu110
1.7 Å
Figure 5.7: Superposition of the two major helix 9 conformations of the analyzed
14-3-3 crystal structures. One 14-3-3σ monomer is shown as grey SES and a bound
Task3 peptide as blue SES. Reference ligand FSC is shown as ball-and-stick model and
semi-transparent yellow SES. Observed helix 9 conformations are represented as green
and red ribbons. The red conformation is only present in crystal structures of space
group C2221. Here, helix 9 is strongly curved most likely due to a charged-assisted hy-
drogen bond of Tyr213 to *Glu110 of a neighboring 14-3-3 symmetry mate. Therefore,
the red conformation seems to be a crystallographic artifact leaving most likely the green
conformation as the biological relevant.
84
Results
We found that the red conformation is only present in the high-resolution structures crys-
tallized in space group C2221. In most of these structures the distorted conformation of helix
9 is most likely due to a charge-assisted hydrogen bond between Tyr213 and *Glu110 of a
neighboring symmetry mate. 14-3-3 structures of other space groups lacking this spatial ar-
rangement possess a straight helix 9. Hence, we subsume that the bent (red) conformation
is a crystal artifact and the straight one (green) is its native conformation. Fortunately, a
high-resolution crystal structure of space group C2221 with a straight helix 9 conformation
was available to us. This structure is not deposited with the PDB and was solved in-house at
the MPI Dortmund. It is a complex of 14-3-3σ◦Task3 with bound FSC as the reference ligand
and it was generated using the procedure described in Section 5.2.5. With a resolution of
1.65 Å this structure is well suited for modeling tasks and we chose it as template for VS.
Conserved Waters
The selection of waters to keep in our docking template was performed using the ConservedWa-
terFinder described in Section 5.2.5. As input structures we used the nine mammalian complex
structures listed in the appendix (Table E.2). The superposed main chain atoms of the 14-3-3σ
monomers yield an average RMSD of 0.48 Å. In total, the analyzed structures contain 2,619
waters. Fig. 5.8A shows the binding pocket with FSC and all resolved crystal waters. To select
waters with a low B-factor, we applied the ConservedWaterFinder using zcut = 1.0, which is
exceeded by 891 waters in total. The B-factor filtered composition in the region of interest is
shown in Fig. 5.8B and contains 87 waters.
The remaining 87 waters were clustered and using a level of 1.5 Å to cut the hierarchy
yielded 29 water clusters. Furthermore, we required clusters to contain at least four members
yielding 11 clusters. These are displayed in Fig. 5.8C and they comprise 60 low B-factor
waters. From these candidates, we chose four clusters to select highly conserved waters to be
preserved for docking.
These clusters were chosen for two reasons. First, they sit deeply buried in the binding
pocket and are trapped between protein and FSC. Second, two of these clusters occupy space,
wherein several alternative conformations of the highly flexible 14-3-3 residue Lys49 place
their primary amine. Fig. 5.8D shows the selected water clusters and observed Lys49 con-
formations. Thus, keeping these waters additionally provides a reasonable alternative to the
selection of an appropriate conformation of Lys49 in the docking template.
Virtual Screening Results
Using the selected 14-3-3◦Task3 complex in combination with the conserved waters chosen
in the previous subsection, we performed the VS workflow as described in Section 5.2.5. The
results are summarized in Table 5.5.
85
5. In Silico Analysis of Protein-Protein Interaction Stabilization
A B
C
HOH P64
HOH A356HOH A242
HOH A388
D
HOH A356
HOH P64
HOH A242
HOH A388
Lys49
Figure 5.8: Conserved water analysis. Binding pocket, reference ligand FSC and waters
within a 11.0 Å radius around the ligand center are shown. 14-3-3σ is shown as green SES,
Task3 as gold SES. Reference ligand FSC is shown as stick model with yellow carbons. (A)
Crystallographic waters from nine 14-3-3 structures. (B) Waters with a B-factor z ≥ 1.0
(C) Low B-factor waters after cluster selection at a threshold of 1.5 Å. Finally selected
waters are highlighted by red spheres centered at the corresponding water positions of our
docking template. Numbering according to PDB entry 3spr. (D) Selected water clusters
and observed conformations of 14-3-3 residue Lys49 (stick model, yellow carbons).
The first step in our VS workflow was a protein-ligand docking of the prepared library
comprising 513,900 conformers, which was generated from 197,062 unique compounds. The
described settings yielded 511,996 conformations, which passed the Glide SP energy funnel.
To select an appropriate docking score cutoff for filtering these docked conformations, we
calculated the docking score of reference ligand FSC in place. Thus, no conformational
sampling was performed. Using the same receptor grid as for protein-ligand docking, FSC
receives a docking score of −7.66 kcal/mol. Based on this value, we decided to apply an upper
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Table 5.5: Filtering results from VS.
VS Step Candidates
Protein-ligand docking 511,996
Reference ligand docking score cutoff 954
MultivalentInteractionAnalyzer 258
Purchased compounds 89
binding energy threshold of −7.0 kcal/mol. Interestingly, only 954 unique compounds fall
below this energy value.
The last filtering step in our VS approach was the application of the MultivalentInteraction-
Analyzer using the observed criteria for PPI stabilization by small molecule ligands. Here, we
applied the same cutoffs as used for the PDB stabilizer screening from Section 5.3.2. These fil-
tering criteria reduced the number of remaining stabilizer candidates down to 258 compounds.
Additionally, our PPI stabilizer filter performed a similar task as a normalization function.
These functions are frequently applied to balance MW and docking score because larger com-
pounds tend to achieve better docking scores due to scoring functions additivity.202,203 This
balancing effect is visualized in Fig. 5.9. The histogram shows that the mean MW is shifted
from 595 Da (σ = 265) down to 396 Da (σ = 95).
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Figure 5.9: MW histogram. Dark grey bars represent a histogram for the 258 top-ranked
docking poses from protein-ligand docking. Light grey bars represent a histogram for the
258 final candidates after application of the PPI stabilization filter.
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Finally, this resulting candidate list was sorted by increasing volume overlap of ligand
poses with reference ligand FSC as described in Section 5.2.5. From the final 100 top-ranked
stabilizer candidates we were able to obtain 89 samples for in vitro testing, which are listed in
the appendix (Table E.4).
In Vitro Validation Experiments
To test the 89 candidate compounds with respect to their ability to stabilize the interaction
of 14-3-3σ and a Task3 phosphopeptide, we performed the described in vitro assay (Maria
Bartel, TU Eindhoven). Results are shown in the appendix (Fig. D.2). Compounds S2, S37 and
S43 showed preliminary stabilizing activity (Fig. 5.10D). Subsequent titration experiments
are shown in Fig. 5.10A and revealed EC50 values of 115.9 µM for S2, 125.2 µM for S37 and
47.3 µM for S43. In comparison, the reference ligand FSC showed an EC50 of 1.0 µM.
The first control experiment was intended to test if candidates interfere with the FP assay
(data not shown). Compound titration without Task3 peptide showed no significant signal
increase. Thus, the measurements seem not to be the result of assay artifacts. The second
control experiment was titration of the compounds against retinoid X receptor with a co-
repressor as an entirely different target to test for unspecific binding to protein. The results,
displayed in Fig. 5.10C, suggest presence of unspecific binding events for compounds S2 and
S37, which classifies them as false positive hits. In contrast, compound S43 shows only a
marginal signal increase at higher concentrations. However, this signal increase at higher
concentrations is observed for most of the 89 tested compounds as can be seen in the appendix
(Fig. D.2). Finally, all compounds were titrated against 14-3-3σ and a phosphorylated 10-mere
from C-Raf (252–264; pSer259), which is shown in Fig. 5.10B. Here, S2 and S37 showed
the same behavior as in the previous assays. In this assay, S43 shows also stabilizing activity,
which could point to unspecific 14-3-3 complex stabilization because the binding pocket in
this mode I complex is markedly smaller. Stabilizer candidate S43 is shown in Fig. 5.11.
Soaking and Crystallography
To test our VS hypothesis and to elucidate if the stabilizer candidate S43 binds as expected,
we performed soaking experiments as described in the Section 5.2.5. Crystals tolerated up
to 0.5 µl compound DMSO stock solution in the crystallization drops. The best data set
from diffraction experiments was evaluated to a resolution of 1.85 Å. After several rounds of
iterative model building, including building of water molecules, and refinement we carefully
checked the difference electron density map for occurrence of compound S43. However, no
extra density could be identified and up to now we were not successful in solving a ternary
complex structure of 14-3-3σ, Task3, and S43.
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2.56 Å
OHO
NH
A B
Figure 5.11: Stabilizer candidate S43. (A) 2D depiction of S43 and 3D conformation
from docking. (B) Comparison of docked S43 (stick model; grey carbons) and crystallized
reference ligand FSC (stick model; yellow carbons). 14-3-3σ is shown in green cartoon
representation and the conserved waters as red spheres. The spatially conserved 14-3-3σ
residue Lys122 is shown as ball-and-stick model.
5.4 Discussion
Stabilization of PPIs is as yet an underrepresented mode of action of small molecules, but it is
a very attractive alternative to active site and PPI inhibition. The majority of currently known
and structurally resolved examples are natural products whose mechanism was coincidentally
discovered. The first rational and successful approach to discover PPI stabilizers by means
of HTS was presented by Rose et al. in 2010.25 Additionally, three in silico trials to find
stabilizers by VS have been published as mentioned in the Section 5.1. However, none of these
works studied the structural properties of already known PPI stabilization examples and tried
to integrate the obtained structural information into novel in silico tools to tailor standard
VS approaches to the identification of PPI stabilizing small molecules. Thus, our aim was
to advance this research area by acquiring quantitative knowledge on the principles of PPI
stabilization and to use it to perform an exemplary stabilizer-tailored VS.
Based on a recent review on structurally characterized stabilized PPIs we selected nine de-
scribed structures and analyzed the contact contributions shared between the protein partners
and the stabilizing ligand.22 A common property of all ligands is the large fraction of surface
area that is buried upon binding into the rim-exposed PPI pockets (> 65 %). However, the
partitioning of the contact areas to the protein chains turned out to be highly imbalanced and
the ratio of contact portions ranges from 0.08 to 0.99. Thus, quite small contact surfaces (≥ 34
Å2) between a ligand and one protein partner seem to be sufficient to cause a stabilizing effect.
Additionally, interesting findings were obtained from ligand analysis itself. The distribution
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of typical structural and physicochemical properties used to assess the druglikeness of a com-
pound, as shown in Table 5.1, indicates that currently known stabilizing small molecules were
perfect drug candidates with exception of FSC. However, the hosts of FSC producing fungi are
plant species and thus other pharmacokinetic requirements are imposed on this molecule. The
druglikeness of the other compounds is especially encouraging because it provides a reason-
able chance to identify stabilizer candidates in currently available compound collections. In
contrast, this is not necessarily given for PPI inhibitors because it has frequently been observed
that these compounds tend to break these properties.20,204
We used the obtained quantitative knowledge on PPI stabilization to implement a tool to
screen in silico for stabilizer candidates and applied it on ligand-based preselected candidate
complexes from the PDB. Indeed, we were able to identify further PPIs whose stabilization by
a ligand has been described in the literature. These examples serve as positive controls and a
validation for the structural properties we used to describe PPI stabilization.
The availability of crystal structures of stabilized PPIs enabled us to assess the ability of
state-of-the-art protein-ligand docking software to correctly predict the binding poses of co-
crystallized ligands. This evaluation is of great interest because docking tools were trained on
datasets that solely contain enzyme-inhibitor complexes. However, the results of our redocking
experiments show that the used docking software Glide is well suited for docking stabilizing
ligands into rim-exposed PPI pockets. Thus, the utilization of this tool to perform a VS for PPI
stabilizers can be regarded a valid approach.
Finally, we used our information on PPI stabilization and the developed tools to design a
VS for PPI-stabilizing small molecules. As physiological target we selected the interaction of
14-3-3σ and Task3 because various high-quality crystal structures of this complex and related
14-3-3 complexes are available. This fact led to the development of a tool to select water
molecules that are spatially conserved across multiple crystal structures. Our method does
not use a scoring function to evaluate energetics but is based only on the experimentally
determined crystallographic water positions and their B-factors. Application on available
14-3-3 complexes significantly reduced the number of crystallographic waters and yielded a
small subset of spatially conserved waters. In our opinion, this tool is of great value for CADD
because it facilitates the selection of waters to be added to the receptor grid.
Docking of ∼200,000 compounds revealed a quite large number of potential candidates
for binding into the PPI pocket, but application of our MultivalentInteractionAnalyzer reduced
these poses to a manageable set of stabilizer candidates. Further docking score filtering using
the FSC score as cutoff and volume overlap sorting of the remaining poses yielded a small set
of final candidates. Thus, our PPI stabilizer-tailored VS successfully scaled the large number
of predicted docking poses down to a set of highly promising stabilizer candidates.
In vitro testing of 89 compounds led to the identification of one final candidate (S43),
which stabilized the 14-3-3σ◦Task3 PPI with an EC50 of ∼ 47 µM. Control experiments ex-
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cluded assay artifacts and promiscuous binding to protein. However, until now crystallization
trials of S43 in complex with 14-3-3σ◦Task3 were not successful. Interestingly, compound S43
also seems to stabilize the PPI of 14-3-3σ and a C-Raf peptide phosphorylated at Ser259.
This peptide is not a mode III motif and exceeds the +1 position. However, Molzan et
al. could show that a reduced pocket is still accessible in this complex.110 They also evaluated
the druggability of this complex and report a DI > 0.7, which classifies this complex as
druggable. In addition, the crystal structure of a FSC-based fragment is presented, which
binds into the 14-3-3ζ◦C-Raf pocket. As can be seen in Fig. 5.11, compound S43 is rather
small and therefore might also fit into the 14-3-3σ◦C-Raf pocket. This hypothesis is indeed
supported when inspecting the superposition of docked S43 onto a 14-3-3◦C-Raf complex as
shown in Fig. 5.12. Subfigure A shows the original ternary complex from VS and Fig. 5.12B
shows a superposition onto a structure of 14-3-3σ and a C-Raf peptide phosphorylated at
Ser259. Obviously, S43 perfectly fits into this pocket, which could explain its activity.
A B
Figure 5.12: S43 docking poses and C-Raf superposition. (A) Docking pose of S43 bound
into the interface pocket of 14-3-3σ (green SES fraction) in complex with Task3 (golden
SES fraction). (B) S43 superposed onto binding pocket from 14-3-3σ (green SES fraction)
in complex with C-Raf (blue SES fraction) from PDB entry 3iqj.
In summary, the presented VS for 14-3-3σ◦Task3 stabilizer candidates yielded one final
hit. Further crystallization experiments, especially co-crystallization, are necessary in order
to elucidate the compound’s mode of action and to verify our hypothesis. On a first glance, a
hit rate of about 1.1 % seems to be quite low for a VS approach in contrast to reports on VS
yielding > 30 % hit rates.205–207 However, the majority of reports yielding such high hit rates
use enzyme targets, which are often well studied and the availability of known ligands with low
complexity enable additional screening techniques. In contrast, PPIs are still no standard target
for in silico drug discovery, especially in case of ligand-induced stabilization. Furthermore, the
stabilization of 14-3-3σ and Task3 seems to be already an intrinsically difficult target. This is
supported by three observations. First, a successful HTS campaign on a closely related target
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complex (14-3-3 and PMA2) resulted in a hit rate < 0.01 %, which is also a low result for in
vitro screening.25 Second, a previous VS campaign on this closely related target yielded no
hits.23 Third, the stabilizer FSC is – from a chemical point of view – a highly complex molecule
with only a handful closely related natural products with similar activity.
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Chapter 6
Virtual Screening for 14-3-3 Protein-
Protein Interaction Inhibitors
The content of this chapter is an extended version of the articles:
Covalent attachment of pyridoxal-phosphate derivatives to 14-3-3 proteins.208
Virtual Screening and Experimental Validation Reveal
Novel Small-Molecule Inhibitors of 14-3-3 protein-protein interactions.209
6.1 Introduction
As described in Section 2.5.1, 14-3-3 proteins bind to numerous partner proteins in mam-
malian cells and are thus directly or indirectly connected to various diseases. Most intensely
studied is 14-3-3’s connection to several types of cancer. For example, 14-3-3ζ is found to be
overexpressed in breast cancer, lung cancer, as well as neck cancer.107 Thus, inhibition of this
14-3-3 homolog could be a beneficial treatment for these cancer types. Also in neurodegener-
ative diseases 14-3-3 proteins have been shown to play crucial roles.210 In pathologic neural
tissues various important binding partners of 14-3-3 have been identified like the microtubule-
associated protein tau. 14-3-3 has frequently been found to influence aggregation of these
partner proteins leading to the formation of neurofibrillary plaques, which is often correlated
with cognitive impairment.211 However, for diseases like Alzheimer’s, the role of these plaques
is still controversial and 14-3-3 inhibitors would be valuable research tools.
In addition, 14-3-3σ has been shown to be released into the extracellular matrix (EM) by
keratinocytes where they act as signaling molecules in several types of fibroblasts.212 Here,
stimulation by 14-3-3 leads to an overexpression of matrix metalloproteinase (MMP) family
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members, especially MMP-1.213 MMPs are exported to the EM where they hydrolyze other
EM components.214 14-3-3 thus influences tissue remodeling, which is a complex process
where a sensitive balance between EM synthesis and its degradation is vital. The extracellular
receptor for 14-3-3 in the plasma membrane has recently been identified as aminopeptidase N
(APN) but the interacting sequence and its binding mode are yet unknown.215 Beside APN’s
enzymatic activity, the protein has various roles on the plasma membrane including ligand
sensing or signal transduction.216 Thus, the interaction of 14-3-3σ and APN possibly forms an
interesting target for diseases where EM remodeling is involved like non-healing wounds.213
Additionally, such inhibitors could form beneficial tool compounds for chemical biology to
study the various functions of APN on the outer membrane.
Goals of the Project
The goal of this project is to identify non-covalently binding and non-peptidic small mole-
cule inhibitors of 14-3-3 PPIs by means of in silico screening. Numerous X-ray structures of
14-3-3 with various binding partners are available from the PDB. These structures represent
different conformational snapshots, which we analyze to obtain detailed information on the
binding mode of phosphopeptides and the flexibility of the protein partners. Based on these
results, we try to define a minimal pharmacophore, which should subsequently be used to
perform a ligand-based VS. The resulting compounds will subsequently be docked into a high-
resolution structure of 14-3-3 to select final candidates for in vitro testing. Putative candidate
compounds will be tested in crystallization trials to solve their structure in complex with
14-3-3. Finally, we plan to test the inhibitors activity in a cellular assay to block the interaction
of 14-3-3 with APN.
Related Work
Several attempts have been done to develop inhibitors for 14-3-3 proteins, which comprise the
search for high-affinity peptides or peptidomimetics and the search for small molecule ligands
as antagonists of 14-3-3 PPIs. Using phage display, Wang et al. were the first to identify a
peptide that binds with high affinity to 14-3-3 and inhibits its PPIs.217 The identified peptide –
known as R18 – is not selective for the different 14-3-3 homologs and has been shown to block
the interaction with C-Raf in vitro. The R18 peptide does not feature a phosphorylated serine
or threonine residue and binds primarily to a hydrophobic patch at the end of the amphipathic
groove. A further development of R18 is its bifunctionalized version which can bind to both
amphipathic grooves of a 14-3-3 dimer.218
Wu et al. employed a microarray-based strategy to screen a custom peptide-small molecule
hybrid library.219 The library they synthesized is based on a tri-peptide with a central phos-
phoserine flanked by two glycines. These peptides were modified using various members of
96
Introduction
a building block library on both ends, thereby generating peptide-small molecule hybrids. In
a microarray-based experiment, 14-3-3-binding peptidomimetics were identified and used for
14-3-3 pull-downs on cell lysate. In combination with immunoblotting, the pull-down experi-
ment revealed disruption of the PPI of 14-3-3 with p53 as well as C-Raf by one peptide-small
molecule hybrid.
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A B
Figure 6.1: Covalent attachment of F101 to 14-3-3. (A) 2D representation of F101 with
the proposed cleavage site highlighted in red. (B) Crystal structure of F101 covalently
bound to Lys120 of 14-3-3ζ (PDB ID: 3rdh) at a resolution of 2.39 Å. (B) is taken from
Zhao et al. (Proc. Natl. Acad. Sci. USA (2011), 108, 16212-6).107
Fu et al. attempted to identify small molecule inhibitors of 14-3-3 via HTS.107,184 They
identified an active inhibitor – Fobisin101 (F101) – that covalently binds to a conserved lysine
in the amphipathic groove of 14-3-3.107 The compound’s binding mode was characterized by
X-ray crystallography and subsequent mass spectrometry (MS) from protein of the dissolved
crystal, which was used for the diffraction experiment. Fig. 6.1 shows F101 and the published
crystal structure. The proposed mechanism for covalent binding starts with an initial cleavage
of the compound’s N=N double bond caused by X-ray radiation with radical formation and
subsequent attachment to Lys120 of 14-3-3ζ. This covalent modification is described to form a
persistent inactivation of 14-3-3 proteins and therefore F101 is proposed as a lead compound
for a unique class of radiation-triggered chemotherapeutics.
An in silico approach for the identification of 14-3-3 PPI inhibitors was described by Cor-
radi et al..220,221 As an intracellular target they aimed to disrupt specifically the interaction
of 14-3-3 with the oncogenic tyrosine kinase BCR-ABL. They employed a combination of
pharmacophore-based virtual screening and molecular docking to select 14 compounds for
biological testing. To generate a pharmacophore model, they used a complex of 14-3-3 with
an artificial phosphopeptide to assign all interactions between phosphopeptide and 14-3-3.
Due to a large number of interactions, they skipped several interactions. Most notably, they
discarded all interactions established by phosphate coordinating residues of 14-3-3. However,
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to account for the phosphate’s negative charge in the pharmacophore model, they created a
rather large negative ionizable feature at this site. The remaining interactions were monitored
in a short MD simulation and revised if their distances or angles deviated from standard values.
The final pharmacophore model was used to screen a library of 200,000 compounds, yielding
99 matches. The subset of 87 Ro5-compliant compounds were then docked into 14-3-3 and
based on a consensus scoring, final compounds were selected for experimental testing. One
compound – BV02 – was found to be active in a cell-proliferation assay monitoring cell viabil-
ity depending on BCR-ABL activity. Additionally, the subcellular localization of BCR-ABL was
analyzed using Western Blotting, which showed increased nuclear localization of this protein.
However, the direct binding of BV02 to 14-3-3 has neither been shown in a biochemical assay
nor by X-ray crystallography. Due to the complexity of the assay, which regulates the activity
and localization of BCR-ABL, it is – in our opinion – not ultimately proven that 14-3-3 is indeed
the target of BV02.
6.2 Materials and Methods
All materials that were used for wet lab experiments and which are not directly described in
the following sections are listed in Table E.6.
6.2.1 Crystal Structure Analysis
We extracted complex structures from the PDB in order to analyze the binding geometries of
mammalian 14-3-3 proteins to their phosphorylated targets. To identify the entries containing
mammalian 14-3-3 proteins we used BLAST through the PDB website to search for protein
sequences similar to 14-3-3σ as the query.222 According to the MSA shown in Fig. 2.11, we
truncated the C-terminal sequence following Glu237 due to low conservation. PDB default
settings for BLAST were used with an e-value cutoff of 10.0 and masking of low complexity
sequences. Using the advanced search interface of the PDB we additionally filtered the BLAST
hits according to the following search criteria:
• Source organism Mammalia
• Experimental Method X-ray diffraction
• Resolution < 2.5 Å
• Number of protein entities > 1
Preparation and analysis of resulting 14-3-3 complex structures were performed using
the Molecular Operating Environment (MOE, version 2010.10).223 Only one 14-3-3 monomer
with bound phosphopeptide per entry was kept. Furthermore, unresolved residues were
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deleted before sequence alignment. Using MOE’s Protein superpose functionality the remaining
14-3-3 monomers were mapped onto each other based on Cα atoms. Default settings were
used with optional Accent Secondary Structure Matches enabled.
Structural flexibility of bound phosphopeptides was analyzed by superimposing them
separately. Here, the corresponding sequences were manually aligned by centering them onto
their phosphorylated residues using the sequence editor of MOE. Based on this alignment, the
all-atom RMSD was calculated between all passively superimposed phosphopeptides.
6.2.2 Virtual Screening
Virtual Compound Library
To ensure maximum diversity in our virtual screening library, we used the ZINC all now subset
(release 11).127 This subset is a comprehensive collection of immediately available compounds
and comprised 8,061,769 compounds at that time. The library was downloaded as a reference
set generated at a pH value of 7 in SMILES format. Compound preparation was performed
using Pipeline Pilot.139 Components from the Chemistry Package were used to reconstruct
molecules from SMILES (Molecule from SMILES), salts were removed (Strip Salts) and the
largest fragment was kept for each entry (Keep Largest Fragment).
Ligand-based Virtual Screening
Ligand-based VS was also performed with Pipeline Pilot. Our filtering workflow started with a
substructure filter (Substructure Filter from File) using default settings. The input was an SD
file containing the query substructure. The second step was a Lipinski Filter, which forwards
only Ro5-compliant compounds. In addition to the Ro5 filter we applied the HTS Filter of the
Chemistry Package to reject poor HTS candidate compounds. The latter comprises compounds
containing non-organic atom types, reactive substructures, or those with MW below 150 Da. To
eliminate candidates with multiple query substructure occurrences and to gain internal rigidity,
the last filter step forwarded only compounds with a single query match and possessing at
least one ring. Finally, a diverse selection was performed on the remaining compounds using
the Diverse Molecules tool with a desired number of 500 compounds to be selected. As a
descriptor we used ECFPs with a maximum diameter of 4 bonds and plain atom types as atom
abstraction.37
Structure-based Virtual Screening
Compounds from ligand-based VS were docked into a high-resolution structure of 14-3-3σ. The
crystal structure we used is a complex of 14-3-3σ and a phosphorylated Task3 peptide (PDB
ID: 3p1n).163 Structure preparation was performed using the Protein Preparation Wizard of
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Schrödinger Maestro with slightly modified settings:224 We kept the peptide and surrounding
waters for optimization of hydrogen bond networks and deleted them afterwards. The receptor
grid was calculated using Glide and centered at the position of the phosphorylated residue.180
The precise receptor grid dimensions are listed in Table 6.1. Default settings were used for all
other parameter options. For protein-ligand docking, the selected compounds were prepared
using LigPrep.225 Parameter settings deviating from default values are listed in Table 6.1.
Finally, the prepared compounds were docked into the generated 14-3-3 receptor grid using
Glide in extra-precision (XP) mode.54,180,181,226 Detailed parameter settings deviating from
default settings are also listed in Table 6.1. Docked compound poses were sorted by increasing
docking score and the top 200 docking poses were manually inspected to choose a subset for
experimental testing.
Table 6.1: Parameter settings for receptor grid generation, ligand preparation, and
protein-ligand docking using PDB entry 3p1n. Only options deviating from default set-
tings are listed.
Glide: Receptor Grid Generation
Grid center x =−17.3 Å, y =−14.7 Å, z = 9.6 Å
Inner box dimensions x = y = z = 12.0 Å
Outer box dimensions x = y = z = 23.0 Å
LigPrep: Ligand Preparation
Ionization Neutralize and ionize
pH-Range 7.0 ± 3
Stereoisomers Use chiralities from input geometry
Glide: Flexible Ligand Docking
Precision Extra precision (XP)
Post-docking minimization poses 20
Output poses per ligand 5
6.2.3 Experimental Validation and X-ray Crystallography
Selected compounds from VS and derivatives from SAR analysis were obtained from Inter-
BioScreen. The pyridoxal-phosphate (PLP) derivative F101 was obtained from Sigma-Aldrich.
2D representations and supplier informations of all compounds are listed in the appendix
(Table E.5). Compounds were delivered as solids, dissolved in DMSO as 20 mM stock solutions
and stored at −20 ° C.
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In Vitro Validation Experiments
To test the compounds’ potential to compete with the binding of a phosphorylated peptide to
14-3-3 in vitro, a fluorescence polarization (FP)-based assay was performed (Dr. Lars Röglin,
CGC Dortmund).184 Active compounds were further tested in a cellular assay for their potency
to inhibit upregulation of MMP-1 mRNA levels in response to extracellular application of
14-3-3 (Nicole Meissner and Svenja Schäfers, CGC Dortmund). Human lung fibroblast cells
(IMR90) were purchased from ATCC.
The compounds’ ability to permeate cell membranes was tested using the parallel artificial
membrane permeation assay (PAMPA) by the LDC Dortmund.227 PAMPA is an in vitro assay to
model passive transmembrane permeation.
Protein Crystallization
For crystallization experiments of all inhibitor complexes we used a C-terminally shortened
construct of 14-3-3σ (14-3-3σ∆C), which was truncated after Thr231. Cloning, expression,
and purification of 14-3-3σ∆C was performed as described by Schumacher et al. and protein
was provided by the Ottmann lab.185
For crystallization trials, 14-3-3◦inhibitor stock solutions were obtained by mixing the
14-3-3σ∆C stock solution, compound DMSO stock solutions and complexation buffer to yield
final concentrations of 12 mg/ml 14-3-3σ∆C and 2 mM compound, respectively. The complex-
ation buffer is listed in the appendix (Table E.7). Complex solutions were incubated overnight
at 4 °C. Crystallization was performed at 4 °C using the hanging-drop or sitting-drop method,
respectively. Crystallization buffers from the 2D grid described in Section 5.2.5 were used.
For the in vitro validated VS hits A1-A14, reservoirs from a 24-well plate were filled with
500 µl of crystallization buffer. Hanging-drops were mixed from 2 µl complex solution with
2 µl crystallization buffer from the reservoir and placed on a cover glass, which was used
to seal the well. Since the final crystallization drops were already cryogenic, crystals were
directly flash-frozen in liquid nitrogen. For the inhibitors from the second compound batch
(B1–B31), a crystallization screening was performed using sitting-drops in 96-well plates.
Plate reservoirs were filled with 75 µl of grid variation buffers C17-C24 column by column
(A-H) using a 96-well pipetting system. Sitting-drops were mixed manually from 1 µl complex
solution with 1 µl crystallization buffer from the reservoir. The 96-well plates were sealed
with transparent adhesive foil. All successful crystallization conditions that yielded suitable
crystals for diffraction experiments are listed in Table 6.2. 96-well plates were stored in an
imaging system, which allowed automatic monitoring of the crystallization drops.
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Table 6.2: Successful crystallization buffers of 14-3-3◦inhibitor complexes from the 2D
grid. The constant ingredients Na-HEPES buffer (95 mM), CaCl2 (190 mM) and Glycerol
(5 % v/v) are not listed.
Compound Condition pH PEG 400 (% v/v)
A1 C24 7.7 28.0
A2 original 7.5 26.6
B1 C17 7.1 27.0
B2 C22 7.3 28.0
B3 C23 7.5 28.0
B4 C21 7.1 28.0
B5 C17 7.1 27.0
B6 C15 7.5 26.0
B7 C21 7.1 28.0
B8 C22 7.3 28.0
B9 C24 7.7 28.0
A3 original 7.5 26.6
F101 original 7.5 26.6
Data Collection
Diffraction experiments were performed in-house and at the Swiss Light Source (SLS) of the
Paul Scherrer Institute Villigen (Switzerland), at beamline PXII. The in-house beamlines used
rotating copper anodes from Rigaku (MicroMAX-007 HF) and from Bruker (AXS MICROSTAR)
as X-ray source. Both beamlines were equipped with a MAR345 image plate. Data processing
was carried out using the software package XDS.186 During this step, choice of the lowest
resolution to trim the data sets was based on three parameter values of the outermost shells.
First, a signal to noise ratio of 4.0 was set as lower cutoff. Second, a completeness of 90.0 %
was used as lower cutoff. Third, we set the upper limit for the redundancy independent
R-factor (Rmeas) to 40.0 %. Crystal parameters and data collection statistics of all complex
structures are listed in the appendix (Table E.9).
Structure Elucidation and Model Building
The CCP4 software suite was used for phase determination and automatic refinement.187
MR was carried out with PHASER (version 2.1.4) using a monomer of 14-3-3σ as a search
model.188 A unique solution was found for every 14-3-3◦inhibitor data set. These initial
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models were used as starting data for iterative cycles of automatic and manual refinement
with REFMAC (version 5.5) and COOT (version 0.6), respectively.178,189 Refinement statistics
of final models are given in the appendix (Table E.9). Corresponding Ramachandran plots
were generated with RAMPAGE and shown in the appendix (Fig. D.3).228 To visualize density
with reduced model bias, simulated annealing composite-omit maps were calculated with
PHENIX.229 The final models of all 14-3-3◦inhibitor complexes were deposited with the PDB.
All corresponding PDB IDs are listed in the crystallographic Table E.9.
6.3 Results
The first part of this section shows the binding geometry conservation of 14-3-3 in complex
with target proteins. Based on the deduced pharmacophore hypothesis the results of ligand-
based and structure-based VS are presented. Experimental hit validation and successfully
solved complex structures are subsequently presented. Finally, we show the true binding mode
of covalent 14-3-3 PLP inhibitors, which was elucidated by X-ray crystallography.
6.3.1 Structure Analysis
The search for complex structures of 14-3-3 and phosphopeptides as described in Section 6.2.1
yielded 14 entries within the PDB, which are listed in Table 6.3. The entries 3iqu and 3iqv
were not used for binding analysis because bound phosphopeptides are truncated duplicates
of the C-Raf construct already present in 3iqj. Entry 3cu8 is also a truncated duplicate of the
construct contained in 3iqj. Although the 14-3-3 isoform in this entry is different from 3iqj,
it was skipped because the surface-exposed residues of all mammalian 14-3-3 isoforms are
entirely conserved in the amphipathic groove. Entry 1qjb was skipped because an artificial
mode I phosphopeptide was already represented by entry 1ywt. Entry 2o02 was skipped
because the binding partner is an unphosphorylated peptide from exoenzyme S, which binds
to a distant surface patch at the end of the amphipathic groove. Thus, nine entries from the
PDB remained for the analysis of phosphopeptide binding geometries.
Superposition of 14-3-3 chains revealed an average Cα RMSD of 0.4 Å for 14-3-3 monomers.
Thus, 14-3-3 adopts identical conformations in all considered cases. In contrast, the passively
superimposed phosphopeptides show highly variable Cα RMSD values as shown in Fig. 6.2.
The bar chart in Fig. 6.2A shows the RMSD values for the phosphorylated residue at position
0, three N-terminal flanking residues (positions −3, −2, −1) and three C-terminal flanking
residues (positions +1, +2, +3). The phosphorylated residue has the lowest Cα RMSD with
0.6 Å and only the −1 residue shows a comparably low RMSD. The RMSD values for the other
flanking residues rapidly increase with the distance to the phosphorylation site and exceed
2.5 Å at the −3-position and at the +2-position. Weblogos representing the relative residue
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Table 6.3: 14-3-3◦phosphopeptide complex structures extracted from the PDB.
PDB ID Residue Resolution (Å) Binding Partner
1qja pSer 2.0 Artificial mode II phosphopeptide
1ywt pSer 2.4 Artificial mode I phosphopeptide
2br9 pSer 1.75 Consensus phosphopeptide
2c63 pSer 2.15 Consensus phosphopeptide
2c1n pSer 2.0 Phosphopeptide from histone H3 (7-14)
2v7d pThr 2.5 Phosphopeptide from integrin β-2 (755-746)
2wh0 pSer 2.25 Phosphopeptide from proteinkinase C (342-373)
3iqj pSer 1.15 Phosphopeptide from C-Raf (255-264)
3lw1 pThr 1.28 Phosphopeptide from p53 (385-294)
1qjb Duplicate of an artificial mode I phosphopeptide
2o02 Non-phosphorylated peptide from exoenzyme S
3cu8 Duplicate of phosphopeptide in 3iqj
3iqu Shortened duplicate of 3iqj
3iqv Shortened duplicate of 3iqj
frequencies for all positions are shown on top of the bars.230 The low sequence conservation
of flanking residues is a possible explanation for their low spatial conservation. Fig. 6.2B
shows the superimposed structures and the diverging phosphopeptides. The high spatial con-
servation of the central phosphoserine or phosphothreonine residue, which is coordinated by
14-3-3 residues Arg56, Arg129, Tyr130, and partially by Lys49 is highlighted. Particularly, the
phosphate group is the only side-chain moiety that is also spatially well conserved.
6.3.2 Virtual Screening and Experimental Validation
Based on the findings of the 14-3-3 complex structure analysis we concluded that the phos-
phate moiety of the phosphorylated amino acid contains the strongest pharmacophoric prop-
erties and combined a ligand-based VS with structure-based docking. The entire filtering
workflow of ligand-based VS is shown in Fig. 6.3A. For ligand-based VS we used a phospho-
nate as an initial substructure filter, which had the following SMARTS pattern:
[C,O][P]([OH])(=[O])([OH])
The initial substructure filter reduced 8,061,769 compounds to 2,349 phosphonate deriva-
tives. Filtering for Ro5 compliance in combination with the HTS filter further reduced the
selection to 1,502 compounds. The last filter ensuring compound rigidity, requiring at least
one ring and rejecting compounds with multiple phosphonates, yielded 1,012 compounds.
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Figure 6.2: Superposition of 14-3-3◦phosphopeptide complexes. (A) Analysis of spatial
and sequence conservation of phosphopeptide residues. Position 0 is the phosphoryla-
tion site. Negative positions indicate N-terminal residues, positive positions indicate C-
terminal residues. The weblogo shows relative residue frequencies for the corresponding
positions (green: polar residues, blue: basic residues, red: acidic residues, black: hy-
drophobic residues). (B) Superposed crystal structures. A single 14-3-3 monomer is rep-
resented as grey cartoon, phosphopeptides are represented as colored ribbons, phospho-
rylated residues are represented as sticks colored by element. The phospho-coordinating
residues of 14-3-3 are also shown as green stick models coloured by element.
Visual inspection of this selection hinted at the presence of several compound clusters. There-
fore, we calculated a diverse set of compounds based on ECFPs with a desired number of 500
compounds in the final selection. As a result, we ended up with 512 representative compounds
for structure-based docking.
Ligand preparation of the selected compounds produced 698 input structures for protein-
ligand docking, which was performed as described in Section 6.2.2. The resulting list of
docking poses was sorted according to decreasing docking score. We visually inspected the
200 top-ranked docking poses, which spanned a docking score range from −10.2 to −7.7 and
comprised 70 different compounds out of the 512 input candidates. From this set, we manually
selected 14 compounds for experimental testing, which we refer to as A1–A14. Our primary
selection criterion was the placement of the phosphonate moiety of the docked compounds
in order to satisfy our pharmacophore hypothesis. The docking ranks and the corresponding
scores for these compounds are listed in the appendix (Table E.5).
The compounds’ potential to compete with binding of a phosphopeptide from C-Raf to
14-3-3 was assessed in an FP-based assay (Dr. Lars Röglin, CGC Dortmund). Fig. 6.3B shows
the results of this validation screen at a compound concentration of 250 µM. Compounds A1
and A2 were validated as true actives because they exceeded our expected cutoff of 50 %
normalized PPI inhibition (Table 6.4). Subsequent titration of A1 and A2 revealed IC50 values
of 30 µM and 116 µM, respectively. The identified compounds were also active in a second
orthogonal assay, which is based on a different physical phenomenon than the FP-based assay
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Figure 6.3: Virtual screening and experimental validation. (A) Results of the ligand-
based filtering workflow, docking, and manual selection. (B) Experimental testing of 14
selected compounds from VS. The bar chart shows normalized percent-inhibition for the
compounds’ potency to disrupt the binding of a phosphopeptide from C-Raf to 14-3-3ζ
at a concentration of 250 µM. Our cutoff for hit selection was a 50 % inhibition (dashed
grey line). We identified A1 and A2 as active inhibitors, whose common scaffold is also
shown.
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and is thus well suited to validate the results of FP measurements. This homogeneous time
resolved fluorescence (HTRF) assay was also performed by Dr. Lars Röglin, CGC Dortmund.
Table 6.4: Active inhibitors from VS validated by in vitro screening.
Compound R1 R2 IC50 (µM)
A1 H 2-(trifluoromethyl)phenyl 30
A2 H 2,5-dimethoxyphenyl 116
6.3.3 Crystallography and Structure-Activity Relationships
To validate our VS hypothesis and to gain deeper insight into the compounds’ mode of action
we tried to obtain structures of compounds A1 and A2 in complex with 14-3-3σ. Using the
procedure described in Section 6.2.3, we successfully grew crystals which diffracted up to a
resolution of 1.6 Å. The initial models resulting from the single MR solutions already showed
extensive residual density in the Fo − Fc electron density maps for both ligands. Iterative
cycles of model building and refinement allowed unambiguous interpretation of compound A1.
Compound A2 has an overall occupancy of only 75 % and reveals two distinct conformations
for its dimethoxybenzene moiety. Both conformations have a an occupancy of 37 % and are
thus equally distributed.
The crystal structures of A1 and A2 are shown in Fig. 6.4. As expected, the phosphonate
groups are coordinated via five hydrogen bonds to Arg56, Arg129, and Tyr130. Interestingly,
the compound orientations are perpendicular to the peptide backbones and the R2 substituents
bind to a region that is not occupied by any currently known peptide. Furthermore, the com-
pounds form an intramolecular and charge-assisted hydrogen bond between a phosphonate
oxygen and the anilide nitrogen. The importance of this interaction is underlined by the ob-
servation that all tertiary amides are inactive (A4–A9). Additionally, para-substitutions seem
detrimental for 14-3-3 binding due to spatial limitations (A10–A12). In our structures, the
14-3-3 protein undergoes no major conformational changes. However, an important observa-
tion is the elongated side-chain conformation of Arg60. Depending on the binding partner
of 14-3-3, this residue also occurs in a bent conformation where the guanidinium group oc-
cupies the pocket where the inhibitors’ variable R2 moieties are located. Since we used a
14-3-3 structure with bent Arg60 for docking, the predicted docking poses only match the
phenylphosphonate moiety when compared to the observed binding geometry. Based on these
preliminary SARs, we evaluated 31 additional compounds containing the validated scaffold
featuring a secondary amide for internal hydrogen bonding (B1–B31). Using the FP assay, we
found nine additional compounds with IC50 values below 200 µM. The most potent compounds
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Figure 6.4: Crystal structures of identified inhibitors bound to 14-3-3σ (grey semi-
transparent SES and cartoon, residues with yellow carbons). (A) Compound A1 (green
carbons). (B) Compound A2 (green carbons). Both compounds display a similar binding
mode for their phenylphosphonic moieties. The main interacting residues of 14-3-3 are
labelled in boldface. The 2,5-dimethoxybenzoic moiety of compound A2 binds in two
different conformations. The intramolecular hydrogen bond is highlighted as dashed
orange line.
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B1 and B2 show IC50 values of 5 µM and 15 µM, respectively These inhibitory concentrations
are close to those of known phosphopeptide ligands.
We also tried to structurally characterize compounds B1–B9 and successfully solved their
complex structures with resolutions below 1.8 Å. All nine inhibitors share the conserved
orientation of the phenylphosphonic moiety, which is stabilized by its intramolecular hydrogen
bond and the conserved hydrogen bonds of phosphonate oxygens to side-chains Arg56, Arg129,
and Tyr130. Additionally, the phosphonic phenylring makes hydrophobic contacts to Val178.
The inhibitors’ variable R2 moieties fill a shallow subpocket enclosed by Arg56, Arg60, Lys49,
and the protein backbone. Due to the variety of chemotypes binding into this pocket, a mainly
hydrophobic contribution can be suggested. This is exemplified by the 14-3-3 complexes
of the two most active compounds B1 and B2, which are shown in Fig. 6.5A and 6.5B. As
shown in Fig. 6.5B, similar van der Waals volumes (Vvdw) are occupied by the aromatic R
2
moiety (2,3-dichlorophenyl, Vvdw = 111 Å3) as well as by the aliphatic R2 moiety (cyclohexyl,
Vvdw = 102 Å3).
Notably, the data collection statistics of some data sets presented in this section suggest,
that the resolution cutoffs used for trimming have been chosen too conservative. This is
especially true for the data sets collected in-house. However, the cutoffs of these data sets
reflect the instrumentation limits, which in these cases led to a preset limit for the minimum
outer resolution.
Structure-Activity Relationships
In summary, we analyzed 43 compounds which share the validated inhibitor scaffold shown in
Fig. 6.3B. These compounds already include a wide range of substitutions and provide deeper
insight into SARs. We were able to group these compounds into 11 different structure-activity
classes, which are annotated in the appendix (Table E.5):
Group 1 comprises all derivatives with tertiary amides in the linker, that is R2 = H. The
secondary amide B2 (15 µM) and its methylated derivative A9 (inactive) demonstrate that
tertiary amides are not tolerated.
Group 2 comprises all aromatic substitutes with a substitution in para-position, which is
not tolerated as shown by B4 (27 µM) and its para-substituted derivative B30 (inactive). Even
the smallest possible para-fluorophenyl leads to an inactive compound (B11). The bicyclic
compounds A14 and B28 fail for the same reason.
Group 3 derivatives are inactive due to an extended linker. Even the elongation by a single
methylene group is deleterious as demonstrated by B4 (27 µM) and B10 (inactive).
Group 4 comprises the acyclic aliphatic compounds, which are all inactive.
Group 5 contains the active alicycles B2 and B8. Here, the larger cyclohexane of B2 is
about eightfold more active than the cyclopentane of B8.
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Figure 6.5: Superimposed crystal structures of B1 and B2 bound to 14-3-3σ. (A) Crystal
structure of B1 bound to 14-3-3σ (grey cartoon; gold mesh: mFo − DFc density map at
3.0σ contour level after protein refinement; blue mesh: 2mFo− DFc simulated annealing
composite-omit map at 1.2σ contour level of the final model) (B) Crystal structure of
B2 bound to 14-3-3σ (same coloring and map contour levels as for B1) (C) Superimposed
B1 (green carbons) and B2 (yellow carbons). Meshes represent the SES of the compounds’
R2 moieties including hydrogen atoms, which occupy a comparable volume (coloring
according to ligand carbons).
Group 6 compounds feature small, electron-withdrawing substituents in ortho-position
(B4: 27 µM), which show a subtle advantage over the meta-position of group 7 compounds
(B5: 32 µM). A combination of both shows an additive effect (group 8, B1: 5 µM). However,
the larger and electron-donating B26 is inactive (group 9).
Finally, group 10 contains 2,5-substituted compounds, which are less active than a 2,4-
substitution present in compound B3 (group 11).
6.3.4 Inhibition of the 14-3-3◦Aminopeptidase N Interaction
Evaluation of the inhibitors’ potency to suppress 14-3-3 triggered upregulation of MMP-1
mRNA levels was performed in a cell-based assay using human IMR90 lung fibroblasts (Nicole
Meissner and Svenja Schäfers, CGC Dortmund). In brief, the influence of extracellular
14-3-3 on MMP-1 mRNA transcription in human lung fibroblasts was analyzed by real-time
quantitative PCR.231 As shown in Fig. 6.6A, treatment with 14-3-3σ for 24 h led to a three-
fold increase of MMP-1 levels compared to untreated cells. When the cells were treated with
14-3-3σ in combination with 200 µM of compound B1 or B2, the 14-3-3-induced transcrip-
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tional increase was suppressed. A subsequent titration experiment of the more potent inhibitor
B1 is shown in Fig. 6.6B and yielded an IC50 value of 81± 15 µM.
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Figure 6.6: Cell-based assay on human lung fibroblasts for MMP-1 mRNA expression. (A)
Treatment of human lung fibroblasts with 14-3-3σ alone as a positive control (+Ctrl) and
co-treated with 200 µM of compounds B1 and B2. As a negative control (-Ctrl) cells were
only treated with DMSO. (B) Relative abundance of 14-3-3σ-stimulated MMP-1 levels
were down-regulated upon treatment with compound B1 in a concentration-dependent
manner and yields an IC50 of 81± 15 µM.
Membrane Permeability
To exclude intracellular effects of compounds B1 and B2, which possibly could interfere with
14-3-3’s extracellular application, the compounds ability to permeate cell membranes using the
parallel artificial membrane permeation assay (PAMPA) was analyzed by the LDC Dortmund.
The measured flux values for compounds B1 and B2 were −10.6 % and −8.7 %, respectively.
Flux values below 5 % classify compounds as having a low membrane permeability, which is
the case for both compounds.
6.3.5 Covalent Inhibition of 14-3-3 PPIs
In the initial validation screen shown in Fig. 6.3B, a third compound (A3) also inhibited the
monitored PPI with lower potency. As this compound does not share the previously described
phenylphosphonate scaffold, we were also interested in obtaining a structure of 14-3-3 in
complex with A3. However, multiple crystallization trials as described in Section 6.2.2 were
not successful and no crystal growth was observed. We speculated that the low binding affinity
of A3 and 14-3-3 – as indicated by its lower potency – is too weak to yield a homogeneous
complex solution, which enables crystal formation.
We thus tried an alternative approach by incubating existing crystals consisting of com-
plexes between 14-3-3 and phosphopeptides from p53 with A3 in order to displace bound
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peptide by compound. Crystals of 14-3-3◦p53 were obtained as described previously.123 We
directly added A3 from a 20 mM DMSO stock solution to hanging-drops containing grown
crystals and incubated them for three days. After this incubation period a crystal was directly
flash-frozen in liquid nitrogen and used for a diffraction experiment.
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Figure 6.7: Crystal structures of covalent PLP binders to 14-3-3. (A) A3 covalently bound
to Lys122 of 14-3-3σ (PDB ID: 3u9x, 14-3-3: grey cartoon, Lys122 with bound compound:
stick-model colored by element, blue mesh: simulated annealing composite-omit map
calculated with PHENIX at 1.3σ contour level, green mesh: mFo − DFc density map
at 3.0σ contour level). The mFo − DFc density map has been calculated after protein
refinement without ligand bias. (B) F101 covalently bound to Lys122 of 14-3-3σ (same
coloring and contour levels as in A). (C) A3 featuring an imine substructure and its
hydrolysis in aqueous solution to PLP and a primary amine. The PLP substructure is
highlighted in red. (D) F101 that already possesses the aldehyde necessary for reacting
with Lys122. The PLP substructure is also highlighted in red. (A) and (B) are taken from
Röglin et al. (Proc. Natl. Acad. Sci. USA (2012), 109, E1051-3).208
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Processing of the collected data set yielded a resolution of 1.8 Å. The initial electron
density after MR indicated that the phosphopeptide was displaced by compound A3 for which
unmodelled Fo − Fc electron density appeared. To our surprise, the compound occupied
another volume in the amphipathic groove and the phosphate moiety was not coordinated as
observed before. In fact, the compound covalently binds to Lys122 of 14-3-3σ by forming a
Schiff base as shown in Fig. 6.7A. The most likely mechanism for this observation is a reversible
imine formation between the lysines primary amine and an aldehyde. As shown in Fig. 6.7C,
compound A3 does not possess an aldehyde group but a secondary imine substructure. This
imine can be hydrolyzed in a weak acidic environment resulting in pyridoxal-phosphate (PLP),
which is one of the most important physiological co-factors.232 PLP can reversibly bind to
lysines and form the modified residue N6-PLP-L-lysine (PSI-MOD 128), which is currently
present in 229 PDB structures (accessed 26/6/2013). The importance of this mechanism is
underlined by the observation, that more than 95 % of PLP in plasma is reversibly linked to a
lysine residue in human serum albumin, which serves as a reservoir and transport system.233
Interestingly, the afore-described 14-3-3 inhibitor F101 is also a PLP derivative, but the
published crystal structure shown in Fig. 6.1 and the proposed reaction mechanism differ
markedly from our observations. Notably, this derivative already features the aldehyde neces-
sary for covalent linking to Lys122 of 14-3-3, as can be seen in Fig. 6.1D. As the high quality
of our X-ray data hardly supports any other covalent binding hypothesis we decided to obtain
a sample of F101 and tried to solve a complex structure with 14-3-3σ.208 Based on our expe-
riences with A3 we also performed soaking experiments. As the compound is highly soluble
in aqueous solution, we dissolved it in crystallization buffer. From this solution we directly
added to a hanging-drop containing crystals of 14-3-3σ and p53 phosphopeptide complexes
to reach 5 mM compound concentration. After an incubation period of eight days, crystals
were frozen in liquid nitrogen and used for a diffraction experiment. The resulting data set
is of comparable quality as for the A3 complex and was refined up to 1.65 Å resolution. The
final model is shown in Fig. 6.1B and F101 shows the same covalent attachment to Lys122
as A3, which supports our observations. We also observed interpretable electron density for
the para-amino-benzoate moiety despite its high flexibility, which argues against radiation
induced cleavage of F101. Additionally, further unmodelled difference electron density nearby
Lys49 indicated the presence of a second covalently bound F101 molecule. To confirm these
observations, we performed an electrospray ionization mass spectrometry (ESI-MS) experi-
ment (Dr. Lars Röglin, CGC Dortmund) and verified the imine formation between 14-3-3ζ and
F101 in solution (Fig. D.5). Overnight incubation followed by dilution revealed two, three,
and four molecules F101 attached to one monomer of 14-3-3.
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6.4 Discussion
We demonstrated a successful in silico screening approach for the identification of 14-3-3 PPI
inhibitors. We were able to identify the first non-covalent and non-peptidic inhibitors of
this important protein family, whose mode of action is completely characterized by X-ray
crystallography and supported by initial SAR studies. As an interesting in vivo assay, we
showed the ability of the identified inhibitors to suppress the upregulation of MMP-1 mRNA
levels, which is normally induced by addition of extracellular 14-3-3σ.
Analysis of nine 14-3-3 complex structures extracted from the PDB yielded insights into
the binding mode of different phosphopeptides to 14-3-3. These X-ray structures form an
ensemble of naturally occurring protein conformations for 14-3-3 and especially for its bound
peptides. For 14-3-3, which we used as the receptor for structure-based docking, the analysis of
its conformations showed only marginal flexibility independent of the bound phosphopeptide.
Thus, using one of the compared structures as a docking template formed a useful and valid
hypothesis. Additionally, the analysis of the bound phosphopeptides revealed only a relatively
small sequence stretch with low flexibility, which we could use to derive a pharmacophore
hypothesis. As expected, this spatially most conserved moiety is the phosphorylated residue
and most prominently its phosphate group.
Interestingly, in the pharmacophore model used for virtual ligand screening created by
Corradi et al., the phosphate was not represented as a group of three spatially related hydrogen
bond acceptors, but as a spherical negative charge.220 To the best of our knowledge, neither
in vitro assay data nor a structure of their inhibitor – BV02 – in complex with 14-3-3 were
published yet. Thus, it is possible that BV02 does not directly interact with 14-3-3 but that it
hits an off-target, which is responsible for the observed cellular effects. This would underline
the importance of the spatial arrangement of the phosphate group and suggests the same
importance of the phosphate’s geometry as its negative charge for binding to 14-3-3.
Using a generalized phosphonate in our ligand-based VS led to a tremendous reduction of
the input library comprising more than eight million compounds. Subsequent filtering steps
and diverse selection yielded a manageable number of compounds for protein-ligand docking.
The final step in our virtual screening approach was docking into a high-resolution crystal
structure of 14-3-3σ. We employed docking to calculate sterically and physicochemically
meaningful poses. We chose the size of the receptor bounding box larger than the default
values to encompass the majority of 14-3-3 ’s amphipathic groove, centered at the phospho-
coordination site. This enabled the docking algorithm to sample compound orientations in both
directions of the amphipathic groove. Despite of these settings, only 70 different compounds
out of 512 passed the Glide docking funnel. We used the 200 top-ranked docking poses for
visual inspection of the placement of the phosphonate moiety, for which various positions were
observed. Rejecting compounds that were not able to establish the conserved hydrogen bonds
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to Arg56, Arg129, Tyr130 via their phosphonate oxygens was a further reasonable restriction,
especially because the overall quite high docking scores gave no further clue for selection. Two
different in vitro assays to monitor the interaction of 14-3-3 and a phosphorylated peptide
from C-Raf yielded two compounds with inhibitory activity above 50 %.
R60 R60
A B
K49
K49
Figure 6.8: Comparison of docking pose (ball-and-stick model, yellow carbons) and X-ray
conformation (ball-and-stick model, grey carbons) of compound A1. (A) 14-3-3σ (grey
SES) from complex structure with A1 (PDB ID: 3t0l). Residue Arg60 is highlighted (green,
semi-transparent SES and stick model). (B) 14-3-3σ structure (grey SES, PDB ID: 3p1n)
used as receptor for docking. Residue Arg60 is highlighted accordingly.
Successful crystallization of these 14-3-3 inhibitor complexes revealed binding modes and
enabled us to validate our virtual screening approach. The most important observation is the
placement of the compounds’ phosphonate groups, which matches our hypothesis. Also impor-
tant is the observation that the inhibitors do not bind in an elongated conformation within the
amphipathic groove but cross it. Thereby, both ligands occupy a quite shallow subpocket at
the upper rim of the groove. These binding modes markedly differ from the selected docking
poses. Superposition of the docked pose of A1 and its crystallized geometry is shown in Fig. 6.8.
Subfigure A shows the superimposed inhibitor conformations in the 14-3-3 structure, which
has been crystallized with A1. Most notable is the conformation of Arg60, which is elongated
and forms one boundary of the shallow subpocket. In contrast, Fig. 6.8B shows the compound
conformations in the 14-3-3 structure, which was used as the docking receptor (PDB ID: 3p1n).
Here, Arg56 adopts a bent conformation where its guanidinium group points into the shallow
subpocket, thereby reducing the volume of the latter. Interestingly, in only one out of the 14
available and analyzed 14-3-3◦phosphopeptide structures Arg60 was in a bent conformation.
Since we accessed these structures in 2010, the number of deposited 14-3-3 entries has nearly
doubled and comprises three additional complexes with bent Arg60. Furthermore, the highly
flexible Lys49 is slightly displaced in the crystallized 14-3-3 conformation, which also enlarges
the subpocket. These two subtile structural changes were responsible for incorrect placement
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of ligands by docking, which underlines the importance of our decision to solely focus on the
correct placement of the phosphonate. It remains speculation, whether the phosphonate of
the identified inhibitors alone is responsible for binding to 14-3-3 and their effect. However,
the inactivity of various tested compounds which should be flexible enough to adopt a suitable
position in the amphipathic groove, contradict this hypothesis.
Crystal structures and in vitro data enabled us to speculate about SAR and led to the
identification of further active inhibitors sharing the conserved scaffold. These additional
structures extended the SAR but the explored chemical space is limited yet and further opti-
mizations might lead to inhibitors with submicromolar activity. First, chemical modifications
should focus on the phenylphosphonate ring because surrounding 14-3-3 offers unexplored
interaction possibilities. For example, polar interactions to Asn175 and Asn226 or extended
hydrophobic contacts to Leu174, Val178 and to the protein backbone are possible. Second,
introduction of a ring system in the linker region to decrease conformational flexibility might
be entropically beneficial. Here, the high quality 14-3-3σ◦inhibitor structures we presented
in this work form an excellent resource to accompany both optimization strategies with in
silico methods. For example, fragment linking tools could suggest alternative chemical linkers
between the phenylphosphonate ring and the R2 moiety.
We further presented an interesting application where we demonstrated the ability of
the compounds to inhibit the overexpression of MMP-1 in human fibroblasts via extracellular
14-3-3 stimulation. Knowledge of the extracellular tasks of 14-3-3 proteins is continuously
growing and this research area can greatly benefit from our results. As chemical biology tools
the most potent inhibitors are already useful to analyze the binding events between 14-3-3 and
its surface receptor APN. The mode of action of our inhibitors suggests a phosphorylation-
dependent binding of APN and possibly facilitates identification of the interacting sequence.
A surprising discovery was PLP derivative A3, which binds covalently to a conserved lysine
in the amphipathic groove. The compound’s ability to attach to the primary amine of lysines
is not directly obvious from its structure because preceding hydrolysis is necessary to form
an aldehyde as the corresponding reaction partner. Structure determination of the covalent
complex revealed its true mode of action. Additionally, we were able to elucidate the true
binding mode of another PLP derivative, which has recently been published.107,208 Finally,
our results on binding of PLP derivatives to 14-3-3 allows us to speculate if this mechanism
is an as yet unknown storage or transport function of 14-3-3 proteins. Binding to an entirely
conserved lysine and the high abundance of 14-3-3 proteins in cells argues for this speculation.
Furthermore, it is already known that PLP is stored and transported in the blood via this
mechanism.233
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Chapter 7
Conclusion and Outlook
The presented thesis covers a broad range of methods in computer-assisted as well as exper-
imental drug discovery. The continuously growing demands by steadily increasing amounts
of structural data in this discipline and the necessity to discover novel ways in drug discovery
were the incitement of this work. The first two chapters are focused on studying theoretical
problems from chemoinformatics. Here, we introduced novel methods that enable meaningful
and efficient classification of large chemical spaces. The obtained results were integrated in
the second part of this work, which focuses on applying computational methods on emerging
targets and its associated problems in modern drug discovery. Accompanied by continuous in
vitro validation and structure elucidation, this work is strongly interdisciplinary.
In Chapter 3, we presented a novel chemoinformatics clustering method for efficient and
fast processing of large chemical spaces. The core of our method is formed by an extremely
fast and parallel algorithm to calculate similarities between 2D binary fingerprints. It was one
of our goals that the entire method is architecture-independent and that it runs on standard
hardware without using specialized instruction sets. Our benchmarking results demonstrate,
that our implementation is as fast as state-of-the-art hardware-dependent methods and can
calculate up to 365 million similarities per second on a desktop computer. This performance
enabled clustering of the available chemical space comprising 17 million compounds in less
than three days. The method is a useful alternative to existing and frequently used tools,
especially because it is a deterministic approach taking all pairwise similarities into account.
The performance of our method creates further interesting perspectives. A possible future
development could be an incremental clustering algorithm. An obvious use case for such a vari-
ant would be the regular update of an already clustered compound database. New compounds
are continuously inserted into the database, which makes an update of the clustering necessary.
For this task, the presented algorithm is perfectly suited because inserted compounds can be
merged into a new inverted index block. The latter can easily be processed against the already
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existing library blocks. As our algorithm reaches already 75 % of its peak performance at a
block size of 100, a weekly or even daily update would be feasible.
Additionally, our method can possibly be transferred to other problem domains in bioinfor-
matics dealing with large amounts of data that can be represented as binary feature vectors. A
possible application could be the clustering of sparsely encoded mass spectra in computational
proteomics. As the implementation is independent of the chemoinformatics layer it could be
adapted with only little efforts.
In Chapter 4, we introduced scaffold families as a concept to generalize the static scaffold
representation of small molecules. Here, our goal was to merge different scaffolds that are
related in a medicinal chemistry way into a single scaffold family. For selected examples,
we showed that connected component decomposition of binary fingerprint-based similarity
networks yields meaningful scaffold families. The method can be used to pre-cluster large
chemical spaces or to estimate the medicinal chemistry diversity in compound data sets.
In the second part of this thesis, computational tools were developed and utilized to
study the modulation of PPIs. In Chapter 5, we studied the small molecule-induced stabiliza-
tion of PPIs. Examples from nature and the recently published proof of concept for rational
in vitro design of a PPI stabilizer inspired us to analyze their structural details. Our goal was
to gain knowledge about this fascinating mode of action and to develop novel approaches for
PPI stabilizer-focused VS. We used the developed tools to screen the PDB and indeed found
unrecognized PPI stabilizers. With that knowledge, we performed a stabilizer VS using the
14-3-3◦Task3 complex as our model system. Using our tools, we finally selected 89 candidates
from VS for in vitro testing. Different biochemical assays to test stabilizing activity and to
exclude artifacts finally left one hit compound. However, we were not able to solve a crystal
structure of the ternary complex with 14-3-3 and Task3 until now and further experiments will
be necessary. Nevertheless, these results are encouraging. The developed tools and procedures
will be of great benefit for the structure-based drug design community. Applying them on
other PPIs is highly desirable. Further theoretical work and research should focus on strategies
to rescore predicted PPI-ligand complexes. Our current structure-based filter does not eval-
uate binding-free energy changes of the target PPI upon ligand binding. Incorporating such
energetic contributions, however, could serve as a final rescoring step and their calculation is
possibly feasible by means of sophisticated molecular dynamics simulations. Studies perform-
ing such simulations have not been published yet and thus, our work serves as an excellent
starting point for such research projects.
In Chapter 6 we examined the inhibition of 14-3-3 PPIs by small molecules. The PDB pro-
vides a large number of crystal structures of 14-3-3 in complex with different protein binding
partners. We used this source of structural information to analyze the binding modes and to
infer a minimal pharmacophore. Based on the latter we set up a VS and indeed identified
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small molecule inhibitor candidates that were validated in vitro. Successful crystallization
experiments enabled us to elucidate complex structures and to perform a SAR studies, which
led to the identification of improved inhibitors. Furthermore, we were able to demonstrate
the activity of our inhibitors in cell-based experiments. The identified compounds are the first
biochemically and structurally characterized reversible small molecule 14-3-3 inhibitors. As
an important signaling hub, 14-3-3 is an attractive target for drug design research. Thus, our
results will be of great interest for researchers working with 14-3-3.
In summary, the results presented in this thesis will be of interest for theoretical and
experimental scientists in chemoinformatics, structural bioinformatics, structural biology, and
drug design communities. Interesting questions and starting points for further research –
experimental as well as theoretical – arise from this work and will contribute to the integration
of PPIs into the druggable genome.
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Abbreviations
Amino acids in a general context are not abbreviated. If we refer to a particular amino acid
within a peptide or protein, standard abbreviations in 3-letter code are used with the residue
position as suffix. Thus, an arbitrary serine at position 256 is abbreviated by Ser256. Within
amino acid sequences, standard abbreviations in 1-letter code are used.
2D Two-dimensional
3D Three-dimensional
A
AANAT Arylalkylamine N-acetyltransferase
AC Adenylyl cyclase
APN Aminopeptidase N
ARF1 ADP ribosylation factor 1
ARP Actin-related protein
ASA Accesible surface area
B
BALL Biochemical algorithms library
bII Block inverted index
BSA Buried surface area
C
CADD Computer-aided drug design
CC Connected component
D
DAPK2 Death-associated protein kinase 2
DHFR Dihydrofolate reductase
137
A. Abbreviations
DI Druggability index
DMSO Dimethyl sulfoxide
E
EC50 Effective concentration 50 %
ECFP Extended connectivity fingerprints
ESI-MS Electrospray ionization mass spectrometry
EM Extracellular matrix
F
F101 Fobisin101
FP Fluorescence polarization
H
HDAC3 Histone deacetylase 3
HTS High-throughput screening
I
IC50 Inhibitory concentration 50 %
iiDS Inverted index data structure
IP4 Inositol tetraphosphate
M
Max Myc-associated factor X
MD Molecular dynamics
MOE Molecular Operating Environment
MMP Matrix metalloproteinase
MR Molecular replacement
MS Mass spectrometry
MSA Multiple sequence alignment
MT Microtubules
MW Molecular weight
N
NMDA N-methyl-D-aspartate
NMR Nuclear magnetic resonance
NRCoRep1 Nuclear receptor co-repressor 1
P
PAMPA Parallel artificial membrane permeation assay
PBFP Path-based fingerprints
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PDB Protein Data Bank
PEG Polyethylene glycol
PLP Pyridoxal phosphate
PMA2 Plasma membrane H+-ATPase 2
Population count Popcount
PPI Protein-protein interaction
R
RARα Retinoic acid receptor α
RMSD Root-mean-square deviation
RNN Reciprocal nearest neighbor
Ro5 Lipinski’s Rule-of-five
S
SAR Structure-activity relationship
SASA Solvent-accessible surface area
SES Solvent-excluded surface
SMILES Simplified Molecular Input Line Entry System
SOD1 Superoxide dismutase 1
T
Task3 TWIK-related acid-sensitive potassium (K+) channel 3
Tps Tanimoto calculations per second
V
VS Virtual Screening
Y
YAP Yes-associated protein
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Contributions
All ideas, approaches and results presented in this work were developed and discussed with
my supervisors Prof. Dr. Oliver Kohlbacher (OK) and Prof. Dr. Christian Ottmann (CO). The
following co-workers also contributed to the different projects:
• Maria Bartel (MB)
• Dr. Sven Hennig (SH)
• Nicole Meißner (NM)
• Dr. Manuela Molzan (MM)
• Dr. Lars Röglin (LR)
• Dr. Lisa Sach-Peltason (LSP)
• Svenja Schäfers (SS)
• Dr. Benjamin Schumacher (BS)
• Dr. Malgorzata Skwarczynska (MS)
Chapter 3: Deterministic Clustering of Large Chemical Spaces
The project was designed by myself, OK, and CO. Additionally, LSP contributed to this project
in the context of her Studienarbeit.134 The inverted index method was reimplemented and
parallelized by myself. All other C++ code was newly developed by myself and embedded
into the software framework BALL.2 Computational experiments were performed by myself.
Data was analyzed and interpreted by myself and OK. The manuscript of the published article
that arose from this work was written by myself.125
Chapter 4: Scaffold Families
The project was designed by myself, OK, and CO. Computational experiments were performed
by myself. Data was analyzed and interpreted by myself and OK.
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Chapter 5: In Silico Analysis of Protein-Protein Interaction Stabilization
The project was designed by myself, OK, and CO. Computational experiments and protein
crystallography were performed by myself. Protein for in vitro experiments was kindly provided
by MM, BS, and MS. The in vitro assays were performed by MB. Results and data were analyzed
and interpreted by myself, OK, and CO.
Chapter 6: Virtual Screening for 14-3-3 Protein-Protein Interaction Inhibitors
The project was designed by myself, LR, SH, OK, and CO. Computational experiments and
protein crystallography were performed by myself. Protein for in vitro experiments was kindly
provided by MM, BS, and MS. The in vitro assays were performed by LR. He also contributed
the ESI-MS experiments. Cellular assays were performed by NM, SS, and SH. PAMPA measure-
ments were provided by the Lead Discovery Center Dortmund. Results and data were analyzed
and interpreted by myself, LR, SH, OK, and CO. Published manuscripts were written by myself
and LR.208,209
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Supporting Figures
β ε η γ σ τ ζ
14-3-3 ζ 0.57 0.73 0.52 0.58 0.77 0.65 0.00
14-3-3 τ 0.73 0.72 0.72 0.79 0.78 0.00 0.65
14-3-3 σ 0.88 1.13 0.70 0.75 0.00 0.78 0.77
14-3-3 γ 0.55 0.92 0.39 0.00 0.75 0.79 0.58
14-3-3 η 0.57 0.89 0.00 0.39 0.70 0.72 0.52
14-3-3 ε 0.79 0.00 0.89 0.92 1.13 0.72 0.73
14-3-3 β 0.00 0.79 0.57 0.55 0.88 0.73 0.57 2bq0
2br9
2c63
3uzd
3lw1
2btp
4fj3
PDB ID
Figure D.1: Pairwise RMSD matrix of all human 14-3-3 homologs. Structure and se-
quence alignment was performed using Protein Superpose from MOE (version 2012.10).
The RMSD values were calculated from superposed Cα backbones of 14-3-3 monomers. N-
terminal tag residues and C-terminal overhangs were trimmed after sequence alignment.
The following optional settings were enabled: Optimize Gap penalties for Superposition,
Accent Secondary Structure Matches. The averaged RMSD value is 0.74 Å.
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Figure D.2: FP-based assay for in vitro validation of selected stabilizer candidates for the
14-3-3σ◦Task3 interaction. The experiments were performed by Maria Bartel from TU
Eindhoven.
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Figure D.3: Ramachandran plots of 14-3-3◦inhibitor complexes generated using RAM-
PAGE.228
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Figure D.4: Ramachandran plots of 14-3-3◦Task3 complexes soaked with stabilizer can-
didates S37 and S43 from VS. Plots were generated using RAMPAGE.228
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Figure D.5: Deconvoluted mass spectrum of 14-3-3ζ after treatment with compound
F101 (Dr. Lars Röglin, CGC Dortmund). A solution of 1 mM 14-3-3ζ was mixed with
F101 (final concentration 5 mM), incubated overnight in the presence of 25 mM tris(2-
carboxyethyl)phosphine (TCEP) and analyzed using ESI-MS after 1:50 dilution with water
(blue peaks). One aliquot was diluted before overnight incubation and ESI-MS analysis
(orange peaks). The resulting mass spectra were deconvoluted using Mag-Tran. Red
marks show the calculated masses for 14-3-3ζ with 0-4 additional F101 moieties cova-
lently linked to 14-3-3 via imine formation. Figure is adapted from Röglin et al. (Proc.
Natl. Acad. Sci. USA (2012), 109, E1051-3).208
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Supporting Tables
Table E.1: Composition of immediately available compound library sorted by compounds
per supplier.
Supplier Name Compounds
Enamine 1,622,458
Uorsy 1,295,301
ChemDiv 1,208,146
Vitas-M Laboratory 846,810
ChemBridge 568,409
Asinex 307,164
TimTec 213,395
Princeton BioMolecular Research 198,537
Life Chemicals 126,358
InterBioScreen 108,216
Total 6,494,794
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Table E.2: Complex structures of 14-3-3σ and mode III phosphopeptides, which were
analyzed in course of the stabilizer VS in Section 5.2.5. Structures obtained from the PDB
were accessed 6/3/2013. In-house structures which have not yet been deposited (n.d.)
with the PDB were also analyzed. The ligand IDs are the identifiers from the Chemical
Components Dictionary of the PDB.
PDB ID Resolution (Å) Ligand ID Construct Peptide C-terminus
3p1s 1.65 FSC C138V, N166H Task3 Val (+1)
3smm 2.00 FJA C138V, N166H Task3 Val (+1)
3smo 1.80 FJA C138V, N166H Task3 Val (+1)
3spr 1.99 FC7 C138V, N166H Task3 Val (+1)
3ux0 1.75 0DV wild-type Task3 Val (+1)
n.d. 1.65 FSC wild-type Task3 Val (+1)
n.d. 1.60 FSC wild-type HAP1a Ile (+1)
n.d. 1.48 FSC wild-type DAPK2 Ser (+1)
3iqv 1.20 FSC wild-type C-Raf 6-mer Thr (+1)
Table E.3: Non-mammalian complex structures of 14-3-3 and mode III phosphopeptides,
which were analyzed in course of the stabilizer VS in Section 5.2.5. Structures obtained
from the PDB were accessed 6/3/2013. The ligand IDs are the identifiers from the
Chemical Components Dictionary of the PDB.
PDB ID Resolution Ligand ID Construct Peptide C-terminus
1o9f 2.70 Å FSC N. tabacum 14-3-3C PMA2 5-mer Val (+1)
2o98 2.70 Å FSC N. tabacum 14-3-3C PMA2 35-mer Ile (+1)
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Table E.4: Selected compounds from stabilizer VS described in Chapter 5.
ID MolPort ID Supplier Catalog No.
S1 MolPort-002-545-968 Vitas-M Laboratory STK700033
S2 MolPort-002-736-096 Vitas-M Laboratory STK686363
S3 MolPort-009-115-861 ENAMINE Ltd. Z968784634
S4 MolPort-000-035-955 Asinex ASN 04060288
S5 MolPort-000-757-021 Vitas-M Laboratory STK662812
S6 MolPort-000-852-152 Vitas-M Laboratory STK622053
S7 MolPort-000-119-910 Asinex ASN 11172668
S8 MolPort-003-006-350 Alinda Chemical IBS-0010522
S9 MolPort-002-578-667 InterBioScreen Ltd. STOCK3S-13326
S10 MolPort-020-083-188 ENAMINE Ltd. Z1136425863
S11 MolPort-008-346-818 InterBioScreen Ltd. STOCK1N-23077
S12 MolPort-002-580-849 InterBioScreen Ltd. STOCK3S-23906
S13 MolPort-001-537-445 Vitas-M Laboratory STK129741
S14 MolPort-002-593-689 InterBioScreen Ltd. STOCK3S-87770
S15 MolPort-009-363-011 ENAMINE Ltd. Z88619050
S16 MolPort-000-758-979 Vitas-M Laboratory STL055571
S17 MolPort-000-006-616 Specs AG-690/10758045
S18 MolPort-000-068-565 Asinex ASN 05338572
S19 MolPort-000-068-574 Asinex ASN 05338581
S20 MolPort-000-728-502 Vitas-M Laboratory STL147606
S21 MolPort-019-745-957 Specs AG-690/34036035
S22 MolPort-006-395-331 Vitas-M Laboratory STL146393
S23 MolPort-009-758-814 InterBioScreen Ltd. STOCK1N-76189
S24 MolPort-000-484-898 ChemDiv, Inc. D074-0284
S25 MolPort-000-748-046 Vitas-M Laboratory STK069487
S26 MolPort-002-322-601 Vitas-M Laboratory STK370217
S27 MolPort-000-409-821 Vitas-M Laboratory STK789593
S28 MolPort-001-975-340 Specs AO-082/13829007
S29 MolPort-002-697-608 Vitas-M Laboratory STK672779
S30 MolPort-002-722-969 Vitas-M Laboratory STK773272
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Table E.4: Continued.
ID MolPort ID Supplier Catalog No.
S31 MolPort-006-811-597 Vitas-M Laboratory STK648895
S32 MolPort-009-421-945 ENAMINE Ltd. Z196494254
S33 MolPort-002-972-593 Vitas-M Laboratory STK199399
S34 MolPort-004-195-644 ENAMINE Ltd. Z31373283
S35 MolPort-005-658-213 ENAMINE Ltd. Z168814872
S36 MolPort-009-357-856 ENAMINE Ltd. Z992226530
S37 MolPort-007-567-493 ChemDiv, Inc. 5275-0079
S38 MolPort-005-911-044 InterBioScreen Ltd. STOCK1N-72125
S39 MolPort-007-640-377 ChemDiv, Inc. C530-0369
S40 MolPort-003-116-786 Life Chemicals Inc. F2325-0245
S41 MolPort-005-650-834 ENAMINE Ltd. Z46493886
S42 MolPort-023-141-229 ENAMINE Ltd. Z1082917684
S43 MolPort-001-953-171 Vitas-M Laboratory STK885541
S44 MolPort-009-294-226 ENAMINE Ltd. Z368533022
S45 MolPort-009-284-060 ENAMINE Ltd. Z356761160
S46 MolPort-009-266-368 ENAMINE Ltd. Z324816790
S47 MolPort-000-051-348 Asinex ASN 04642642
S48 MolPort-003-881-792 Vitas-M Laboratory STK367994
S49 MolPort-008-276-745 Asinex SYN 15028367
S50 MolPort-016-642-207 Asinex ADD 13552951
S51 MolPort-016-642-832 Asinex ADD 14244518
S52 MolPort-016-676-781 Asinex AOP 22040411
S53 MolPort-016-680-954 Asinex ART 22837893
S54 MolPort-016-712-663 Asinex LEG 16295076
S55 MolPort-016-717-984 Asinex SYN 22855182
S56 MolPort-016-720-760 Asinex SYN 22962998
S57 MolPort-016-721-543 Asinex SYN 22982454
S58 n.a. ENAMINE Ltd. Z26388880
S59 n.a. ENAMINE Ltd. Z1247351969
S60 n.a. ENAMINE Ltd. Z1191626709
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Table E.4: Continued.
ID MolPort ID Supplier Catalog No.
S61 n.a. ENAMINE Ltd. Z195915686
S62 n.a. ENAMINE Ltd. Z32662649
S63 n.a. ENAMINE Ltd. Z56909743
S64 n.a. ENAMINE Ltd. Z1222029545
S65 MolPort-004-985-406 ChemBridge Corp. 43480567
S66 MolPort-016-587-281 ChemBridge Corp. 7776956
S67 MolPort-016-628-317 ChemBridge Corp. 94488956
S68 MolPort-005-078-830 ChemBridge Corp. 43408944
S69 MolPort-005-031-693 ChemBridge Corp. 21944477
S70 MolPort-020-225-776 ChemBridge Corp. 84937785
S71 MolPort-021-767-739 ChemBridge Corp. 73024304
S72 MolPort-005-089-370 ChemBridge Corp. 49023446
S73 MolPort-016-618-320 ChemBridge Corp. 71629761
S74 MolPort-019-801-389 ChemBridge Corp. 18869608
S75 MolPort-008-364-330 ChemBridge Corp. 28313054
S76 MolPort-020-215-374 ChemBridge Corp. 65587844
S77 MolPort-019-822-802 ChemBridge Corp. 90809011
S78 MolPort-020-227-977 ChemBridge Corp. 89013059
S79 MolPort-002-152-386 ChemBridge Corp. 5476872
S80 MolPort-019-901-874 ChemBridge Corp. 95035132
S81 MolPort-005-020-915 ChemBridge Corp. 17996934
S82 MolPort-019-892-017 ChemBridge Corp. 56037516
S83 MolPort-005-021-540 ChemBridge Corp. 18217624
S84 MolPort-020-204-818 ChemBridge Corp. 46200622
S85 MolPort-005-132-482 ChemBridge Corp. 75500017
S86 MolPort-021-751-748 ChemBridge Corp. 26210901
S87 MolPort-020-214-644 ChemBridge Corp. 64233937
S88 MolPort-016-618-878 ChemBridge Corp. 72905872
S89 MolPort-005-049-413 ChemBridge Corp. 29279862
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Table E.5: Compounds from 14-3-3 inhibitor development described in Chapter 6 with
supplier information (IBS: InterBioScreen, S.-Aldr.: Sigma-Aldrich). In addition to the
compounds’ supplier IDs an internal identifier is provided (ID), which is used in this thesis.
The IC50 values were determined using an FP-based competition assay by Dr. Lars Röglin
(’n.a.’: > 500 µM, ’-’: not measured). The SAR column indicates the membership of
the compound to one out of 11 different SAR groups. The SAR groups are discussed
in Section 6.3.3. The table is divided in SAR groups. The first block contains all active
inhibitors sorted by increasing IC50 values.
Molecule ID Rank XP Score Supplier (ID) IC50 (µM) SAR
P
N
H
O
O
O
OH
OH
Cl
Cl B1 n.a. n.a. IBS (6S-30541) 5 8
PO
N
H
O
OH
OH O
B2 n.a. n.a. IBS (6S-21429) 15 5
P
N
H
O
O
OH
OH O
Cl
Cl
B3 n.a. n.a. IBS (6S-31619) 16 11
P
N
H
O
O
O
OH
OH
Cl
B4 n.a. n.a. IBS (6S-31676) 27 6
P
N
H
O
O
O
OH
OH
F
F
F
A1 44 -8.64 IBS (6S-23126) 30 6
PO
N
H
O
OH
OH O
Cl B5 n.a. n.a. IBS (6S-30099) 32 7
P
N
H
O
O
O
OH
OH
F
F
F
Cl
B6 n.a. n.a. IBS (6S-26034) 36 10
P
N
H
O
O
O
OH
OH
O
O
A2 85 -8.29 IBS (6S-23618) 116 10
PO
N
H
O
OH
OH O
O
B7 n.a. n.a. IBS (6S-35412) 118 7
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Table E.5: Continued.
Molecule ID Rank XP Score Supplier (ID) IC50 (µM) SAR
PO
N
H
O
OH
OH O
B8 n.a. n.a. IBS (6S-26169) 128 5
PO
N
H
O
OH
OH O
F
F
F
B9 n.a. n.a. IBS (6S-25642) 165 7
P
N
O
O
O
OH
OH
A4 83 -8.31 IBS (6S-19901) n.a. 1
P
N
O
O
O
OH
OH
A5 123 -8.05 IBS (6S-22115) n.a. 1
P
N
O
O
O
OH
OH
A6 64 -8.43 IBS (6S-26036) n.a. 1
N
PO
O
O
OH
OH
A7 69 -8.41 IBS (6S-39852) n.a. 1
P
N
N
O
O
O
O
OH
OH
O
A8 165 -7.82 IBS (6S-39246) n.a. 1
P
N
O
O
O
OH
OH
A9 57 -8.52 IBS (6S-30315) n.a. 1
PO
N
H
O
O
OH
OH O
OH
A10 27 -8.83 IBS (6S-27243) n.a. 2
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Table E.5: Continued.
Molecule ID Rank XP Score Supplier (ID) IC50 (µM) SAR
PO
N
H
O
O
OH
OH O
O
A11 39 -8.67 IBS (6S-20951) n.a. 2
P
N
H
O
O
O
OH
OH
Cl
Cl
Cl
A12 30 -8.81 IBS (6S-30980) n.a. 2
PO
N
H
O
O
O
OH
OH O
A14 38 -8.68 IBS (6S-35347) n.a. 2
PO
N
H
O
OH
OH O
F
B11 n.a. n.a. IBS (6S-23301) n.a. 2
P
N
H
O
O
O
OH
OH
O O
B12 n.a. n.a. IBS (6S-25681) n.a. 2
PO
N
H
O
OH
OH O
Cl
O
B14 n.a. n.a. IBS (6S-33871) n.a. 2
PO
N
H
O
OH
OH O
Cl
B15 n.a. n.a. IBS (6S-39499) n.a. 2
PO
N
H
O
OH
OH O
Cl
B17 n.a. n.a. IBS (6S-23881) n.a. 2
PO
N
H
O
OH
OH O
O
B19 n.a. n.a. IBS (6S-26928) n.a. 2
PO
N
H
O
OH
OH O
B21 n.a. n.a. IBS (6S-29765) n.a. 2
PO
N
H
O
OH
OH O
B22 n.a. n.a. IBS (6S-29992) n.a. 2
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Table E.5: Continued.
Molecule ID Rank XP Score Supplier (ID) IC50 (µM) SAR
PO
N
H
O
OH
OH O
Cl
Cl
B23 n.a. n.a. IBS (6S-30569) n.a. 2
PO
N
H
O
O
O
OH
OH O
B28 n.a. n.a. IBS (6S-39700) n.a. 2
P
N
H
O
O
O
OH
OH
Cl Cl
B30 n.a. n.a. IBS (6S-31316) n.a. 2
PO
N
H
O
OH
OH O
Cl
B10 n.a. n.a. IBS (6S-30286) n.a. 3
PO
O
N
H
O
OH
OH O
B16 n.a. n.a. IBS (6S-23822) n.a. 3
P
N
H
O
O
O
OH
OH
B18 n.a. n.a. IBS (6S-24610) n.a. 3
PO
O
OH
OH O
N
H
B20 n.a. n.a. IBS (6S-28426) n.a. 3
PO
N
H
O
OH
OH O O
B24 n.a. n.a. IBS (6S-32535) n.a. 3
PO
N
H
O
OH
OH O
O
B25 n.a. n.a. IBS (6S-34461) n.a. 3
PO
N
H
O
OH
OH O
O
B31 n.a. n.a. IBS (6S-37412) n.a. 3
PO
O
N
H
OH
OH O
B13 n.a. n.a. IBS (6S-37402) n.a. 4
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Table E.5: Continued.
Molecule ID Rank XP Score Supplier (ID) IC50 (µM) SAR
PO
N
H
O
OH
OH O
B27 n.a. n.a. IBS (6S-37663) n.a. 4
PO
N
H
O
OH
OH O
B29 n.a. n.a. IBS (6S-43021) n.a. 4
P
N
H
O
O
O
O
OH
OH
O
B26 n.a. n.a. IBS (6S-36239) n.a. 9
P
N
O
O
N
O
OH
OH
OH
OH
A3 25 -8.85 IBS (1N-29704) n.a. 12
PN
H
O
O
O
OH
HO
OH
A13 142 -7.92 IBS (1N-27073) n.a. 12
P
N
OH
O
O
O
OH
OH
N
N
OH
O
F101 n.a. n.a. Sigma-Aldrich
(MRS 2159)
- -
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Table E.6: Materials used for wet lab experiments.
Product Supplier
24-well plates Linbro® Tissue Culture Plates ICN Biomedicals
96-well plates Greiner 609171, CrystalQuick™ Jena Bioscience
Pipettes Eppendorf Research® Eppendorf, Hamburg
Pipetting system Liquidator96© Steinbrenner Laborsysteme
Adhesive foil HDClear™ Packaging Tape ShurTech Brands
Imaging System Rock Imager 1000 Formulatrix, Waltham
Table E.7: Complexation buffer to dilute 14-3-3σ∆C◦inhibitor stock solutions for crystal-
lization.
Unit Concentration
HEPES mM 20.0
MgCl2 mM 2.0
2-Mercaptoethanol mM 2.0
pH 7.5
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Table E.8: Crystallization condition for 14-3-3σ complexes with short phosphopeptides
reported by Schumacher et al..185 2D grid variation of this condition used for crystalliza-
tion experiments of 14-3-3◦inhibitor complexes. The original condition corresponds to
Qiagen® initial screening buffer no. 16 from the JCSG Core I Suite.
95 mM Na-HEPES (pH) PEG 400 (% v/v) Glycerol (% v/v) CaCl2 (mM)
Original 7.5 26.6 5.0 190
C1 7.1 23.0 5.0 190
C2 7.3 24.0 5.0 190
C3 7.5 25.0 5.0 190
C4 7.7 26.0 5.0 190
C5 7.1 27.0 5.0 190
C6 7.3 28.0 5.0 190
C7 7.5 23.0 5.0 190
C8 7.7 24.0 5.0 190
C9 7.1 25.0 5.0 190
C10 7.3 26.0 5.0 190
C11 7.5 27.0 5.0 190
C12 7.7 28.0 5.0 190
C13 7.1 23.0 5.0 190
C14 7.3 24.0 5.0 190
C15 7.5 25.0 5.0 190
C16 7.7 26.0 5.0 190
C17 7.1 27.0 5.0 190
C18 7.3 28.0 5.0 190
C19 7.5 23.0 5.0 190
C20 7.7 24.0 5.0 190
C21 7.1 25.0 5.0 190
C22 7.3 26.0 5.0 190
C23 7.5 27.0 5.0 190
C24 7.7 28.0 5.0 190
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Table E.9: Data processing and refinement statistics. Values for outermost resolution
shells in parentheses.
Compound Information
ID S43 F101
PDB ID not deposited not deposited
Crystal Parameters
Dimensions a,b,c (Å) 81.7, 111.6, 62.4 82.3, 112.3, 62.8
Angles α,β,γ (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Space group C2221 C2221
Data Collection Statistics
Beamline Rigaku Bruker
Wavelength (Å) 1.5418 1.5418
Resolution (Å) 29.75-1.85 (2.00-1.85) 19.60-1.65 (1.75-1.65)
Measured reflections 100449 (20245) 191999 (21100)
Unique reflections 24713 (5079) 34969 (5475)
Completeness 99.9 (100.0) 99.1 (97.6)
Redundancy 4.1 (4.0) 9.1 (6.4)
I/σ(I) 14.6 (4.1) 20.1 (4.6)
Rmeas (%)
a 7.5 (39.6) 6.3 (38.6)
Refinement Statistics
Resolution (Å) 29.76-1.85 (1.89-1.85) 19.60-1.65 (1.69-1.65)
Number of atoms 2171 2511
Rwork (%) 21.7 (26.0) 14.4 (18.4)
Rfree (%) 25.8 (37.6) 19.1 (25.4)
RMS bond lengths (Å) b 0.020 0.021
RMS bond angles (°) b 1.929 1.972
Averaged B-factors (Å2)
Total 21.2 19.6
Compound n.a. 32.2
Ramachandran plot residues
Favoured regions (%) 95.7 98.2
Allowed regions (%) 3.4 1.8
Disallowed regions (%) 0.9 0.0
a Redundancy independent R-factor (intensities).234
b RMSD from ideal geometry values.
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Table E.9: Continued.
Compound Information
ID A1 A2 B1
PDB ID 3t0l 3t0m 4dhu
Crystal Parameters
Dimensions a,b,c (Å) 82.4, 112.8, 62.7 82.1, 112.3, 62.4 82.3, 112.5, 62,5
Angles α,β,γ (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Space group C2221 C2221 C2221
Data Collection Statistics
Beamline SLS SLS, Rigaku Rigaku
Wavelength (Å) 0.9778 0.9778, 1.5418 1.5418
Resolution (Å) 45.62-1.6 (1.70-1.60) 45.42-1.62 (1.70-1.62) 19.54-1.67 (1.75-1.67)
Measured reflections 338818 (54028) 245634 (21990) 262477 (21104)
Unique reflections 38584 (6363) 36467 (4759) 33635 (4129)
Completeness 99.2 (99.4) 98.6 (96.7) 98.8 (94.1)
Redundancy 8.8 (8.5) 6.7 (4.6) 7,8 (5.1)
I/σ(I) 23.9 (5.9) 13.9 (4.0) 45.0 (13.2)
Rmeas (%)
a 5.4 (43.0) 9.7 (43.7) 3.4 (13.3)
Refinement Statistics
Resolution (Å) 45.62-1.60 (1.64-1.60) 45.42-1.62 (1.66-1.62) 19.55-1.67 (1.71-1.67)
Number of atoms 2460 2467 2525
Rwork (%) 15.7 (19.2) 15.5 (19.5) 13.3 (16.8)
Rfree (%) 18.9 (22.7) 19.8 (24.8) 17.6 (24.6)
RMS bond lengths (Å) b 0.021 0.026 0.019
RMS bond angles (°) b 1.997 2.223 1.718
Averaged B-factors (Å2)
Total 22.3 20.8 16.9
Compound 25.8 30.6 17.8
Ramachandran plot residues
Favoured regions (%) 96.2 95.2 97.1
Add. allowed regions (%) 3.8 4.8 2.9
Gen. allowed regions (%) 0.0 0.0 0.0
Disallowed regions (%) 0.0 0.0 0.0
a Redundancy independent R-factor (intensities).234
b RMSD from ideal geometry values.
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Table E.9: Continued.
Compound Information
ID B2 B3 B4
PDB ID 4dht 4dhs 4dhr
Crystal Parameters
Dimensions a,b,c (Å) 82.3, 112.3, 62.5 81.2, 112.0, 62.3 82.2, 112.3, 62.5
Angles α,β,γ (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Space group C2221 C2221 C2221
Data Collection Statistics
Beamline SLS Rigaku SLS
Wavelength (Å) 0.9778 1.5418 0.9778
Resolution (Å) 45.52-1.80 (1.95-1.80) 19.47-1.74 (1.80-1.74) 45.49-1.40 (1.50-1.40)
Measured reflections 103583 (20590) 257320 (15990) 275724 (39272)
Unique reflections 26906 (5697) 28634 (2647) 56179 (10309)
Completeness 98.7 (99.1) 96.1 (93.1) 98.2 (97.7)
Redundancy 3.8 (3.6) 8.9 (6.0) 6.9 (5.4)
I/σ(I) 13.4 (4.1) 30.9 (6.8) 23.0 (4.1)
Rmeas (%)
a 8.4 (36.0) 6.7 (31.9) 3.9 (34.8)
Refinement Statistics
Resolution (Å) 45.62-1.80 (1.85-1.80) 19.47-1.74 (1.78-1.74) 45.49-1.40 (1.44-1.40)
Number of atoms 2390 2417 2421
Rwork (%) 16.4 (22.4) 15.3 (21.7) 12.7 (18.1)
Rfree (%) 20.6 (29.8) 19.3 (26.8) 15.8 (24.0)
RMS bond lengths (Å) b 0.024 0.018 0.026
RMS bond angles (°) b 1.924 1.646 2.301
Averaged B-factors (Å2)
Total 20.2 16.4 19.5
Compound 19.8 20.2 21.3
Ramachandran plot residues
Favoured regions (%) 96.2 97.1 97.6
Add. allowed regions (%) 3.8 2.9 2.4
Gen. allowed regions (%) 0.0 0.0 0.0
Disallowed regions (%) 0.0 0.0 0.0
a Redundancy independent R-factor (intensities).234
b RMSD from ideal geometry values.
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Table E.9: Continued.
Compound Information
ID B5 B6 B7
PDB ID 4dhq 4dhp 4dho
Crystal Parameters
Dimensions a,b,c (Å) 82.3, 112.4, 62.6 82.3, 112.2, 62.4 81.9, 111.7, 62.3
Angles α,β,γ (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Space group C2221 C2221 C2221
Data Collection Statistics
Beamline Rigaku Rigaku Rigaku
Wavelength (Å) 1.5418 1.5418 1.5418
Resolution (Å) 19.56-1.75 (1.85-1.75) 19.53-1.75 (1.85-1.75) 19.46-1.70 (1.85-1.70)
Measured reflections 206270 (20537) 234914 (22063) 166297 (23894)
Unique reflections 29498 (4413) 28885 (4268) 31209 (6750)
Completeness 99.3 (98.4) 97.9 (95.9) 98.0 (96.2)
Redundancy 10.0 (4.7) 10.6 (6.8) 5.3 (3.5)
I/σ(I) 39.1 (13.7) 28.3 (7.3) 29.0 (8.0)
Rmeas (%)
a 3.8 (11.5) 7.0 (27.7) 4.2 (17.0)
Refinement Statistics
Resolution (Å) 19.56-1.75 (1.80-1.75) 19.53-1.75 (1.80-1.75) 19.46-1.70 (1.74-1.70)
Number of atoms 2543 2475 2403
Rwork (%) 15.1 (19.3) 15.6 (20.2) 16.2 (19.5)
Rfree (%) 18.9 (23.7) 19.6 (25.2) 20.2 (23.1)
RMS bond lengths (Å) b 0.017 0.015 0.016
RMS bond angles (°) b 1.571 1.488 1.571
Averaged B-factors (Å2)
Total 16.3 15.7 16.4
Compound 15.5 21.2 25.6
Ramachandran plot residues
Favoured regions (%) 96.1 95.6 96.6
Add. allowed regions (%) 3.9 4.4 3.4
Gen. allowed regions (%) 0.0 0.0 0.0
Disallowed regions (%) 0.0 0.0 0.0
a Redundancy independent R-factor (intensities).234
b RMSD from ideal geometry values.
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Table E.9: Continued.
Compound Information
ID B8 B9 A3
PDB ID 4dhn 4dhm 3u9x
Crystal Parameters
Dimensions a,b,c (Å) 82.2, 111.8, 62.4 82.2, 112.3, 62.4 82.2, 112.1, 62.7
Angles α,β,γ (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Space group C2221 C2221 C2221
Data Collection Statistics
Beamline Rigaku Bruker Rigaku
Wavelength (Å) 1.5418 1.5418 1.5418
Resolution (Å) 45.41-1.80 (1.80-1.90) 19.52-1.70 (1.85-1.70) 45.54-1.80 (2.0-1.8)
Measured reflections 34486 (14026) 176142 (23320) 157300 (26966)
Unique reflections 26775 (3757) 31580 (6598) 26966 (7058)
Completeness 99.0 (94.4) 98.2 (93.1) 99.0 (97.0)
Redundancy 5.0 (3.7) 5.6 (3.5) 5.8 (3.8)
I/σ(I) 32.4 (12.0) 30.7 (9.7) 35.8 (16.0)
Rmeas (%)
a 3.8 (11.7) 3.9 (15.1) 4.9 (9.0)
Refinement Statistics
Resolution (Å) 45.41-1.80 (1.85-1.80) 19.52-1.70 (1.74-1.70) 45.54-1.80 (1.85-1.80)
Number of atoms 2412 2474 2548
Rwork (%) 15.0 (18.4) 15.4 (21.8) 13.6 (17.3)
Rfree (%) 18.5 (24.0) 18.7 (23.1) 18.8 (22.6)
RMS bond lengths (Å) b 0.024 0.022 0.017
RMS bond angles (°) b 1.904 1.882 1.584
Averaged B-factors (Å2)
Total 18.1 17.0 17.6
Compound 20.7 22.5 21.4
Ramachandran plot residues
Favoured regions (%) 97.1 96.2 96.0
Add. allowed regions (%) 2.9 3.8 4.0
Gen. allowed regions (%) 0.0 0.0 0.0
Disallowed regions (%) 0.0 0.0 0.0
a Redundancy independent R-factor (intensities).234
b RMSD from ideal geometry values.
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